Engineering novel antibody-based molecules to probe the role of the immunoglobulin hinge and generate a potential cancer vaccine by Leong, Tein Foong
 
 
Engineering novel antibody-based 
molecules to probe the role of the 
immunoglobulin hinge and generate 
a potential cancer vaccine 
 
Tein Foong Leong 
 
 
A thesis submitted for the degree of 
Doctor of Philosophy 
University of Dundee 
May 2017 
TABLE OF CONTENTS  
CHAPTER ONE: GENERAL INTRODUCTION......................................... 1  
1.1 The immune system....................................................................................... 2 
1.2 The adaptive immune system........................................................................ 3 
1.3 Immunoglobulin classes................................................................................ 5 
1.4 General features of antibody structure.......................................................... 9 
1.5 Fab arms........................................................................................................ 11 
1.6 Fc region........................................................................................................ 12 
1.7 Fc receptors................................................................................................... 17 
1.7.1 Fcg receptors (FcgRs)........................................................................... 17 
1.7.2 Neonatal Fc receptor (FcRn)................................................................ 19 
1.8 Hinge region.................................................................................................. 24 
1.8.1 Antibody flexibility involving the hinge region.................................. 29 
1.8.2 Hinge proteolysis................................................................................. 33 
1.9 Different antibody formats and engineering.................................................. 38 
1.10 Fc-fusion proteins........................................................................................ 43 
1.10.1 Factors affecting the selection of fusion partner............................... 46 
1.11 Recombinant antibody technology.............................................................. 47 
1.12 Project aims................................................................................................. 50 
CHAPTER TWO: MATERIALS AND METHODS..................................... 52 
2.1 General materials........................................................................................... 53 
2.1.1 Chemicals............................................................................................. 53 
2.1.1 General solutions and buffers .............................................................. 53 
2.2 Antibodies and other detecting substances.................................................... 53 
2.3 Molecular biology materials.......................................................................... 56 
2.3.1 Buffers, solutions and materials........................................................... 56 
2.3.2 Restriction enzymes............................................................................. 57 
2.3.3 DNA ligase........................................................................................... 57 
2.3.4 DNA molecular weight markers.......................................................... 58 
2.3.5 DNA polymerase................................................................................. 58 
2.3.6 Competent cells.................................................................................... 58 
2.3.7 Primers................................................................................................. 58 
2.4 Molecular biology methods.......................................................................... 60 
2.4.1 Restriction digestion............................................................................ 60 
2.4.2 Polymerase Chain Reaction (PCR) DNA amplification............................. 61 
2.4.3 Agarose gel electrophoresis........................................................................ 62 
2.4.4 DNA purification from agarose gel............................................................ 62 
2.4.5 DNA ligation............................................................................................... 63 
2.4.6 Transformation of competent DH5α cells.................................................. 63 
2.4.7 Plasmid DNA amplification........................................................................ 64  
2.4.8 Plasmid DNA extraction............................................................................. 65 
2.4.9 DNA concentration and purity.................................................................... 65 
2.4.10 DNA sequencing....................................................................................... 66 
2.5 Tissue culture materials....................................................................................... 66 
2.5.1 Cell lines and growth conditions............................................................... 66 
2.5.2 Plastic ware................................................................................................ 67 
2.6 Tissue culture methods........................................................................................ 67 
2.6.1 Thawing of frozen cells............................................................................. 67 
2.6.2 Cell maintenance or expansion.................................................................. 67 
2.6.3 Harvesting cells.......................................................................................... 67 
2.6.4 Freezing cells for storage........................................................................... 68 
2.7 Protein analysis materials.................................................................................... 68 
2.7.1 Buffers and solutions................................................................................. 68 
2.7.2 Protein molecular weight markers............................................................. 69 
2.8 Protein analysis methods..................................................................................... 69 
2.8.1 Preparation of dialysis tubing.................................................................... 69 
2.8.2 Preparation of Protein G Sepharose.......................................................... 70 
2.8.3 Antibody purification on Protein G Sepharose......................................... 70 
2.8.4 Protein dialysis.......................................................................................... 70 
2.8.5 Protein concentration................................................................................. 71 
2.8.6 Antibody and Fc-fusion protein concentration determination................... 71 
2.8.7 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)............................ 71 
2.8.8 Western blotting......................................................................................... 73 
2.8.9 Coomassie staining and destaining of SDS gels....................................... 74 
2.8.10 ELISA...................................................................................................... 74 
 
CHAPTER THREE: GENERATION OF ANTI-NIP WILDTYPE 
 HUMAN IgG1 AND DIFFERENT HINGE MUTANT ANTIBODIES............ 76 
3.1 Introduction.......................................................................................................... 77 
3.1.1 Bivalent antigenic distance of an antibody.............................................. 77 
3.1.2 The disulphide bond between heavy (H) and light (L) chains................. 82 
3.1.3 The benefits of introns and their removal by mRNA splicing................. 83 
3.1.4 The hinge region of human IgA1 and its O-linked glycans..................... 85 
3.1.5 Jacalin, an O-linked glycan binding lectin............................................... 87 
3.1.6 Anti-NIP variable domain........................................................................ 87 
3.2 Aims.................................................................................................................. 88 
3.3 Materials and methods...................................................................................... 89 
3.3.1 Materials................................................................................................... 89 
3.3.1 Plasmids................................................................................................... 89 
3.3.3 Construction of anti-NIP antibody plasmids........................................... 90 
3.3.3.1 Reintroducing missing sequence EPKSCDKT into  
the pTAHG expression vector.................................................... 90 
3.3.3.2 Repairing the CH1 region of fixed pE1001, pTF1 and pTF2.... 92 
3.3.3.3 Generation of O-linked negative mutant expression vector....... 94 
3.3.3.4 Insertion of sequence encoding murine anti-NIP variable  
heavy domain (VNIP)................................................................. 96 
3.3.4 Production and characterisation of recombinant antibodies..................... 98 
3.3.4.1 Antibody production and purification from FreeStyle 293-F 
cells............................................................................................. 98 
3.3.4.2 Characterisation of antibody heavy and light chains.................. 100 
3.3.4.3 Determination of NIP antigen recognition by ELISA................ 100 
3.3.4.4 Determination of O-linked glycosylation by ELISA.................. 100 
3.4 Results............................................................................................................... 101 
3.4.1 Restoration of missing DNA sequences................................................... 101 
3.4.2 Generation of O-linked negative mutant heavy chain expression  
plasmid................................................................................................... 103 
3.4.3 VNIP insertion......................................................................................... 104 
3.4.4 Amino acid sequence of the hinge region of different antibodies........... 105 
3.4.5 Production and characterisation of recombinant antibodies.................... 105 
3.4.6 NIP antigen recognition........................................................................... 109 
3.4.7 Determination of O-linked glycosylation................................................ 111 
3.5 Discussion......................................................................................................... 112 
 
CHAPTER FOUR: PRODUCTION AND CHARACTERISATION OF dsDNA 
MOLECULAR RULERS..................................................................................... 117 
4.1 Introduction....................................................................................................... 118 
4.1.1 Antibody maximum bivalent antigenic distance...................................... 119 
4.1.2 dsDNA as a molecular “ruler” to measure maximum bivalent antigenic 
distance................................................................................................... 122 
4.1.3 Monovalent streptavidin and biotin association....................................... 125 
4.2 Aims.................................................................................................................. 126 
4.3 Materials and methods...................................................................................... 127 
4.3.1 Materials and buffers.............................................................................. 127 
4.3.2 Generation of NIP-conjugated DNA oligonucleotides (45bp  
and 55bp)................................................................................................ 129 
4.3.2.1 Cleavage of DNA oligonucleotide and deprotection of  
5¢ amino modifiers...................................................................... 129 
4.3.2.2 NIP hapten coupling................................................................... 130 
4.3.2.3 DNA acrylamide gel electrophoresis purification...................... 130 
4.3.2.4 DNA oligonucleotide extraction from acrylamide gel............... 131 
4.3.2.5 Purification of DNA using High Performance Liquid 
Chromatography (HPLC)........................................................... 132 
4.3.3 Characterisation of NIP-conjugated DNA.............................................. 133 
4.3.3.1 Formation of dsDNA.................................................................. 133 
4.3.3.2 DNA polyacrylamide gel electrophoresis................................... 133 
4.3.3.3 Staining od DNA gel.................................................................. 134 
4.3.3.4 ELISA analysis........................................................................... 134 
4.4 Results............................................................................................................... 135 
4.4.1 Conjugation of NIP-hapten to DNA and purification of NIP-DNA....... 135 
4.4.2 Formation of double stranded DNA........................................................ 136 
4.4.3 The estimated length of each DNA fragment.......................................... 139 
4.4.4 NIP-dsDNA antigen recognition............................................................. 140 
4.5 Discussion.......................................................................................................... 141 
 
CHAPTER FIVE: FUNCTIONAL ANALYSES OF RECOMBINANT 
ANTIBODIES........................................................................................................ 147 
5.1 Introduction........................................................................................................ 148 
5.1.1 Surface plasmon resonance (SPR) analyses............................................ 150 
5.1.2 Rosette test............................................................................................... 152 
5.2 Aims................................................................................................................... 154 
5.3 Materials and methods....................................................................................... 155 
5.3.1 Materials and buffers............................................................................... 155 
5.3.2 Surface plasmon resonance analysis....................................................... 156 
5.3.2.1 Immobilisation of NIP-dsDNA on CM4/CM5 sensor chip........ 156 
5.3.2.2 Determination of binding of anti-NIP antibodies to 
immobilized NIP-dsDNA........................................................... 157 
5.3.2.3 Investigation of maximum bivalent antigenic distance in SPR 
experiments................................................................................. 158 
5.3.3 Rosetting assay........................................................................................ 159 
5.3.3.1 Analysis of Fcg receptor expression on THP-1 cells using flow 
cytometry..................................................................................... 159 
5.3.3.2 Derivatisation of RBC with NIP................................................. 160 
5.3.3.3 Coating of NIP-derivatised RBC with anti-NIP antibodies........ 160 
5.3.3.4 Rosetting assay............................................................................ 161 
5.4 Results................................................................................................................ 161 
5.4.1 The success of different immobilisation.................................................. 161 
5.4.2 Binding to NIP-dsDNA assessed by SPR analysis.................................. 163 
5.4.3 Estimation of the likely maximum bivalent antigenic distance of the 
different antibodies.................................................................................. 163 
5.4.4 Determination of Fcg receptor expression on THP-1 cells...................... 176 
5.4.5 Rosetting assay........................................................................................ 177 
5.5 Discussion.......................................................................................................... 179 
 
CHAPTER SIX: GENERATION OF Fc FUSION PROTEIN 
EXPRESSION PLASMIDS........................................................................... 186 
6.1 Introduction........................................................................................................ 187 
6.1.1 Melanoma-associated antigen (MAGE) A protein family....................... 191 
6.1.2 Fusion of MAGE-A2 with IgG1 Fc......................................................... 194 
6.1.3 The role of FcRn in the concept of MAGE-A2-Fc (MFc) fusion  
protein as cancer vaccine......................................................................... 195 
6.2 Aims................................................................................................................... 198 
6.3 Materials and methods....................................................................................... 199 
6.3.1 Plasmids................................................................................................... 199 
6.3.2 Construction of Kz-hMFc and Kz-mMFc plasmids................................ 199 
6.3.2.1 Generation of hMFc (MAGE-A2 fused with wt hIgG1 Fc) 
expression plasmid.................................................................... 199 
6.3.2.2 Generation of Kz-hMFc expression plasmid.............................. 203 
6.3.2.3 Amplification of sequence encoding the murine IgG2a Fc  
region........................................................................................ 205 
6.3.3 Production and characterisation of hMFc and mMFc............................ 209 
6.3.3.1 hMFc and mMFc production and purification from  
FreeStyle 293-F cells............................................................... 209 
6.3.3.2 Characterisation of hMFc and mMFc........................................ 210 
6.3.3.3 Prediction of unstructured region of hMFc................................ 211 
6.4 Results............................................................................................................... 211 
6.4.1 Generation of hMFc expression plasmid................................................ 211 
6.4.2 Introduction of Kozak consensus sequence into the hMFc  
expression plasmid................................................................................. 213 
6.4.3 Generation of mMFc expression plasmid............................................... 215 
6.4.4 Production and characterisation of Fc fusion protein............................. 218 
6.4 Unstructured region of hMFc.................................................................... 221 
6.5 Discussion......................................................................................................... 223 
 
CHAPTER SEVEN: ANALYSIS OF ANTIGEN CROSS PRESENTATION 
ELICITED BY Fc FUSION PROTEIN.............................................................. 231 
7.1 Introduction....................................................................................................... 232 
7.1.1 Formation of MFc immune complexes (IC)........................................... 236 
7.1.2 B3Z T cells.......................................................... ................................... 236 
7.2 Aims.................................................................................................................. 238 
7.3 Materials and methods...................................................................................... 238 
7.3.1 Materials and buffers.............................................................................. 238 
7.3.2 Plasmids.................................................................................................. 241 
7.3.3 Incorporation of SIINFEKL peptide to MFc.......................................... 241 
7.3.3.1 Insertion of SIINFEKL peptide DNA encoding sequence to  
mMFc expression plasmid......................................................... 241 
7.3.4 Production and characterisation of SIIN-mFc........................................ 245 
7.3.4.1 SIIN-mMFc production and purification from FreeStyle  
293-F cells.................................................................................. 245 
7.3.4.2 Characterisation of SIIN-mFc.................................................... 246 
7.3.5 Generation of bone marrow derived dendritic cells and splenic  
derived dendritic cells............................................................................ 247 
7.3.5.1 Bone marrow dendritic cell (BMDC) isolation and culture....... 247 
7.3.5.2 Splenic dendritic cell (SDC) isolation and culture..................... 247 
7.3.5.3 Harvesting BMDC and SDC...................................................... 248 
7.3.6 Antigen presentation assay...................................................................... 248 
7.3.6.1 Formation of IC.......................................................................... 248 
7.3.6.2 B3Z antigen presentation assay................................................... 249 
7.3.7 Investigation of the expression level of different Fc receptors................ 250 
7.3.7.1 Flow cytometry analysis.............................................................. 250 
7.3.7.2 Preparation of cell lysate and whole liver lysate......................... 250 
7.3.7.3 Western blotting.......................................................................... 251 
7.4 Results................................................................................................................ 252 
7.4.1 Incorporation of SIINFEKL peptide into MAGE-A2............................. 252 
7.4.2 Production and characterisation of SIIN-mMFc...................................... 253 
7.4.3 Antigen presentation assay...................................................................... 256 
7.4.4 Investigation on the expression level of different Fc receptors in DC.... 260 
7.5 Discussion.......................................................................................................... 262 
 
CHAPTER EIGHT: CONCLUDING REMARKS............................................ 267 








LIST OF FIGURES  
 
CHAPTER ONE 
1.1 A diagram illustrating the general structure of human IgG1............................ 6 
1.2 A diagram illustrating the structure of the immunoglobulin fold of typical 
variable and constant domains of an immunoglobulin.................................... 10 
1.3 A diagram illustrating the mechanism of antibody activation of the  
complement cascade, initiated by the binding of C1q to IgG Fc region......... 13 
1.4 A diagram illustrating the key residues located in the hIgG1 Fc region  
which are required for effector mechanisms................................................... 14 
1.5 A diagram illustrating the expression of different human Fcg receptors  
(FcgRs) by different immune cells and their binding affinity......................... 18 
1.6 A schematic diagram illustrating the characteristics of neonatal Fc 
receptor (FcRn)............................................................................................... 20 
1.7 A schematic diagram illustrating the function of neonatal Fc receptor 
(FcRn).............................................................................................................. 22 
1.8 Alignment of the amino acid sequences of the hinge region of different 
immunoglobulins from various species using COBALT................................ 26 
1.9 A schematic diagram illustrating the potential flexibility of a human  
IgG1 molecule................................................................................................. 30 
1.10 A schematic diagram illustrating the different immune complexes  
formed, due to different Fab arms arrangements............................................ 32 
1.11 A schematic diagram illustrating sites in the hinge regions of human  
IgA1 and IgG1 that are susceptible to cleavage.............................................. 34 
1.12 A schematic diagram illustrating the different antibody formats that 
 have been engineered..................................................................................... 40 
 
CHAPTER THREE 
3.1 A schematic diagram illustrating the bivalent antigenic distance of  
antibodies........................................................................................................ 78 
3.2 A schematic diagram illustrating the differences in lengths of the upper  
hinge region of different human IgG antibodies............................................. 81 
3.3 A schematic diagram illustrating the nine potential O-linked  
glycosylation sites located at the hinge region of human IgA1...................... 86 
3.4 Chemical structure of 4-hydroxy-3-iodo-5-nitrophenyl acetic  
acid (NIP) hapten............................................................................................ 88 
3.5 A schematic diagram illustrating the procedure to reintroduce sequence  
encoding the missing amino acids.................................................................. 91 
3.6 A schematic diagram of the repair of the exon upstream to CH1.................... 93 
3.7 Generation of O-linked negative mutant heavy chain expression vector........ 95 
3.8 Anti-NIP variable heavy domain (VNIP) insertion.......................................... 97 
3.9 Determination of correct orientation of Anti-NIP variable heavy  
domain (VNIP)................................................................................................ 98 
3.10 Results of molecular cloning for heavy chain repair...................................... 102 
3.11 Results of molecular cloning for generating O-Linked negative mutant 
 heavy chain construct..................................................................................... 104 
3.12 A representative result for determination of VNIP orientation...................... 105 
3.13 Coomassie staining of purified antibodies after SDS-PAGE......................... 107 
3.14 Western blotting of purified antibodies.......................................................... 108 
3.15 NIP binding ELISA........................................................................................ 110 
3.16 ELISA result of O-linked glycans detection using jacalin............................. 111 
 
CHAPTER FOUR 
4.1 A diagram illustrated the advantage of longer maximum bivalent antigenic 
distance in antigen binding when the targeted antigen density is low and 
individual antigen molecules are spaced relatively far apart.......................... 121 
4.2 The concept of using dsDNA as a molecular “ruler” to measure the  
maximum bivalent antigenic distance of an antibody..................................... 124 
4.3 A comparison of HPLC elution profiles of unconjugated and  
NIP-conjugated 45bp DNA samples............................................................... 136 
4.4 HPLC chromatography profiles of different DNA samples............................. 137 
4.5 Polyacrylamide DNA electrophoresis.............................................................. 138 
4.6 ELISA result of antigen recognition of 20bp NIP-dsDNA/Strep by  
anti-NIP wt hIgG1........................................................................................... 141 
4.7 ELISA result of antigen recognition of 20bp NIP-dsDNA/Strep by  
anti-NIP wt hIgG1........................................................................................... 142 
 
CHAPTER FIVE 
5.1 A schematic diagram of different scenarios following monovalent  
streptavidin immobilisation on a CM5 sensor chip........................................ 152 
5.2 A schematic diagram illustrating rosette formation......................................... 153 
5.3 Results of SPR analyses of different anti-NIP IgG antibodies binding to  
20bp NIP-dsDNA at different concentrations between 2nM and 28nM 
surface............................................................................................................. 164 
5.4 A comparison of SPR profiles of 20nM and 2nM concentrations of 
 different antibodies binding to the 20bp NIP-dsDNA surface....................... 167 
5.5 A comparison of SPR profiles of 20nM and 2nM concentrations of 
 different antibodies binding to 45bp NIP-dsDNA surface............................. 171 
 
5.6 A comparison of SPR profiles of 20nM concentrations of different  
antibodies binding to different concentration of 45bp-dsDNA  
immobilised surface......................................................................................... 173 
5.7 A comparison of SPR profiles of 20nM and 2nM concentrations of 
 different antibodies binding to the 55bp NIP-dsDNA surface....................... 175 
5.8 Result of flow cytometry analysis of FcgRI and FcgRII expression on  
THP-1 cells...................................................................................................... 177 
5.9 Formation of rosettes with THP-1 cells and NIP-derivatized red blood  
cells coated with different concentrations of anti-NIP antibodies................... 178 
5.10 A diagram illustrating the proposed binding activity of different  
anti-NIP hinge mutant antibodies (wt hIgG1, 0.5HA, 1HA and ONeg)  
to different NIP-dsDNA bivalent ligands........................................................ 181 
 
CHAPTER SIX 
6.1 A schematic diagram illustrating the process of antigen cross presentation 
mediated by FcRn in a dendritic cell............................................................... 188 
6.2 A schematic diagram illustrating the MAGE-A protein family members  
aligned based on the MAGE Homology Domain (MHD) .............................. 192 
6.3 A schematic diagram illustrating the general structure of MAGE-A2-Fc  
fusion protein (MFc)........................................................................................ 195 
6.4 A schematic diagram illustrating the concept of MAGE-A2-Fc (MFc)  
fusion protein as a cancer vaccine.................................................................... 197 
6.5 A schematic diagram illustrating the generation of the MAGE-A2-hFc  
expression vector.............................................................................................. 200 
6.6 A schematic diagram illustrating the incorporation of the Kozak consensus 
sequence into the hMFc expression vector....................................................... 204 
6.7 A schematic diagram illustrating the generation of MAGE-A2-mFc  
Fc-fusion protein expression vector.................................................................. 206 
6.8 Results of molecular cloning for the generation of the hMFc expression  
plasmid.............................................................................................................. 212 
6.9 The DNA sequence encoding hMFc and corresponding translated protein 
sequences.......................................................................................................... 214  
6.10 Results of molecular cloning for the generation of mMFc expression  
plasmid.............................................................................................................. 216 
6.11 The DNA sequence encoding mMFc and corresponding translated protein 
sequences.......................................................................................................... 217 
6.12 Coomassie and western blot staining of purified hMFc (human MAGE-A2 
fused with wt hIgG1 Fc region) and mMFc (human MAGE-A2 fused with 
murine IgG2a Fc region) after SDS-PAGE and western blotting.................... 220 
6.13 Result of prediction of unstructured regions in hMFc..................................... 222 
 
6.14 A diagram illustrating the aligned sequences of the Mage Homology  
Domain (MHD) of MAGE-A2,-A3 and -A4............................................... 229 
 
CHAPTER SEVEN 
7.1 A schematic diagram illustrating the NFAT-lacZ reporter construct.............. 237 
7.2 A diagram illustrating the ApaI site within MAGE-A2 DNA sequence  
and the design of primer Siinfekl1 for the incorporation of SIINFEKL  
peptide............................................................................................................. 241 
7.3 A schematic diagram illustrating the incorporation of sequence encoding  
the SIINFEKL peptide into MAGE-A2 and the generation of an  
expression vector............................................................................................ 243 
7.4 Results of molecular cloning for the incorporation of SIINFEKL peptide  
into mMFc...................................................................................................... 253 
7.5 The DNA sequence encoding SIIN-mMFc and corresponding translated  
protein sequences............................................................................................ 254 
7.6 Coomassie staining and western blot of purified SIIN-mMFc (human  
MAGE-A2 with SIINFEKL incorporation fused with murine IgG2a Fc  
region) and mMFc (human MAGE-A2 fused with murine IgG2a Fc region)  
after SDS-PAGE and western blotting........................................................... 256 
7.7 β-galactosidase enzyme activity of B3Z T cells following MAGE-A2 Fc  
fusion protein antigen cross presentation by BMDC...................................... 258 
7.8 β-galactosidase enzyme activity of B3Z T cells following MAGE-A2 Fc  
fusion protein antigen cross presentation by SDC.......................................... 259 
7.9 Flow cytometry analyses of the expression level of different Fcg receptors  
on the surface of bone-marrow derived dendritic cells (BMDC) and spleen 
derived dendritic cells (Spleen DC)................................................................ 261 
7.10 Western blotting for the detection of FcRn expression. DC were lysed  




LIST OF TABLES  
CHAPTER TWO 
2.1 List of antibodies and other detecting compounds used................................... 54 
2.2 List of amplifying primers used........................................................................ 58 
2.3 List of sequencing primers used........................................................................ 59 
2.4 Reaction mix for restriction digestion............................................................... 60 
2.5 Reaction condition for PCR DNA amplification.............................................. 61 
2.6 List of steps for typical PCR DNA amplification............................................. 61 
2.7 Reaction conditions for DNA ligation.............................................................. 63 
2.8 List of cell culture conditions and details of each cell line used....................... 66 
2.9 Details of the medium used for freezing different cell lines............................. 68 
 
CHAPTER THREE 
3.1 Amount of DNA required for FreeStyle 293-F cells transfection..................... 99 
3.2 The type of antibody plasmid required for transfection.................................... 99 
3.3 DNA sequencing results and the translated protein sequences of the hinge  
region of different antibodies........................................................................... 106 
 
CHAPTER FOUR 
4.1 DNA sequence and modifications of purchased oligonucleotides.................... 128 
4.2 DNA sequence and modifications of synthesised oligonucleotides.................. 128 
4.3 Reaction conditions for NIP hapten coupling.................................................... 130 
4.4 Details of the HPLC devices used..................................................................... 132 
4.5 Recipe for 20% DNA polyacrylamide gel......................................................... 134 
4.6 Estimated length of each DNA fragment........................................................... 140 
 
CHAPTER FIVE 
5.1 Details of generated CM4/CM5 sensor chips.................................................... 163 
 
CHAPTER SIX 
6.1 Amount of DNA required for FreeStyle 293-F cells transfection..................... 210 
 
CHAPTER SEVEN 
7.1 Supplement details to make complete RPMI medium....................................... 239 
7.2 Amount of DNA required for FreeStyle 293-F cells transfection..................... 246 
ACKNOWLEDGEMENTS  
 
Firstly, I would like to thank my supervisor, Prof. Jenny Woof, for her guidance, 
advice and encouragement throughout my PhD project. I am very grateful to her 
because of her generosity in supporting my study through provision of laboratory 
materials and aiding my participation in conferences. I cannot thank her enough for 
what she had provided me throughout these four years. 
 
I am indebted with many people within Division of Cell Signalling and Immunology 
and Division of Cancer Research for their support and advice. They have provided 
me with crucial materials that have aided the progression of this project. Without 
their materials, this project may not be completed successfully. Ask around and they 
will provide you with all the things you need. I would also like to thank Saira Ashraf 
and Timothy Wilson from Oligonucleotide Synthesis Service, University of Dundee, 
for their help and teaching as well as allowing me to use their equipment to carry out 
my experiments. 
 
A special thanks to my fellow lab-mates, Lois Paton and Ruby, for being great 
friends and companions throughout my time in the lab. Both our happy and difficult 
times together shall always be remembered. 
 
Finally, a great thank you to some of the people that are very precious to me. Thank 
you to my parents, Danny Leong Chee Kheong and Ho Yin Leng, for their 
unconditional and endless love and support. To both my siblings, Leong Yu Ting and 
Leong Wan Er, your stories have kept me entertained all this while. And to Phoebe 
Su Wan Tyng, thank you for being by my side with your unwavering love and 








I hereby declare that the candidate below is the author of this thesis, that all the 
references cited have been consulted by the candidate, that the work of which the 
thesis is a record has been carried out by the candidate, except where clearly stated, 




Tein Foong Leong 
 
I hereby declare that Tein Foong Leong has carried out his research under my 
supervision, and has fulfilled the conditions of the relevant Ordinance and 
Regulations of the University of Dundee, so that he is qualified to submit the 




Professor J. M. Woof 
Professor and Associate Dean (Quality & Academic Standards) 
Division of Cell Signalling and Immunology 
University of Dundee 
 
SUMMARY OF CONTENTS  
In different immunoglobulin (Ig) isotypes, the hinge region, which separates the 
antigen-binding Fab region from the Fc region, varies considerably in length. The 
hinge region is believed to provide flexibility for the Ig to conduct better positioning 
for antigen binding via the Fab arms or better receptor association via the Fc region. 
However, the reason for the difference in hinge length among different Igs is not 
fully understood. In this project it is hypothesised that the longer the upper hinge 
length of an IgG the further the distance that the antigen binding sites at the tips of 
Fab arms are able to reach between neighbouring antigens. 
 
In order to investigate the relation between upper hinge region of IgG and the 
distance between antigen binding sites, human IgG1 mutants specific for the hapten 
NIP which featured different upper hinge lengths were generated. Rigid bivalent 
ligands or “molecular rulers” (dsNIP-DNA) comprising defined lengths of double 
stranded DNA with NIP covalently attached to both ends were produced. ELISA 
tests demonstrated that anti-NIP human IgG1 bound to dsNIP-DNA. Through 
employment of molecular rulers of different lengths, surface plasmon resonance 
experiments indicated that the maximum distance between antigen binding sites is 
influenced by the length of the upper part of the IgG hinge. In addition, the role of 
upper hinge length on the ability of IgG to bridge between antigen on a target cell 
surface and Fc receptors on the surface of a phagocyte was investigated. Rosette 
formation between antibody-coated erythrocytes and Fc receptor-positive effector 
cells was utilised as an assay for this bridging. When anti-NIP human IgG1 hinge 
mutants were compared to wildtype IgG1, differences in rosette formation efficiency 
were observed indicating that the upper hinge region has a role in facilitating the 
bridging between an antigenic target cell and effector cell.  
 
In a second IgG engineering approach, potential cancer vaccines that feature the Fc 
region of IgG fused to the tumour associated cancer-testis antigen, MAGE-A, were 
generated and tested. Such vaccines are designed to promote formation of immune 
complexes, which are preferentially taken up by dendritic cells via their FcRn 
receptors, with the aim of stimulating a strong anti-tumour immune response. Human 
MAGE-A2 fused to either human IgG1 Fc or mouse IgG2a Fc had been successfully 
produced and purified using Protein-G Sepharose. Results from Coomassie staining 
and western blotting analyses suggested that the Fc fusion proteins were suffering 
from protein aggregations and possibly protein degradations. To test if MAGE-A2 Fc 
fusion protein can be a potential cancer vaccine, an 8 amino acid peptide sequence, 
SIINFEKL, was incorporated into MAGE-A2 protein of the Fc fusion protein 
containing mouse IgG2a Fc. IgG-immune complexes of SIINFEKL incorporated Fc 
fusion protein were incubated with bone marrow derived dendritic cells (BMDC) and 
corresponding cytotoxic T cells, B3Z, to investigate the induction of antigen cross 
presentation. Unfortunately, SIINFEKL incorporated Fc fusion protein was unable to 
activate B3Z T cells. Further investigation showed that BMDC seems to have a low 
expression of FcRn receptor, which is crucial for inducing an effective antigen cross 
presentation, and might be the reason for the unsuccessful antigen cross presentation 
assay. As a result, further investigations are required to determine if MAGE-A2 Fc 
fusion protein can be a potential cancer vaccine. More studies are also required to 
understand the characteristics of MAGE-A2 Fc fusion protein to minimise protein 
aggregations or protein degradations. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1 The immune system 
Our immune system can be categorised into two different systems, specifically the 
innate and adaptive immune systems (Dempsey et al., 2003; Janeway et al., 2001c). 
Both immune systems defend and protect our body from the various challenges 
imposed by foreign organisms or dangerous compounds. The innate immune system 
consists of a range of components including the skin barrier, mucous secretions, 
different types of leukocytes (white blood cells), different types of cytokines and the 
complement protein system. The skin barrier and mucous secretions form a first line 
of defence which prohibits the entry of foreign microorganisms into the body. 
However, if a microorganism manages to breach through the initial defence and gain 
entry into the body, it will have to survive attack by leukocytes. There are different 
types of leukocytes in the immune system, the key ones being known as monocytes, 
macrophages, dendritic cells, eosinophils, neutrophils, basophils and lymphocytes 
(Dempsey et al., 2003; Janeway et al., 2001c). Lymphocytes can be divided into B 
cells, T cells, and natural killer cells (NK cells). Monocytes express a receptor family 
known as pattern recognition receptors (PPRs) on their cell surface which can 
recognise certain bacterial/viral molecules such as carbohydrates, peptides and 
nucleic acids leading to receptor activation (Dempsey et al., 2003; Janeway et al., 
2001c). Once activated, the PPRs trigger a series of downstream signaling 
mechanisms that lead to the production and secretion of cytokines that contribute and 
mediate other defence mechanisms, such as leukocyte recruitment and activation. In 
addition, neutrophils, macrophages and monocytes are capable of phagocytosing 
microorganisms, containing them within a phagosome and subsequently killing them 
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by fusion of the phagosome with a lysosome loaded with different types of lethal 
enzymes. The components of the microorganism are digested and presented on a 
protein complex known as the major histocompatibility complex (MHC) (Dempsey 
et al., 2003; Janeway et al., 2001c). There are two classes of MHC protein complex, 
namely MHC class I and MHC class II. Both are responsible for linking the innate 
immune system to the adaptive immune system. The major difference between the 
innate and adaptive immune systems is that adaptive immunity displays specificity 
and memory whereas innate immunity does not (Janeway et al., 2001c). Specificity 
refers to the ability to recognise specific structural motifs (epitopes) that are either 
displayed by MHC complexes or expressed on the surface of pathogens/cells and 
distinguish foreign from self. Memory is the ability of generating a long-lived 
response, which is usually faster and stronger, to an antigen that has previously been 
encountered. 
 
1.2 The adaptive immune system 
The adaptive immunity is divided into two categories, specifically cellular and 
humoral immunity (Dempsey et al., 2003; Janeway et al., 2001c). The main factor 
that distinguishes these from each other is the involvement of proteins known as 
antibodies. Antibodies, also called immunoglobulins, are responsible for the 
clearance of foreign pathogens. Antibodies bind to the target pathogen and initiate 
effector mechanisms which usually result in the destruction of the target pathogen 
via mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC), 
antibody-dependent cellular phagocytosis (ADCP) and complement-dependent 
cytotoxicity (CDC) (Burton, 1987; Janeway et al., 2001e; Janeway et al., 2001c; 
Schroeder Jr and Cavacini, 2010).  
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Cellular immunity is not mediated by antibodies, rather it is the activation of 
lymphocytes coordinated via the secretion of cytokines to further strengthen the 
immune response. T lymphocytes (or T cells), named as such because they mature in 
the thymus, originate from common precursors known as haematopoietic stem cells 
and are often categorised into two major sub-populations, namely cytotoxic T cells 
and T-helper cells. Both sub-populations are differentiated by the expression of cell 
surface molecules classified by CD (cluster of differentiation) number. Cytotoxic T 
cells express CD8, and thus are also known as CD8+ T cells, whereas T-helper cells 
express CD4, gaining the name CD4+ T cells. Besides that, both CD8+ and CD4+ T 
cells express an important receptor known as the T cell receptor (TCR), which is 
highly specific in epitope recognition, to carry out their main immunological 
functions. CD8+ T cells use their TCR to bind to a complex of foreign antigen with 
MHC class I molecules that are present in all nucleated cells and thereby decide if a 
lethal response should be initiated. On the other hand, CD4+ T cells use their TCR to 
bind to a complex of foreign antigen with MHC class II molecules that are only 
present on antigen presenting cells such as monocytes and B cells. Such interaction 
initiates secretion of a variety of cytokines to help the activation and differentiation 
of other immune cells, most importantly B cells. In addition, a sub-population of 
activated T cells form memory T cells which can stimulate a stronger and more rapid 
immune response if the same antigen is encountered. 
 
In contrast, humoral immunity involves antibodies that are found to be present in 
various body fluids, including blood, saliva and mucous secretions (Dempsey et al., 
2003; Burton, 1987; Schroeder Jr and Cavacini, 2010). Antibodies are produced and 
secreted by B cells when they are activated, usually via antigen binding and with the 
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help of CD4+ T cells. B cells, named as such because they mature in the bone 
marrow and spleen, also originate from haematopoietic stem cells and express 
membrane-bound antibodies as receptors, known as B-cell receptors (BCR). Each 
BCR is also highly specific in epitope recognition and is key to B cell activation 
which occurs upon BCR binding to its target antigen along with appropriate 
stimulation from CD4+ T cells (Janeway et al., 2001c). Following activation, B cells 
may differentiate into antibody secreting B cells or memory B cells. The former 
produce and secrete antibodies that have the same specificity for the target antigen 
that the BCR previously bound to. On the other hand, memory B cells are long lived 
cells that provide immunological memory towards the antigen that the BCR 
recognised. They are able to proliferate at a higher response rate if the same antigen 
is encountered again.  
 
One interesting fact is that each T and B cell expresses only one kind of TCR or 
BCR; no two are the same unless they originate from a common ancestor (Janeway 
et al., 2001c). Similarly, an activated B cell will only secrete antibody of one 
specificity and this never changes. The unique antigen recognition of TCR and BCR 
govern the specificity of the adaptive immune response whereas the long lived 
memory B and T cells and their rapid response are responsible for the memory 
function of the adaptive response.  
 
1.3 Immunoglobulin classes 
All immunoglobulins (Ig) are formed from a basic unit of four polypeptide chains 








together by disulphide bonds (Dempsey et al., 2003; Burton, 1987; Schroeder Jr and 
Cavacini, 2010), as shown in Figure 1.1. The number and arrangement of disulphide 
bonds varies between the different antibody classes and subclasses. Light chain 
exists in two different forms, termed kappa (ĸ) and lambda (λ), and both have a 
Figure 1.1: A diagram illustrating the general structure of human IgG1. IgG is formed from 
two heavy chains (grey) and two light chains (yellow), which are linked together by 
disulphide bonds. The IgG structure is divided into different regions: two identical Fab arms, 
hinge region and Fc region. Each heavy chain consists one variable domain (VH) and three 
constant domains (CH1-3). Each light chain consists one variable domain (VL) and one 
constant domain (CL). Each CH2 domain carries an N-linked oligosaccharide attached at 
asparagine 297. The antigen binding sites are located at the tip of the Fab arms. 
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molecular weight of approximately 25kDa. An individual antibody molecule will 
always have either kappa or lambda light chains, never both. Different heavy chains 
account for the five different Ig classes, and are named alpha (α), gamma (γ), epsilon 
(ε), mu (μ) and delta (δ), which determine the five antibody classes IgA, IgG, IgE, 
IgM and IgD respectively. Heavy chains have a molecular weight of 50-75kDa 
depending on the antibody class. Only one class of light chain will be expressed by a 
differentiated B cell. In contrast, the expression of heavy chain may change by a 
process known as isotype switching (Janeway et al., 2001d). A B cell always begins 
its antibody expression with IgM. IgD is usually expressed at the same time. In the 
later immune response, the process of isotype switching allows the B cell to change 
it heavy chain expression to either IgG, IgE or IgA. However, one rule of isotype 
switching is that B cell can only change its heavy chain expression in the following 
sequence IgM > IgD > IgG > IgE > IgA (Janeway et al., 2001d). For example, if the 
B cell switches to IgE at the beginning, it can only further switch to IgA in a later 
immune response and can never switch back to IgM, IgD or IgG. 
 
In humans, IgA has two subclasses, namely IgA1 and IgA2, and is often 
characterised as a secretory antibody since it is the most abundant antibody in 
exocrine secretions, such as saliva, milk, and secretions of the intestinal and 
respiratory tracts. More importantly, IgA is usually found as a dimer in secretions, 
where two IgA monomers are joined together by a protein known as joining chain or 
J chain and a polypeptide known as secretory component. However, in the serum, 
IgA exists mainly as monomers (Woof and Russell, 2011). 
 
IgG is the most abundant antibody in the serum but is often found in secondary 
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immune responses when an antigen is encountered for a second or subsequent time. 
In humans, there are four subclasses of IgG, known as IgG1, IgG2, IgG3 and IgG4. 
Among all human antibody classes, IgG is the only one that can cross the placenta 
into the foetal blood circulation, and helps to protect newborn infants until they begin 
to make their own IgG. Similar to IgM, IgG is capable of complement fixation via 
the classical pathway that greatly improves pathogen clearance. 
 
IgM is the first antibody, along with IgD, to be expressed by naïve B cell as BCR 
and is produced in a primary immune response when a particular antigen is first 
encountered. IgM exists in polymeric form, usually as a pentamer where five IgM 
subunits are linked together by J chain. Hexamers of IgM also occur (Petrui et al., 
2011). IgM is considered the most efficient antibody in complement fixation due to 
its polymeric format. 
 
In most individuals, IgE has an extremely low concentration in the serum. However, 
some individuals make IgE responses to harmless environmental antigens, often 
known are allergens. In these individuals IgE is often found bound to a specific 
receptor, known as FceRI that is expressed on the surface of mast cells. When 
receptor-bound IgE binds to target allergen, mast cell degranulation is induced 
resulting in the symptoms associated with allergy. Thus, IgE is responsible for 
majority allergic reactions. IgE also plays an important role in protection against 
helminths and other parasites (Gould et al., 2003). 
 
IgD remains as a rather mysterious antibody as not much is known about it. There is 
very little IgD in serum; however, it is expressed together with IgM, on the surface 
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of naïve B cells, acting as a BCR. The main role of IgD is still unclear but recent 
studies have suggested that IgD may have an immunological function involving 
basophil activation in the respiratory tract (Chen and Cerutti, 2011). 
 
1.4 General features of antibody structure 
An immunoglobulin molecule is divided into the three different regions, namely the 
Fab regions (which will be referred to also as Fab arms), Fc region and hinge region 
(Burton, 1987; Schroeder Jr and Cavacini, 2010). All immunoglobulins share the 
same basic structure in which the Fab regions are separated from the Fc region by the 
hinge region, as shown in Figure 1.1. The Fab arms and the Fc region are formed by 
different domains of the antibody. In detail, each of the light and heavy chains fold 
into several domains, each of which is formed by two b-sheets packed against each 
other via hydrophobic and other non-covalent interactions and further stabilised by a 
disulphide bond (Burton, 1987; Schroeder Jr and Cavacini, 2010; Janeway et al., 
2001e). Such folding is also known as the “immunoglobulin fold” which is 
illustrated in Figure 1.2. All immunoglobulins have two different types of domain 
termed the variable and constant domains. The variable domain is located at the N-
terminus and the constant domains form the subsequent domains. Variable domains 
are designated as VL, for that in the light chain, and VH, for that in the heavy chain. 
Constant domains are designated as CL, for that in the light chain, and CH1, CH2, 
CH3 and CH4, for those in the heavy chain. The immunoglobulin fold of variable 
domains is formed from 9 b-strands whereas that of constant domains is formed from 
7 b-strands as indicated in Figure 1.2.  
 
An antibody has two Fab arms and they are formed by the pairing of the VH and 
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CH1 domains of the heavy chains with the VL and CL domains respectively of the  
light chains. On the other hand, the Fc region refers to the CH2 and CH3 homodimer 
region and the lower hinge section of the antibody as indicated in Figure 1.1. Finally, 
the hinge region separates the Fab arms and the Fc region. Notably, the hinge region 
of IgM and IgE is replaced with an additional pair of constant domains. In contrast, 
the hinge regions of IgD and the subclasses of IgG and IgA vary in length. It is 
believed that the hinge region provides flexibility to the antibody molecule and 
allows both the Fab arms and Fc region to adopt a variety of conformations that aid 
protein-protein/antigen interactions, which will be explained in section 1.7 below. 
In the case of IgG, the inter-heavy chain disulphide bonding occurs at the hinge 
region which aids assembly into the homodimer structure shown in Figure 1.1. The 
Figure 1.2: A diagram illustrating the structure of the immunoglobulin fold of typical variable 
and constant domains of an immunoglobulin. LEFT) The variable domain is formed from two 
b-sheets (green and blue) which consist of nine anti-parallel b-strands. Complementary 
determining regions 1 (CDR1), 2 and 3, are shown in red. RIGHT) Constant domains are 
formed from two b-sheets (green and blue) which consist of seven anti-parallel b-strands (green 
and blue). N, N-terminus; C, C-terminus. Image generated from the X-ray crystal coordinates of 
VH domain of chain K and CH1 domain of chain H of B12 human IgG1 heavy chain (PDB ID 
1HZH) and modified using Chimera software. 
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role of each region will be described in more detail in other sections below. 
 
1.5 Fab arms 
Fab is the abbreviation for “fragment antigen-binding” and each antibody has two 
Fab arms as shown in Figure 1.1. The Fab arm functions as an antigen recognition 
site and this is mediated through its paired variable domains, located at the tip of the 
Fab arms. The VH and VL each have three complementarity determining regions 
(CDRs), shown in Figure 1.2, which are further supported within each V domain by 
four framework regions (FRs). The six CDRs together form the antigen binding site 
which binds with high specificity and affinity to antigen which has a complementary 
three dimensional structure. CDRs are highly variable in sequence and length due to 
the mechanism regulating the random selection of the genes encoding the variable 
region, also known as VDJ recombination (Kumagai and Tsumoto, 2002; Burton, 
1987; Janeway et al., 2001b). In brief, the variable region is encoded by three 
different gene segments known as V (variable) segment, D (diversity) segment (only 
in heavy chains) and J (joining) segment (Janeway et al., 2001b; Kumagai and 
Tsumoto, 2002). There are multiple V, D or J gene segments that are available for 
the formation of both heavy and light chain variable domain. For example, the 
human heavy chain locus contains about 65 V gene segments, 27 D gene segments 
and 6 J gene segments (Janeway et al., 2001b). Selection of each segment to generate 
the final VDJ (heavy chain) or VJ (light chain) combination is completely random. 
As a result, this produces a huge diversity of specificities capable of recognising a 
huge variety of different antigens. It has been estimated that the human antibody 
repertoire is at least 1011 or more (Janeway et al., 2001b).  
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1.6 Fc region 
Fc is the abbreviation for “fragment crystallisable”. The Fc region contains several  
binding sites for different endogenous proteins which are required for the initiation 
of effector mechanisms such as CDC and ADCC and for prolonging plasma half-life. 
CDC is activated when C1q, a protein of the complement system, binds to the CH2 
domain of the Fc region of either IgG or IgM to initiate the complement cascade 
(Duncan and Winter, 1988; Idusogie et al., 2000; Schneider and Zacharias, 2012). 
The activation of the classical complement cascade via antibody initiation is 
dependent on the binding of at least two of the C1q globular heads to the CH2 
domains of the Fc regions of IgG or IgM antibodies (Idusogie et al., 2000). IgM is a 
very efficient complement activator mainly due to its natural state as a pentamer. 
Once IgM has undergone a conformational change from planar to staple 
conformation upon binding to an antigenic surface, it exposes sufficient binding sites 
for efficient binding of C1q (Schroeder Jr and Cavacini, 2010). On the other hand, 
IgG exists as a monomer in the serum. Thus, it is believed that multiple IgG 
molecules binding to a target pathogen and localised close together are required to 
activate complement. Recently, investigations by Diebolder and colleagues showed 
that IgG molecules are capable of assembling into hexamers via Fc-Fc interactions 
and such hexamers can bind Clq (Diebolder et al., 2014). Binding of C1q then 
promotes a series of protein cleavages and recruitments which ultimately promotes 
the formation of a membrane attack complex (MAC) on the target cell surface 
(Janeway et al., 2001a). MAC forms a pore in the target cell membrane and causes 
cell death by the influx of water and removal of electrolytes from the cell (Janeway 
et al., 2001a). The complement cascade mechanism driven by antibodies is 







Figure 1.3: A diagram illustrating the mechanism of antibody activation of the complement 
cascade, initiated by the binding of C1q to IgG Fc region. C1q associates with C1r and C1s 
to form the C1 complex. This process activates C1s to cleave C4 into C4b that recruits C2, 
which is subsequently cleaved into C2a and forms the C3 convertase (C4b2a). C3 convertase 
acts on C3 to produce C3a and C3b. C3b is later recruited to the cell surface forming C5 
convertase (C4b2a3b) which cleaves C5, generating C5b that then associates with C6 and 
C7 to recruit C8. The complex, C5b678, induces polymerisation of several C9 molecules to 
form a ring structure that penetrates the lipid bilayer and generates the membrane attack 





Duncan and Winter identified the CH2 domain residues critical for binding of C1q to 
mouse IgG2b to be Glu318, Lys320 and Lys322 (Duncan and Winter, 1988). 
However, these residues did not seem to apply to human IgG (hIgG) since they are 
conserved in all hIgG subclasses yet the subclasses exhibit different complement 
activation capabilities. Idusogie and colleagues later reported that the critical 
residues for C1q binding by hIgG1 were Asp270, Lys322, Pro329, and Pro331 
(Idusogie et al., 2000), indicated in Figure 1.4. As a result, the authors further 
suggested that there might be species differences in C1q binding by IgG (Idusogie et 
al., 2000). 
 
On the other hand, effector cell functions such as ADCC, ADCP, respiratory burst, 
and enzyme or mediator release are mediated through cell surface Fc receptor 
Figure 1.4: A diagram illustrating the key residues located in the hIgG1 Fc region which are 
required for effector mechanisms. One heavy chain of the Fc is shown in white and the other in 
grey. N-linked oligosaccharides are shown in stick format. Residues in yellow are crucial for the 
binding to Fcg receptors. Residues in green are crucial for the binding of C1q and complement 
activation. Residues in red are crucial for binding to FcRn. The crystal structure is of the Fc 
region of human IgG1 (B12) (PDB ID: 1HZH). The image was generated using Chimera.  
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binding (Daëron, 1997; Burton, 1987; Schroeder Jr and Cavacini, 2010). Importantly, 
each antibody class has its own Fc receptors and the binding sites for each Fc 
receptor differs (Woof and Burton, 2004). For IgA1, the binding site for its specific 
receptor Fca receptor I (FcaRI) is located at the interface of the CH2 and CH3 
domains of the IgA Fc region (Carayannopoulos et al., 1996; Pleass et al., 1999). 
The crystal structure of IgA Fc in association with FcaRI showed that only one 
heavy chain, out of two, of IgA1 was bound to a single FcaRI, therefore, it is 
possible that a single IgA1 is capable of binding to two FcaRI, although the 
physiological relevance is unclear (Woof and Burton, 2004; Herr et al., 2003). In 
contrast, the binding site on IgG for Fcg receptors (FcgRs) was shown to centre of the 
lower hinge region, Leu234-Gly237, of the CH2 domain (Woof et al., 1986; Duncan 
et al., 1988; Shields et al., 2001), indicated in Figure 1.4. In the solved crystal 
structures of IgG Fc in complex with either FcgRI, FcgRII or FcgRIII, residues 
Leu234-Gly237 were proven to be critical in making direct contact with the FcgRs 
and the stoichiometry of IgG:FcgR was found to be 1:1 (Lu et al., 2015; Kiyoshi et 
al., 2015; Sondermann et al., 2000; Radaev et al., 2001; Ramsland et al., 2011). The 
different types of FcgRs will be described in subsequent section 1.7.1.  
 
Another important feature about the Fc region is the presence of N-linked 
oligosaccharides and for IgG this glycosylation occurs at Asn297 (Burton, 1987; 
Schroeder Jr and Cavacini, 2010). Glycosylation at Asn297 is particularly important 
in maintaining optimal binding to FcgRs (Tao and Morrison, 1989; Jefferis, 2005) It 
was described that the affinity of IgG1 and IgG3 for FcgRI was reduced by 2 orders 
of magnitude upon aglycosylation, while binding to FcgRII and FcgRIII was 
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completely abolished (Lund et al., 1990). On the other hand, other studies have 
reported smaller effects of IgG aglycosylation on Clq binding and complement 
activation (Leatherbarrow et al., 1985). More importantly, the composition of the 
oligosaccharide attached at Asn297 displays strong heterogeneity and studies have 
shown that the effector mechanisms of IgG were affected by the different types of 
glycan present on Asn297 (Anthony et al., 2012; Forthal et al., 2010; Raju, 2008). 
For example, afucosylated hIgG1 which lacks the addition of fucose to the IgG core 
glycan, displays binding to FcgRIIIa with increased binding affinity by up to 50 fold 
(Anthony et al., 2012). Similarly, Li and colleagues showed that core fucosylated 
IgG had a reduced ADCC activity in NK cell activation assay compared to 
afucosylated IgG. In addition, the authors demonstrated that when the core of the 
glycan is fucosylated, the presence of terminal sialylation significantly decreased 
ADCC activity in cell-based assay. In contrast, sialylation had no significant impact 
in ADCC activity when the core glycan is afucosylated (Li et al., 2017). Recently, 
Dekkers and colleagues reported the selective production of IgG with different 
glycan composition by manipulating the addition of substrates and the expression of 
glycosyltransferases, which should further improve the understanding of the role of 
different glycan moieties in antibody functionality (Dekkers et al., 2016).  
 
Finally, the Fc region of IgG is also responsible for prolonging the plasma half-life 
through association with an Fc receptor known as FcRn. The role of FcRn will be 





1.7 Fc receptors 
1.7.1 Fcg receptors (FcgRs) 
As mentioned before, key effector mechanisms of IgG are highly dependent on the 
interaction with FcgRs. In humans, there are three classes of FcgR, namely FcgRI 
(CD64), FcgRII (CD32) and FcgRIII (CD16), as indicated in Figure 1.5. FcgRI has 
three extracellular domains while the other FcgRs have two. More importantly, 
FcgRI has the highest binding affinity for IgG and is capable of binding to monomer 
IgG (Boross et al., 2008). The expression of FcgRI on monocytic and myeloid cells 
can be upregulated by stimulation with interferon g (IFN-g) and interleukin 10 (IL-10) 
(Perussia et al., 1983; Velde et al., 1993). On the other hand, both FcgRII and 
FcgRIII have a lower binding affinity than that of FcgRI, shown in Figure 1.5, and 
only interact with aggregated IgGs such as immune complexes (IC) (Boross et al., 
2008). The interaction of IgG-IC or IgG-coated targets with FcgRs leads to the 
transduction of either an activating or inhibitory signal. The activating signal is 
mediated through the immunoreceptor tyrosine-based activation motif (ITAM) which 
is located either in the cytoplasmic domain of the receptor, as in the case of FcgRIIa 
and FcgRIIc, or the associated FcR g chain homodimer, as is the case for FcgRI and 
FcgRIIIa, as shown in Figure 1.5. On the other hand, FcgRIIb is the only receptor 
that transmits an inhibitory signal via the immunoreceptor tyrosine-based inhibitory 
motif (ITAM) that is located in the cytoplasmic domain of the receptor (Boross et al., 
2008; Guilliams et al., 2014). It has been reported that Fcgriib (the gene encoding 
FcgRIIb) knockout mice generate a stronger immune response both in vivo and in 
vitro (Nimmerjahn and Ravetch, 2008). In addition, dendritic cells (DC) 
demonstrated a spontaneous maturation when they were deficient in FcgRIIb 
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expression (Nimmerjahn and Ravetch, 2008). 
 
The diversity of FcgRs is further extended by the presence of polymorphisms in their 
extra- and intra-cellular domains. For example, two single amino acid substitutions at 
position 27 and 131 of the extracellular domain of human FcgRIIa gave rise to two 
variants, namely  low-responder (Trp27 and His131) and high responder (Glu27 and 
Arg131), which reacted differently to mouse IgG1 (Warmerdam et al., 1990). On the 
other hand, it was found that the cytoplasmic domain of FcgRIII expressed by NK 
cells had an extension of 21 amino acids when compared to the FcgRIII expressed by 
PMN cells and that this difference was due to a change in the expression of a 
transcript which replaced the UGA termination codon to CGA and extended 
corresponding protein translation (Ravetch and Perussia, 1989). Finally, Bruhns and 
colleagues sensationally investigated the specificity and affinity of different human 
Figure 1.5: A diagram illustrating the expression of different human Fcg receptors (FcgRs) by 
different immune cells and their binding affinity. Based on their function, different FcgRs can 
mediate either activating signals via ITAM (green box) or inhibiting signals via ITIM (red box). 
FcgRIIIb is a glycosylphosphatidylinositol (GPI)-linked activating receptor that has no intracellular 
tail. PMN cells are polymorphonuclear leukocytes, such as NK cells, eosinophils and basophils. 
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FcgRs, including polymorphic variants, for all human IgG subclasses (Bruhns et al., 
2009). The authors demonstrated that most human FcgRs had a measureable affinity 
for all IgG subclasses except for FcgRI, which did not bind IgG2, and FcgRIIIb, 
which did not bind IgG2 and IgG4, when binding to either monomeric or IC form of 
IgG (Bruhns et al., 2009). In addition, different binding affinities were observed for 
all IgG subclasses on different FcgRs. For instance, IgG3 bound FcgRIIIb with an 
affinity 25-fold higher than IgG4 and IgG1 bound FcgRIIa approximately 5 fold 
higher affinity than IgG3. It was also shown that FcgRIIIaV158 is a high affinity 
receptor for IgG3 but not IgG1, IgG2 and IgG4 (Bruhns et al., 2009). These findings 
suggests that the binding affinity and specificity of FcgRs to IgG is dependent not 
only on the different types of receptor or IgG subclasses but also on the 
polymorphism on the receptor and IgG subclasses . 
 
1.7.2 Neonatal Fc receptor (FcRn) 
In human, IgG1, IgG2 and IgG4 have a long plasma half-life of around 21 days 
except IgG3 which is around 7 days (Morell et al., 1970; Janeway et al., 2001d) 
when compared to the other antibodies (5-8 days for IgA and IgM) (Janeway et al., 
2001d). The reason for the shorter half  life of IgG3 is due to a key amino acid 
residue substitution which affected FcRn binding and will be explained below. More 
importantly, IgG is the only antibody that is transferred from the mother to the foetus 
via the placenta to provide short term immunity (Roopenian and Akilesh, 2007; 
Brekke and Sandlie, 2003). The long plasma half-life and specific transport of IgG 
are found to be associated with a unique Fc receptor known as the neonatal Fc 
receptor (FcRn) (Roopenian and Akilesh, 2007; Burmeister et al., 1994). 
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FcRn is expressed by different cell types, such as epithelial cells, endothelial cells, 
placental syncytiotrophoblasts, dendritic cells and macrophages, within the 
endosome and also on the cell surface (Boross et al., 2008; Roopenian and Akilesh, 
2007). The general structure of FcRn is similar to that of MHC Class I molecule in 
that the FcRn is a heterodimer consisting of a MHC Class I-like heavy chain 
associating with a b2-microglobulin, as shown in Figure 1.6A. The crystal structure 
of rat FcRn with human IgG Fc complex had been solved and the binding site of 
FcRn on IgG Fc region is located at the CH2-CH3 domain interface as shown in 
Figure 1.6 (Roopenian and Akilesh, 2007; Burmeister et al., 1994). More importantly, 
Figure 1.6: A schematic diagram illustrating the characteristics of neonatal Fc receptor (FcRn). A) 
The general structure of FcRn. The FcRn heavy chain (purple), that consists of three extracellular 
domains, pairs with b2-microglobulin (red). B) FcRn binds to the CH2-CH3 domain interface of 
IgG Fc region. C) The solved crystal structure of rat FcRn: human IgG Fc complex (PDB ID: 
1FRT). Different domains of each of the proteins are highlighted in different colours. Purple, FcRn 
heavy chain; Red, b2-microglobulin; Blue, single heavy chain of human IgG Fc region. 
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the authors observed that the stoichiometry of FcRn:IgG was 2:1 (Burmeister et al., 
1994). Uniquely among different Fc receptors, the association of FcRn with IgG is 
strictly dependent on pH. At normal physiological pH 7.4, FcRn does not bind to IgG. 
However at an acidic pH of 6.0-6.5 FcRn will interact strongly with IgG (Roopenian 
and Akilesh, 2007). The key residues in IgG that are involved in the association with 
FcRn are Ile253, His310, His433 and His435, indicated in Figure 1.3. Notably, 
His310, His433 and His435 get protonated at acidic pH 6-6.5 and form salt bridges 
with anionic residues Glu117, Glu132 and/or Glu135 and Asp137 on the heavy chain 
of FcRn. On the other hand, hydrophobic residue Ile253 interacts with Trp133 of 
FcRn (Roopenian and Akilesh, 2007). For IgG3, the amino acid in position 435 was 
found to be an arginine instead of histidine (Stapleton et al., 2011). This substitution 
of H435 to R435 of IgG3 does not abolish FcRn-mediated recycling but the FcRn 
dependent recycling activity was significantly inhibited when IgG1, which has H435, 
is present (Stapleton et al., 2011). Further findings demonstrated that IgG3 allotype 
which contained H435 had a comparable FcRn binding to IgG1 (Stapleton et al., 
2011). At physiological pH 7.4, the histidine residues are deprotonated and it is 
possible that the interaction of Ile253 alone is not sufficient to maintain a secure 
binding. Thus, the interaction of FcRn/IgG Fc is abolished. Nonetheless, it is this pH 
dependent manner of FcRn that helps to prolong IgG plasma half-life and transport 
IgG across the placenta. For placental transfer, as indicated in Figure 1.7A, it is 
expected that syncytiotrophoblasts which are bathed in maternal blood internalise 
serum maternal IgG into endosomes. The endosomes are gradually acidified and 
when the pH drops to pH 6.0-6.5 FcRn binds to the IgG Fc. The IgG containing 
endosome then transports the FcRn bound IgG by fusing with the cellular membrane 





FcRn with IgG is abolished and the maternal IgG is released into the foetal blood 
circulation.  
 
In the context of immune defence system, IgG in lamina propria is endocytosed by 
FcRn expressing epithelial cells lining the mucosal site or gut lumen and the 
subsequent association with FcRn in acidified endosomes protects the IgG from 
degradation and allows the IgG to be transported to the extracellular environment to 
encounter foreign antigens (Pyzik et al., 2015; Dickinson et al., 1999), as shown in 
Figure 1.7B.  More importantly, antigens that are bound by IgG forming IC can be 
endocytosed by the same epithelial cells lining the mucosal site or gut lumen (Pyzik 
et al., 2015; Dickinson et al., 1999). Using the similar transport mechanism 
involving FcRn, the IgG IC are transported from the gut lumen or mucosal sites 
across the FcRn-expressing epithelial cell into the lamina propria in which dendritic 
cells are present (Pyzik et al., 2015). Such a mechanism allows the presentation of 
foreign antigens to dendritic cells which could stimulate a suitable immune response 
as a defensive mechanism to prevent foreign pathogen invasion.  
 
In normal circulation, as indicated in Figure 1.7C, serum IgG is expected to be 
internalised via endocytosis by endothelial cells lining the blood vessels into 
endosomes. The endosomes are gradually acidified and when the pH drops to pH 
6.0-6.5 FcRn binds to the IgG Fc and prevents it from being degraded. Weflen and 
colleagues showed that unbound FcRn and FcRn bound to monomeric IgG were 
sorted into recycling sorting tubules, which emerged from early endosomes, and 
directed the FcRn receptor and IgG away from lysosomal degradation 
pathway(Weflen et al., 2013), which other endocytosed materials are destined to  
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enter.  In contrast, cross linking of FcRn by IgG-IC was demonstrated to enter the 
lysosomal pathway and be degraded (Weflen et al., 2013). Monomeric IgG which 
bound to FcRn is then recycled and transported back to extracellular surface where it 
is released at pH 7.4. This process prolongs the plasma half-life of IgG (Roopenian 
and Akilesh, 2007).  
 
Finally, FcRn was recently found to be involved in promoting antigen cross 
presentation to activate cytotoxic T cells (Baker et al., 2013; Baker et al., 2011; 
Baker et al., 2014). More details on the role of FcRn in promoting antigen cross 
presentation will be described in Chapter 6. In brief, a similar mechanism of IgG 
recycling was identified. However, instead of recycling IC containing IgGs and their 
antigen, the IC were sorted into antigen processing vesicles after the FcRn 
association. In the process, antigen digestion will occur and derived peptides can be 
presented on MHC-Class I molecules, leading to cytotoxic T cell activation (Baker et 
al., 2013; Baker et al., 2011; Baker et al., 2014).  
 
1.8 Hinge region 
The hinge region separates the Fab arms from the Fc region. Notably the hinge 
length varies considerably between immunoglobulin isotypes, even those of the same 
class. For example, the hinge of human IgG1 (hIgG1) comprises 17 amino acids, 
human IgA2 has a hinge of 7 amino acids, while that of human IgG3 is much longer, 
stretching to 63 amino acids (Burton, 1987). More importantly, the variability of the 
differences in hinge length applies to other immunoglobulins from different species 
as well.  
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For IgG, the hinge region can be divided into three sections, the upper hinge, the 
middle hinge and the lower hinge, as defined by Burton (1987). The upper hinge 
starts immediately after the cysteine residue that forms the disulphide bond with light 
chain and continues until the amino acid residue immediately before the subsequent 
cysteine residue, which forms the disulphide bond with heavy chain. The middle 
hinge, also known as the core hinge, starts from the first cysteine residue that forms 
an inter heavy chain disulphide bond and continues to the last cysteine residue that 
forms such a bond. Finally, the lower hinge starts immediately after the last cysteine 
residue of the middle hinge and continues until the start of the CH2 domain. Using 
human IgG1 as an example, the upper hinge is formed by Asp221-Thr225, the 
middle hinge consists of Cys226-Cys229 and the lower hinge is made up of Pro230-
Gly237, as shown in Figure 1.8A. On the other hand, the hinge region of human IgA 
is not categorised into different sections as human IgG1 because after the Cys220 
that forms disulphide bonding with light chain, the next cysteine residue, Cys241, is 
located at the start of the CH2 domain. As a result, the entire section from Cys220 to 
Cys241 of human IgA1 is considered as the hinge region of the antibody (Burton, 
1987), as shown in Figure 1.8B. 
 
To enable a better look into the diversity and variation of the hinge region of 
different antibodies, a comparison of the hinge regions of different IgG and IgA 
antibodies of different species is shown in Figure 1.8.  For IgG antibodies, human 
IgG1 is used as a guide to align all other different IgG antibodies together, according 
to the amino acid residues mentioned earlier which define the three hinge sections. 
As indicated in Figure 1.8A, the hinge regions of different IgG antibodies differ 





 Figure 1.8: Alignment of the amino acid sequences of the hinge region of different immunoglobulins from various species using COBALT 
(https://www.stva.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?CMD=Web). A) Different IgG antibodies from various species are aligned with human IgG1. The 
hinge region of IgG is divided into three sections; upper hinge, middle hinge and lower hinge. Upper hinge starts after Cys220 that forms a disulphide bond with 
light chain and ends before Cys226 that forms the first inter-heavy chain disulphide bond. Middle hinge starts with Cys226 and ends with Cys229 that forms the 
last inter-heavy chain disulphide bond. Lower hinge starts with Pro230 and ends just before Pro238 which is the start of the CH2 domain. B) Different IgA 
antibodies from various species are aligned with human IgA1. The hinge region of IgA1 starts at Cys220 that forms a disulphide bond with light chain and ends 
just before Cys241 which is the start of CH2 domain. The numbering listed is according to the EU numbering of human IgG1 and the BUR numbering of IgA1 
(Putnam et al., 1979). RheMa, Rhesus macaque; W.Boar,  Wild BoarB.F. Bat, Black fruit bat. 
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IgG3 is significantly longer than that of any other IgG antibodies. On the other hand, 
the lower hinge region seems to be quite conserved between different IgG antibodies 
in which the lower hinge consists of different combinations of prolines (P), glutamic 
acid (E), leucine (L) and glycine (G). In particular, the region Leu234-Gly237 of 
human IgG1 which is critical for binding to FcgRs seems to be partly conserved 
across IgGs of different species. However, some IgGs exhibited 1-2 amino acids 
substitutions as shown in Figure 1.8A which have been shown to have major impact 
on FcgR binding (Woof et al., 1986). In contrast, according to the hinge of human 
IgA1 the hinge region can be defined as starting after Cys220 that forms a disulphide 
bond with light chain and ending with the subsequent cysteine residue, Cys241, that 
forms a disulphide bond with heavy chain and which is located at the start of the 
CH2 domain. Different IgA antibodies are aligned based on the hinge region of 
human IgA1 as indicated in Figure 1.8B. 
 
The hinge region is particularly important because it keeps the Fab arms distanced 
away from the Fc region thereby allowing access by C1q and FcgRs to the upper 
parts of the Fc region. Hinge deleted human IgG1 antibodies such as Mcg (Guddat et 
al., 1993), Dob (Silverton et al., 1977) and Lec (Rivat et al., 1976) have been shown 
to be unable to activate complement or bind Fcg receptors (Klein et al., 1981). All 
these mutant antibodies have a 15 amino acid hinge deletion which starts after 
Val216, resulting in complete loss of the upper and middle hinge (Rivat et al., 1976; 
Guddat et al., 1993; Steiner and Lopes, 1979). The lower hinge region which 
contains the core binding site for FcgRs, as described earlier, was not deleted. 
However, the failure of all three antibodies to associate with FcgRs was suggested to 
be due to the obstruction at the FcgR binding site due to close approach of the CH1 
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and CH2 domains because of the hinge deletion (Guddat et al., 1993; Silverton et al., 
1977). The same reasoning was suggested for failure in complement fixation of Mcg, 
Dob and Lec as the binding site for C1q was located at the top region of CH2 domain, 
as indicated in Figure 1.3. Such studies support the notion that separation of the Fab 
arms away from the Fc region by the hinge region is one of the major factors in 
initiating proper Ig effector mechanisms. 
 
1.8.1 Antibody flexibility involving the hinge region 
The flexibility of an antibody can be divided into two categories, segmental 
flexibility and hinge flexibility, as shown in Figure 1.9. Segmental flexibility 
involves the region between two domains, such as the region that connects VH to 
CH1 or CH2 to CH3, which is a very small region that consists of around 5-6 amino 
acid residues. It is believed that this small domain-connecting region grants small 
free movements to the connected domains as a whole to move about, as indicated in 
Figure 1.9A, for better positioning to conduct antibody function such as antigen or 
receptor interaction. For the region involving VH-CH1, segmental flexibility is likely 
to help in coordinating a more precise match with epitope orientation leading to a 
more secure antigen binding. In contrast, segmental flexibility of the region 
involving CH2-CH3 in IgG is likely to help in exposing the histidine residues critical 
for association with FcRn.  
 
The importance of segmental flexibility was established by structural analysis of IgM 
and IgE because both these antibodies lack the hinge region. Instead they possess an 
additional constant domain (CH2), and therefore, any structural bending observed is 
most likely due to segmental flexibility. Feinstein and Munn used electron 
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microscopy to analyse the structural features of pentameric IgM and showed that 
upon binding to Salmonella flagella the pentameric IgM adopted a conformational 
structure resembling a “table” in which the Fab arms were bent about 90º to the Fc 
region (Feinstein and Munn, 1969). Although the exact location of the bend was not 
reported, the only possible position for the bend was the region connecting the 
domains together. On the other hand, Drinkwater and colleagues used several 
techniques such as molecular dynamics and protein crystallisation and showed that 
IgE could adopt both linear or bent conformations in solution, which further 
demonstrated the presence of segmental flexibility (Drinkwater et al., 2014). Finally, 
segmental flexibility is also shown by studies analysing the angle, termed the elbow 
angle, between two domains (Saphire et al., 2001; Stanfield et al., 2006; Guddat et 
al., 1993). It was reported that the elbow angle between pairs of variable and 
Figure 1.9: A schematic diagram illustrating the potential flexibility of a human IgG1 molecule. A) 
Segmental flexibility which occurs at the region that connects two domains together and allows 
small free movements to each of the connected domains as a whole. B) Hinge flexibility uses the 
middle hinge which contains the interchain disulphide bonds as a central point and grants the upper 
and lower hinge region certain flexibility to enable both Fab arms and Fc region to take up different 
positions conducive to better antigen/receptor binding. Hinge flexibility assumes that the hinge 




constant domains of different crystallised antibodies were 118º for Mcg (hingeless 
hIgG1), 147º for Dob (hingeless hIgG1) and 174º for Kol (hIgG1) while those 
recorded of B12 (hIgG1) were 170º and 174º (Saphire et al., 2001; Guddat et al., 
1993). In addition, Stanfield and colleagues developed a programme which used the 
crystallised Fab 8F5 fragment as a standard and aligned up to 536 different 
crystallised Fab fragment structures deposited in the RCSB Protein Data Bank (PDB) 
to analyse the diversity of the elbow angles of antibody Fab regions (Stanfield et al., 
2006). The authors reported that the elbow angle ranged from 115º to 225º and that 
the majority of Fab fragments containing lambda light chains showed a greater elbow 
angle than those containing kappa light chains (Stanfield et al., 2006). All these 
reported different elbow angles suggest that segmental flexibility might be an 
important structural feature in antibody functionality, such as antigen or receptor 
binding. 
 
On the other hand, hinge flexibility is granted by the hinge region and refers to the 
flexibility of the antibody which uses the core hinge that contains the interchain 
disulphide bonds as central point and enables both the Fab arms, via upper hinge 
flexibility, and Fc region, via lower hinge flexibility, to take up different positions 
conducive for better antigen/receptor binding, as indicated in Figure 1.9B. These 
flexibilities are highly dependent on the upper hinge and lower hinge amino acid 
residue compositions and it is assumed that both regions are flexible rather than rigid 
rod-like structures. Hinge flexibility, presumably upper hinge flexibility, was 
elegantly demonstrated by Roux and colleagues in a study utilising various wildtype 
and hinge modified mutant antibodies of identical antigen specificity (idiotype). 




to form polymeric complexes and it was shown that they formed different complexes 
ranging from dimers to tetramers or higher polymers, using electron microscopy 
(Roux et al., 1998). This observation suggested that the upper hinge region has a 
certain degree of flexibility because higher polymeric complexes such as tetramers 
were expected to form only when the Fab arms are more “open”, as indicated in 
Figure 1.10B. In addition, the crystal structure of the anti-HIV human IgG1, B12, 
showed that the Fab arms adopted an asymmetrical conformational structure which 
suggests that the upper hinge had a certain degree of flexibility (Saphire et al., 2001). 
On the other hand, the flexibility of the lower hinge region of IgG was shown by the 
crystal structure of human IgG1 Fc in complex with FcγRIII in which the lower 
hinge region was bent to a certain angle relative to the Fab for successful association 
with FcγRIII (Sondermann et al., 2000). Finally, hinge flexibility was demonstrated 
in the studies performed by Sandin and colleagues in which they used cryo-electron 
tomography to analyse the conformation of murine IgG2a in solution (Sandin et al., 
Figure 1.10: A schematic diagram illustrating the different immune complexes formed, due to 
different Fab arms arrangements. A) Formation of dimeric immune complex due to the Fab 
arms being “close” together, causing a bivalent binding of one anti-Id antibody to a single Id-
antibody. B) Formation of tetrameric immune complex due to the Fab arms being more 
“open”, allowing each anti-Id antibody to bind two different Id antibodies. Idiotype (Id) 
antibody, blue and yellow. Anti-Id specific antibody, red and green. 
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2004) . The authors aligned the Fc region of four different IgG2a structures together 
and showed that the Fc regions were very similar to each other. However, the Fab 
arms of each of the IgG2a molecules demonstrated different conformational 
structures and positions, strongly suggesting the presence of hinge flexibility (Sandin 
et al., 2004). In a different study, the angle between two Fab arms, termed hinge 
angle, of several crystallised antibodies had been compared together (Saphire et al., 
2002). It was reported that the hinge angle of B12 (hIgG1) was 148º, Mcg (hingeless 
hIgG1) was 185º and Kol (hIgG1) was 132º while that of a murine IgG2a, 231, and a 
murine IgG1, 61.1.3, were 172º and 115º respectively (Saphire et al., 2002). These 
reported hinge angles hint at the diversity of the different conformers that the Fab 
arms of an antibody can adopt at different times due to the flexible movement 
granted, most likely, by the upper hinge region. 
 
1.8.2 Hinge proteolysis 
Antibodies form one of the major defences against bacterial pathogens. As a result, 
some bacterial pathogens have evolved to produce proteases which target 
immunoglobulins, causing lost of functionality. The hinge region is the site mainly 
targeted by different proteases. In particular, the hinge region of human IgA1 is 
found to contain several bacterial protease cleavage sites (Mistry and Stockley, 2011), 
as shown in Figure 1.11. IgA1 proteases seemingly have only one purpose which is 
to abolish the effector function of IgA1 in mucosal secretions by cleaving the 
antibody into three fragments, i.e. two Fab and one Fc fragments. The Fab fragments 
may still bind to target pathogen, however, elimination mechanisms such as 
respiratory burst or phagocytosis cannot be initiated due to the absence of the Fc 
fragment. Thus, the survival and invasion rates of the protease-secreting pathogen is  
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greatly increased.  
 
The hinge region of IgA1 mainly consists of a mixture of proline, serine and 
threonine residues. Notably, all identified IgA1 proteases cleave the hinge region at 
sites C-terminal to a proline residue, such as proline-serine or proline-threonine 
bonds, as indicated in Figure 1.11A. Intriguingly, the presence of protease binding 
sites within the hinge do not necessarily always lead to cleavage as it seems that 
Figure 1.11: A schematic diagram illustrating sites in the hinge regions of human  
IgA1 and IgG1 that are susceptible to cleavage. A) Identified cleavage sites for bacterial proteases 
within the hinge region of human IgA1. B) Identified cleavage sites within the hinge region of 
human IgG1 for different proteases. Diagram adapted from (Mistry and Stockley, 2011; Janeway et 
al., 2001c) and (Brezski and Jordan, 2010). 
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there are certain requirements for the cleavage to happen (Senior et al., 2000; Senior 
and Woof, 2005). In brief, Senior and colleagues generated a human IgA2/A1 mutant 
antibody by inserting a seven amino acid sequence derived from human IgA1 into 
the hinge region of human IgA2 and carried out enzyme cleavage on the IgA2/A1 
antibody. The new hinge sequence of IgA2/A1 contained cleavage sites for the IgA1 
proteases of S. pneumoniae and S. oralis. However, only the protease from S. 
pneumoniae and not S. oralis was able to cleave the IgA2/A1 antibody, suggesting 
that the protease of S. oralis required additional factors to mediate efficient cleavage 
(Senior et al., 2000). The same group later performed different combinations of 
amino acid substitutions and subtractions at the hinge region of the IgA2/A1 
antibody and showed that some IgA1 proteases required a certain distance between 
Fab and Fc region to carry out the protease cleavage (Senior and Woof, 2005). 
Notably, some proteases that cleave at the IgA1 hinge region were found to require 
certain recognition sites within the CH3 domain of IgA1 in order to carry out the 
cleavage activity (Chintalacharuvu et al., 2003; Senior and Woof, 2006). 
 
On the other hand, human IgG has also been identified to contain several cleavage 
sites for different proteases (Brezski and Jordan, 2010; Virella and Yeh, 1977; Baici 
et al., 1982), as indicated in Figure 1.11B.  Notably, some of the proteases that 
cleave human IgG are endogenous enzymes, such as plasmin, Cathepsin G and 
Human Neutrophil Elastase (HNE). As an example, plasmin is an enzyme found in 
the blood and is involved in wound healing mechanisms. Similarly, IgG is also 
highly found in the blood. Thus, the presence of plasmin might be considered as a 
threat to antibody functionality. However, it is not known if the cleavage of IgG by 
plasmin happens spontaneously in vivo. Intriguingly, Virella and Yeh showed that 
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although the same classes of different monoclonal human IgGs were used during the 
plasmin cleavage experiment, different monoclonal antibodies showed different 
susceptibility to plasmin cleavage (Virella and Yeh, 1977). For instance, when three 
different monoclonal hIgG1s, WEI, GIA and STO, were incubated with plasmin for 
up to 72 hours, both WEI and GIA were cleaved by plasmin but not STO (Virella 
and Yeh, 1977). Similar to the case with IgA1, pathogenic bacteria have developed 
certain proteases to cleave human IgG as a means to survive. Such proteases include 
glutamyl endopeptidase V8 (GluV8) of Staphylococcus aureus and immunoglobulin-
degrading	enzyme of Streptococcus pyogenes (IdeS) (Brezski and Jordan, 2010). For 
example, IdeS was shown to cleave IgG at the Gly236-Gly237 bond that is located 
within the IgG lower hinge region crucial for FcgR binding (von Pawel-Rammingen 
et al., 2002). Indeed, IdeS treatment of S. pyogenes that had been pre-incubated with 
immune plasma prevented the bacteria being killed when they were further incubated 
with phagocytes. The survival of S. pyogenes is most likely due to the abolishment of 
IgG effector function after IgG Fc region cleavage by IdeS. In comparison untreated 
S. pyogenes were readily killed (von Pawel-Rammingen et al., 2002). Interestingly, it 
was later discovered that IdeS has a second binding site at the IgG Fc region and that 
this IgG Fc binding is required for the cleavage activity of IdeS at the lower hinge 
region of IgG (Vincents et al., 2004). Interestingly, such a finding is reminiscent of 
the requirement of certain hIgA1 proteases for Fc elements in order to drive efficient 
substrate cleavage, as mentioned above. 
 
The cleavage of immunoglobulins not only abolishes their effector function but can 
also result in induction of an antibody response against the cleaved Fab and Fc 
fragments. Antibodies capable of recognising cleaved Fab and Fc fragments were 
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found to be very specific in their antigen recognition which is against the cleaved site 
of the fragments, especially the C-terminal neoepitopes of Fab or F(ab´)2 (Ryan et al., 
2008; Falkenburg et al., 2017; Terness et al., 1995). As a result, these antibodies are 
also known as anti-hinge antibodies (AHA). AHA were reported to be found in the 
serum of healthy individuals and patients suffering from rheumatoid arthritis (RA) or 
systemic lupus erythematosus (SLE) (Falkenburg et al., 2017). In addition, AHA 
were also identified in the synovial fluid of patients with rheumatoid arthritis (Ryan 
et al., 2008). The immunogenic effect of these Fab and Fc fragments along with 
AHA is not entirely clear yet. However, studies had shown that the immune 
complexes formed by Fab fragments and AHA seems to have a role in complement 
amplifications (Fumia et al., 2008). The CH1 domain of IgG contains a binding site, 
mainly Ser132, for the complement cascade protein, C3b. However, the formation of 
C3b-IgG is considered to be a rare event (Vidarte et al., 2001; Shohet et al., 1993). 
To investigate the link between Fab fragment, AHA, and complement amplification, 
Fumia and colleagues generated F(ab´)2 fragments by utilising pepsin digestion and 
incubated these with AHA purified from pooled whole human IgG to generate 
F(ab´)2-IC. Using 125I-iodinated C3 to monitor C3 activation, the authors showed that 
F(ab´)2-IC had a stronger C3 activation when compared to control IgG-IC (Fumia et 
al., 2008). More importantly, a weak C3 activation was observed when F(ab´)2 was 
incubated in AHA depleted plasma. However, when AHA was reintroduced into the 
plasma the activation of C3 was dramatically increased (Fumia et al., 2008),  
suggesting that the AHA played a major role in complement amplification. It is 
suggested that the formation of F(ab´)2-IC increased the overall conformational 
stabilisation of F(ab´)2 and allowed a higher probability of C3b activation due to 
more concentrated binding sites being available within F(ab´)2-IC (Fumia et al., 2008; 
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Lutz and Fumia, 2008). 
 
1.9 Different antibody formats and engineering 
With the increasing knowledge on antibody biology, modification of the structural 
features of immunoglobulins, also known as antibody engineering, has been vastly 
conducted with the ultimate aim of improving antibody functionality for therapeutic 
applications.  
 
The identification that the antigen binding site is governed by the CDR generated the 
idea of grafting the CDRs of a mouse monoclonal antibody, (i.e. homogeneous 
antibody derived from a single clone), into a human IgG for therapeutic purposes 
(Queen et al., 1989; Carter et al., 1992; Harding et al., 2010). For example, Queen 
and colleagues attempted to transfer the CDRs of a mouse monoclonal anti-human 
interleukin 2 receptor (IL-R2) to a human IgG1 that had high homology to the 
original mouse antibody within the framework regions (Queen et al., 1989). The 
authors reported that the so-called humanised antibody had a binding affinity for IL-
R2 about 1/3 of that of the murine antibody (Queen et al., 1989). This approach has 
greatly enhanced the use of humanised antibodies in clinical applications. However, 
some humanised antibodies are reported to be immunogenic (Getts et al., 2010; 
Harding et al., 2010). It was believed that the murine/rodent CDRs grafted into 
human antibodies contain epitopes that can stimulate the production of host 
antibodies and/or be presented on MHC Class II molecules which activate T helper 
cells, causing the production of cytokines that result in upregulation of an undesired 
immune response (Getts et al., 2010; Harding et al., 2010). To tackle this obstacle, 
Lee and colleagues inserted the entire human immunoglobulin variable region 
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repertoire into the genome of mouse embryonic stem cells and silenced the mouse 
variable region genes (Lee et al., 2014). This approach resulted in the generation of 
unique mice which are capable of producing antibodies with human variable regions 
and mouse constant domains (Lee et al., 2014). More importantly, the variable 
region of these antibodies can be cloned and fused with different human 
immunoglobulin constant domains to generate fully human antibodies with minimal 
immunogenicity for therapeutic purposes. Over the years, besides the improvement 
in the generation of humanised monoclonal antibodies, different antibody formats 
have been generated through antibody engineering and some them are described in 
Figure 1.12.  
 
Sometimes the antigen epitope that is targeted is well hidden within a tissue structure 
and accessibility to the epitope might be hindered by neighbouring structural features. 
In such a scenario, the full length antibody might be too large to gain access to the 
target epitope. However, the antibody could be cleaved at the hinge region to 
produce smaller antigen binding fragments, such as F(ab´)2 or Fab fragments, to 
achieve better penetration into tissues to reach the target epitope. Indeed, the use of 
F(ab´)2 and Fab fragments has yielded promising results for radioimmunotherapy in 
mouse models when compared to full length monoclonal IgG antibody. This 
outcome was reasoned to be due to an improved and homogenous tumour uptake 
because of the smaller molecular size of F(ab´)2 and Fab fragments (Behr et al., 2000; 
Sandström et al., 2012).  
 
An scFv molecule has a molecular weight even smaller than that of an Fab fragment 




Figure 1.12: A schematic diagram illustrating the different antibody formats that have been 
engineered. A) Full length antibody. B) Full length antibody is cleaved at the lower hinge region to 
produce F(ab´)2. C) Full length antibody is cleaved at the upper hinge region to produce two Fabs. 
D) Both variable domains of light and heavy chains are joined together by a linker peptide to 
produce scFv. E) Two scFvs are joined together by a linker peptide to produce a tandem scFv. 
When one of the scFv is targeting a T cell receptor, the molecule is also known as a Bi-specific T-
cell engager (BiTE). F) Two scFvs are fused to the Fc region of an antibody to produce scFv-Fc. 
G) A full length antibody capable of recognising two different target antigens is known as a 
bispecific antibody. H) Four different variable domains of light and heavy chains are joined 
together to produce a diabody which can bind two different target antigens. I) A desired protein 
fused to the Fc region of an antibody to produce an Fc-fusion protein. 
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together by a peptide chain, and yet it retains the original antigen binding capability 
(Chames et al., 2009). The development of scFv started when Inbar and colleagues 
could produce the Fv demonstrated that cleavage of a Fab fragment of murine IgA 
under acidic conditions fragment and yet still retain the antigen binding capability 
(Inbar et al., 1972). scFv is a very small monovalent molecule and was reported to 
have a plasma half-life of only around 2 hours (Chames et al., 2009). Thus, it is 
expected that scFv may have limited clinical application. As a result, scFv is usually 
fused to other proteins to achieve a target specific homing mechanism. For example, 
Lorenzo and colleagues fused human anti-ErbB-2 receptor scFv to human RNase and 
showed that cell toxicity was achieved in a dose dependent manner in ErbB-2-
positive cells (Lorenzo et al., 2004). In addition, two scFvs can be fused together to 
generate a product called a tandem scFv, as indicated in Figure 1.12. One of the 
significant achievements based on tandem scFv was the development of Bi-specific  
T-cell engagers (BiTE) (Huehls et al., 2015; Smits and Sentman, 2016). BiTE 
molecules are bispecific tandem scFv in which one of the target antigens is a T cell-
specific molecule, usually the T cell receptor component CD3, while the other target 
antigen is a tumour-specific molecule (Huehls et al., 2015; Smits and Sentman, 
2016). It appears that both antigen binding sites of BiTE must be associated with 
target antigens to stimulate cytotoxicity activity from T cells. Indeed, no expression 
of cytokines related to the activation of T cells, such as interferon gamma and 
tumour necrosis factor alpha (TNF-a), were observed in the absence of dual antigen 
binding (Smits and Sentman, 2016). In 2014, Blinatumomab (anti-CD19 and anti 
CD3) was the first BiTE to be approved by the US Food and Drug Administration 
(FDA) to treat Philadelphia chromosome–negative relapsed or refractory precursor 
B-cell acute lymphoblastic leukaemia (R/R ALL) (Przepiorka et al., 2015). 
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Although these different small fragments derived from antibody engineering have 
shown rewarding results in terms of tumour penetration and specific protein homing 
mechanisms, they all suffer from short plasma half-life mainly due to the absence of 
the IgG Fc region which could associate with FcRn to prolong plasma half-life, as 
described in earlier sections. Therefore, there are also different engineered antibody 
formats that preserved the IgG Fc region such as bispecific antibodies and Fc-fusion 
proteins. A bispecific antibody has dual antigen specificity as the name suggests. In 
the past, bispecific antibodies were generated by quadroma technology which is the 
fusion of two different hybridomas. One popular bispecific antibody called Triomab, 
is a fusion between rat IgG2b and murine IgG2a, enabling easy purification and the 
capability of activating human FcgRs (Lindhofer et al., 2011; Lindhofer et al., 1995). 
At present, many different techniques have been developed to improve the 
generation of bispecific antibodies, such as “knobs-into-holes” engineering 
(Ridgway et al., 1996) and Fab-arm exchange technology (Labrijn et al., 2013). 
'Knobs-into-holes' engineering utilises a single amino acid change of T366Y to 
generate the “knob” in the CH3 domain of one heavy chain and another mutation 
Y407T to generate the “hole” in the CH3 domain of the other heavy chain (Ridgway 
et al., 1996). The authors reported that the generation of bispecific antibody due to 
the pairing of “knobs-into-holes” technology represented up to 92% of the protein 
pool when compared to the pairing of wildtype heavy chains, which was up to 57% 
(Ridgway et al., 1996). On the other hand, Fab-arm exchange technology introduces 
single matched point mutations of K409R at one heavy chain and F405L in the other 
heavy chain to achieve a strong heterogeneous CH3 domain dimerization between 
two different heavy chains following mild reduction (Labrijn et al., 2013). Finally, 
Fc fusion proteins represent a unique from of antibody engineering because the Fab 
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region of the antibody is replaced with an unrelated protein while the Fc region is 
retained, indicated in Figure 1.12I. Further details on Fc-fusion proteins are 
described in the next section. 
 
1.10 Fc-fusion proteins 
As mentioned above, Fc-fusion proteins involve the fusion of a desired protein to the 
Fc region of an antibody, usually hIgG1 Fc, although the use of IgA and IgM Fc has 
also been attempted (Czajkowsky et al., 2012). The reason for this is mainly to take 
advantage of the long plasma half-life of IgG through association with FcRn 
(Roopenian and Akilesh, 2007; Czajkowsky et al., 2012) and to obtain a slower renal 
clearance due to a larger size granted by the Fc region (~50kDa) (Kontermann, 2011). 
Alternatively, because of the presence of the intact IgG Fc in Fc-fusion proteins, the 
effector function capability of IgG can be taken advantage of. For example, Fc-
fusion proteins can interact with FcgRs to induce ADCC activity (Deng et al., 2015; 
Sioud et al., 2015).  
 
There are several Fc-fusion proteins that have reached the clinic such as etanercept, 
alefacept, belatacept, aflibercept and abatacept (Czajkowsky et al., 2012). 
Intriguingly, all the Fc-fusion proteins listed above function as protein inhibitors. As 
an example, etanercept is a TNF-a inhibitor in which the TNF receptor is fused to 
the Fc region of human IgG1 (Haraoui and Bykerk, 2007). TNF-a is a trimeric 
cytokine produced mainly by activated macrophages and T cells and has a major role 
in immune regulatory responses (Haraoui and Bykerk, 2007). Two distinct cell 
surface TNF receptors, termed p55 and p75, exist and can be cleaved to produce 
soluble monomeric TNF receptor, which acts as natural TNF-a inhibitor (Haraoui 
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and Bykerk, 2007). Fusion of monomeric TNF receptor, p75, to IgG1 Fc generates a 
dimeric TNF-a binding protein (etanercept) due to IgG Fc being a homodimer 
protein itself (Mohler et al., 1993). As a result, and given the trimeric nature of TNF-
a, the avidity of etanercept is expected to be stronger than natural soluble 
monomeric TNF receptors. Indeed, etanercept was shown to have an increased 
binding affinity for TNF-a of up to 50-fold higher than that of monomeric TNF 
receptor. As a result, it has been shown to be able to prevent killing by a normally  
lethal dose of lipopolysaccharides (LPS) in mouse models, mainly by inhibiting the 
effector mechanisms of TNF-a (Mohler et al., 1993). More importantly, it was 
reported that the elevated serum levels of TNF after injection of LPS alone or LPS 
with human IgG (control) lasted for around 2 hours whereas it lasted at least 4 hours 
in mice injected with LPS and etanercept (Mohler et al., 1993), which is most likely 
due to the recycling capability of etanercept via FcRn association.  
 
Using conventional techniques, generation of an antigen-specific antibody suitable 
for clinical therapy takes a long time, because of the requirement for antigen 
immunisation, purification of antigen-specific antibodies from animal models, 
selection of suitable antibody with superior antigen specificity and high affinity, and 
humanisation of the monoclonal antibody before it can be used in clinical therapy. 
The production of antigen-specific Fc-fusion proteins allows one to bypass these 
procedures because the natural ligand/receptor of the target antigen may already have 
been identified, such as TNF-a and TNF receptor for etanercept. Thus, the fusion of 
this natural ligand/receptor to the antibody Fc is all it that is necessary to generate an 
“antibody-like” molecule that could bind specifically to targeted antigen and initiate 
antibody effector functions. Indeed, Deng and colleagues successfully generated a 
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Fc-fusion protein, termed NKp80-Fc, by fusing the natural killer cell-activating 
receptor (NKp80) to hIgG1 Fc because the availability of an antibody specific to the 
natural ligand of NKp80, activation-induced C-type lectin (AICL), was lacking 
(Deng et al., 2015). The authors reported that NKp80-Fc could direct NK cells to 
AICL-expressing leukaemia cells and trigger ADCC killing activity of NK cells in 
vitro (Deng et al., 2015). In an in vivo experiment, the introduction of a combination 
of NK cells and NKp80-Fc was shown to be able to inhibit tumour progression from 
AICL-expressing U937 xenografts in mouse models, in comparison to control, a 
combination of NK cells alone, or NK cells and hIgG (Mohler et al., 1993). Such 
findings suggest that Fc-fusion proteins may serve as an attractive alternative option 
to replace antibody-based therapies. 
 
Alternatively, Fc-fusion protein has also been used as a mode of transport to deliver 
antigenic vaccine across the mucosal barrier (Ye et al., 2011). Such transport is 
believed to be mediated mainly via FcRn. Ye and colleagues had fused the herpes 
simplex virus type-2 (HSV-2) glycoprotein gD to murine IgG2a Fc, hereby named as 
gD-Fc. Following immunisation of mice with the generated Fc-fusion protein via the 
mucosal pathway, they demonstrated that the immunised mice showed an efficient 
induction of antibody, B and T cell immune responses and could survive a lethal 
challenge with the relevant virus. It is most likely that gD-Fc was endocytosed by 
FcRn-expressing epithelial cells and upon introduction onto the mucosal surface and 
is transported across the epithelial barrier after associating with FcRn, as described 
earlier in Figure 1.7B. The gD-Fc is then expected to form immune complexes due to 
host antibody recognising the HSV-2 gD protein and being phagocytosis by nearby 
dendritic cells via FcgR-mediated phagocytosis. Finally, the gD-Fc is then digested 
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and presented on both MHC Class I and II, thus initiating a specific anti HSV-2 
immune response.  
 
In summary, all these findings suggest that the outcome of using Fc-fusion protein 
can be quite rewarding. However, many investigations have to be carried out upon 
generation of a new Fc-fusion protein to confirm the characteristics of the fused 
protein partner and the molecule as a whole in terms of its stability, binding affinity, 
and toxicity. 
 
1.10.1 Factors affecting the selection of fusion partner 
Although Fc fusion proteins are emerging as an alternative option in the generation 
of new therapeutic drugs due to some of the advantages mentioned earlier, there are 
certain factors that one has to take into consideration in the selection of the Fc fusion 
partner.  One of the factors is the stability of the selected protein after fusion with 
IgG Fc and in secreted soluble formation. If the protein partner becomes unstable 
after Fc fusion, it will not be able to carry out its intended function and might not be 
secreted because unstable protein usually suffers from protein misfolding and 
aggregation which ultimately leads to protein degradation (Del Pozo-Yauner et al., 
2015). For example, light-chain amyloidosis (AL) is one of the diseases that is 
caused by protein misfolding and aggregation which could ultimately leads to organ 
proteotoxicity and dysfunction. Thus, the stability of the fused protein has to be 
confirmed to avoid a similar outcome (Cooley et al., 2014).  Secondly, the binding 
affinity of the fused partner for its targeted antigen has to taken into consideration 
because the binding affinity of natural ligand/receptor interactions varies and might 
be rather low. The antibody Fc is a homodimeric molecule, and therefore the 
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generation of Fc fusion protein is expected to result in a slight increase in antigen 
avidity due to doubling of the binding sites for targeted antigen, which is similar to 
the structural feature of etanacept mentioned earlier. However, if the binding affinity 
of the dimeric fused protein is still low, one option is to generate a polymeric Fc-
fusion protein to increase overall binding avidity (Nagashima et al., 2011; Mekhaiel 
et al., 2011). Mekhaiel and colleagues successfully induced the formation of a 
hexameric Fc-fusion protein in an attempt to increase the association with FcgRII 
and FcgRIII, which only bind aggregated IgG IC, by inserting the 18 amino acid 
tailpiece of human IgM and mutating Leu309 to cysteine to enhance the formation of 
polymers (Mekhaiel et al., 2011). Therefore, this technique may be used in the case 
of low binding fusing partners to generate hexameric Fc-fusion proteins with 
improved overall binding avidity. 
 
1.11 Recombinant antibody technology 
Since the generation of a hybridomas capable of producing an infinite supply of 
identical monoclonal antibody (Kohler and Milstein, 1975), the technology in 
antibody production has expanded enormously. Currently, specific oligonucleotides 
can be used to clone the DNA sequences of the variable domains of an antibody and 
fuse these with the DNA sequences of different antibody heavy chain constant 
regions (Karu et al., 1995), including those of different species, to produce a desired 
complete monoclonal antibody DNA sequence. Subsequently, such DNA sequences 
are usually cloned into an expression vector and transfected into suitable host cells to 
drive the expression of the antibody. These techniques are known as “recombinant 
antibody technology”. Currently, there are a variety of both prokaryotic and 
eukaryotic hosts available for antibody production as reviewed by Frenzel et al. 
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(2013). In brief, Escherichia coli (E. coli) is one of the popular choices for a 
prokaryotic host since recombinant antibody expression in E. coli can yield up to 
several grams per litre of extracellular production (Frenzel et al., 2013). However, 
there are certain limitations in bacterial antibody expression. For instance, antibody 
fragments can only be produced in E. coli in the non-native state which is due to the 
incompetent protein folding mechanism that involves disulphide bonds (Skerra and 
Pluckthun, 1988; Frenzel et al., 2013). However, this obstacle can be overcome if the 
antibody fragment is directed to the oxidative periplasm of the bacterium which 
favours the formation of disulphide bonds (Skerra and Pluckthun, 1988; Frenzel et 
al., 2013). The production of the full length 150kDa antibody is quite challenging in 
bacterial expression due to the need of the correct homodimer pairing of the Fc 
region which involves disulphide bonding. Therefore, E. coli is usually selected for 
the expression of scFv due to its smaller molecular size and the fact that it does not 
require homodimer pairing (Skerra and Pluckthun, 1988). In addition, due to 
difference in post-translation modifications between prokaryotic and eukaryotic hosts, 
the successful expression of full length antibody is usually in an aglycosylated 
version in E. coli (Simmons et al., 2002; Mazor et al., 2007). One of the major 
problems with aglycosylated antibody is the significant reduction in the binding 
affinity  for FcgRs and C1q as mentioned earlier (Jefferis, 2005; Mazor et al., 2007; 
Simmons et al., 2002). Therefore, one has to consider the importance of the effector 
functions of the antibody product if E. coli is selected as the expression host. 
 
In regards to eukaryotic expression systems, almost 95% of clinically approved 
recombinant antibodies are produced by mammalian cells.  This choice is because 
mammalian cells have sufficient protein production machineries to handle 
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mammalian protein folding, post-translational modification and protein secretion, 
which makes the produced antibody almost indistinguishable from those expressed in 
the human body (Frenzel et al., 2013). As a result, the immunogenicity of the 
antibody protein is significantly lowered, which is a major advatange for therapeutic 
purposes. Chinese hamster ovary (CHO) and human embryonic kidney cell line 
(HEK293) are two of the main mammalian cell lines used for antibody expression 
(Frenzel et al., 2013; Karu et al., 1995). Although not from a human origin, the N-
linked glycosylation profile of proteins produced in CHO cells are very close to 
those made by human cells as both cell lineages express the same N-linked glycan 
core structures but may differ in the expression of the extra glycan moieties on the 
core structure (Higel et al., 2016; Hossler and Khattak, 2009). However, numerous 
studies had been carried out to overcome such obstacles which include the use of 
sequence interfering RNA (siRNA) to prevent expression of the enzyme 
fucosyltransferase, that is required for fucosylation, generating mutant CHO cells 
which do not express fucosyltransferase, or upregulating the expression of the 
enzyme sialyltransferase, that is required for sialylation (Butler and Spearman, 2014). 
As a result, the difference in the N-linked glycosylation profile between antibodies 
generated in CHO cells and those found in humans is greatly reduced. On the other 
hand, due to the human origin of HEK293, it is expected that the glycosylation 
profile of antibodies expressed in HEK293 will be very similar to those found in 
natural human serum. As a result, HEK293 cells are also widely used for transient 
antibody expression for many research purposes (Frenzel et al., 2013; Vink et al., 
2014). Recently, Vink and colleagues reported the transient expression of an 
antibody produced from a modified HEK-293 cell line known as FreeStyleTM 293-F 
(HEK-293F) at up to 400 mg/ml in less than 7 days (Vink et al., 2014). As a result, 
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the transient expression of antibody from mammalian cell lines seems to be a good 
choice for a quick and efficient way to obtain sufficient amounts of antibody for 
research purposes. 
 
1.12 Project aims 
Over the years, there have been very many investigations to expand understanding of 
antibody biology. However, there are still areas regarding the structural features of 
antibodies that remain to be discovered. Notably, the hinge region of different 
antibodies varies considerably, but the precise impact of such variations on function 
is still incompletely understood. Alongside this, recombinant antibody technology 
and antibody engineering has allowed development of novel antibody formats which 
may be tested for their value for therapeutic use. Each of the novel antibody formats 
has demonstrated their own advantages and limitations and further expanded 
understanding of antibody biology. The research work of this thesis similarly aimed 
to expand knowledge of antibody biology. The main hypotheses and aims of this 
project are listed below: 
 
1. It was hypothesised that a mutant human IgG1 antibody with an extended 
upper hinge length would have an increased antigenic binding distance, i.e. 
the distance between two neighbouring antigens bound by the Fab arms of the 
antibody. To test this hypothesis, this project aimed to a) engineer various 
human IgG1 mutants with different upper hinge lengths to investigate the 
relationship between the upper hinge length and the antigenic distance of an 
antibody and b) to develop a novel molecular distance measuring system to 
calculate the antigenic distance of an antibody. 
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2. It was hypothesised that Fc-fusion proteins designed to promote antigen cross 
presentation via FcRn engagement and subsequent activation of cytotoxic T 
cells against cancer cells might serve as potential cancer vaccines. To test this 
hypothesis, this project aimed to fuse a protein which is specifically 
expressed by cancer cells to IgG Fc. Upon successful production of the Fc-
fusion protein, the aim was to characterise the protein and investigate the 





























2.1 GENERAL MATERIALS 
 
2.1.1 Chemicals 
All chemicals used in the laboratory were purchased from Sigma-Aldrich or VWR 
International unless otherwise stated. 
 
2.1.2 General solutions and buffers 
 
Water 
Deionised water from a Milli-Q Ultra-Pure system (Millipore) was used. For tissue 
culture usage, Milli-Q water was autoclaved prior to use. 
 
Phosphate buffered saline (PBS) 
A 10X stock solution of PBS (1.37M NaCl, 27mM KCl, 100mM Na2HPO4, 18mM 
KH2PO4, pH7.2) was prepared and autoclaved. This stock solution was diluted to 1X 
with Milli-Q water prior to use. 
 
PBS-Tween (PBS-T) 
0.05% (v/v) Tween 20 was added to PBS. 
 
2.2 ANTIBODIES AND OTHER DETECTING SUBSTANCES 
A list of antibodies and other detecting agents that were used during protein analyses 
were included in Table 2.1 along with details of host species and clonality (if known), 
conjugation (if any), manufacturer (if known) and their final concentration used in 
the protein analyses application. 
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1 μg/ml - Blot 
0.2 μg/ml - 
ELISA 
2. Anti human IgG (P0214) 
Rabbit 
polyclonal HRP DAKO 
1 μg/ml - Blot 









- Biotin Vector Laboratories 








- HRP Invitrogen 0.2 μg/ml - ELISA 
 








monoclonal FITC Abcam 
1.25 μg/ml per 
1x105 - 1x108 









monoclonal FITC Abcam 
10 μg/ml per 































Polyclonal - R&D Systems 































Polyclonal FITC SAPU 









polyclonal - Sigma 
10 μg/ml - 
Flow 
cytometry 
13. Anti actin (A2103) 
Rabbit 
polyclonal - Sigma 








polyclonal HRP Sigma 4 μg/ml - Blot 
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monoclonal - Sigma 
12.5 μg/ml - 
Assay 


























1 μg/ml - Blot 














2.3 MOLECULAR BIOLOGY MATERIALS 
 
2.3.1 Buffers, solutions and materials 
 
Tris-acetate-EDTA (TAE) 
A 50X stock solution of TAE buffer (2M Tris, 1M glacial acetic acid, 50mM EDTA 
(disodium salt), pH 8) was prepared and autoclaved. This stock solution was diluted 
to 1X with Milli-Q water prior to use. 
 
Tris-Borate-EDTA (TBE) 




Luria-Bertani (LB) Broth 
LB Broth was prepared using LB Broth (Sigma) according to manufacturer’s guide, 
20g in 1 litre of Milli-Q water, and autoclaved. Ampicillin (Sigma) was added to a 
final concentration of 100 μg/ml if required. Completed LB Broth is stored at 4ºC 
and warmed to room temperature prior to use. 
 
Luria-Bertani (LB) agar plates 
LB Broth with 1.5% BactoTM Agar (Becton, Dickson and Company) was prepared by 
adding 15g of BactoTM Agar to 1 litre of LB Broth and autoclaving. The solution was 
allowed to cool to room temperature before adding ampicillin to a final concentration 
of 100 μg/ml. 
LB agar plates were prepared by pouring the final LB Broth solution in to 90mm 
Petri Dishes (Thermo Fisher Scientific) and allowed to cool and solidify. LB agar 
plates were stored at 4ºC prior to use. 
 
2.3.2 Restriction enzymes 
All restriction enzymes were purchased from New England Biolabs or Invitrogen, 
Thermo Fisher Scientific. 
 
2.3.3 DNA Ligase 






2.3.4 DNA Molecular weight markers 
Quick-Load® Purple 2-Log DNA Ladder (0.1-10.0 kb) (N0550) molecular weight 
markers were purchased from New England Biolabs. 
 
2.3.5 DNA Polymerase 
KOD Hot Start DNA polymerase kit (Novagen, 71086-3) was purchased from EMD 
Millipore. 
 
2.3.6 Competent cells 
Subcloning EfficiencyTM DH5αTM competent cells (Invitrogen, 18265-017) were 
purchased from Thermo Fisher Scientific. 50μl cells were aliquoted into sterile 1.5ml 
microfuge tubes on ice and stored at -80ºC prior to use. 
 
2.3.7 Primers 
Primers were purchased from Eurofins Genomics. All primers are reconstituted to a 
final concentration of 100 pmol/μl with Milli-Q water and stored at -20ºC. 
 
Table 2.2: List of amplifying primers used 
 Name of primer  Direction DNA sequence (5´- 3´) 
 
 Restoration of lost amino acids (See Chapter 3) 
1. DS3 Forward AGGACTCTACTCCCTCAGCAGC 
2. GUHIAS Reverse AGTTTTGTCACAAGATTTGGGCTCAACTTTCTTGTCCACCTTGGTGTTGC 
3. GUHIS Forward GAGCCCAAATCTTGTGACAAAACTCCCTCAACTCCACCTACCCCATC 






 Generation of O-linked negative mutant (See Chapter 3) 









 Generation of MAGE A2-Fc fusion protein (See Chapter 6) 
7. MAGEForwShort Forward GCGCGCAAGCTTATGGGATGGAGCTGTATC 









10. IgGForw Forward TAGCGGAGGGAGTAGCAGTGACAAAACTCACACATG 
11. MAGE-Fc Kosak Forward GCGCGCAAGCTTCCACCATGGGATGGAGCTG 
12. MouseFcForw Forward CAGTAGCGGAGGGAGTAGCAGTCCTCCATGCAAATGCCCAGCA 
13. MouseFcRev Reverse GCGCGCGAATTCTGAGCTCATTTACCCGGAGTC 





Table 2.3: List of sequencing primers used 
 Name of primer Direction DNA sequence (5´- 3´) 
1. CGamma1BacSeq Reverse GATTCACGTTGCAGATGTAGG 
2. VNIPSEQ1 Forward GCTGATGCAGACAGACATCCTCAGC 
3. UPIgGCH2Forw Forward CACGTCCACCTCCATCTCTTC 
4. 3’VHIgGSCG1 Reverse CTTGCACTTGTACTCCTTGCC 
5. UPHindIIIForw Forward GCTGTTAACGGTGGAGGGCAG 
6. pEIgGENDRev Reverse GAAGTATGTACAGGGGGTACG 
7. MidMAGEForw Forward CTGCTCCTCAAGTATCGAGCC 
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8. MIDMageFcRev Reverse CCACTTCCACCACCTCAATGC 
9. MidIgG2aRev Reverse GCTGGGAGGTCTTTGTTGTTG 
10. MidIgG2aFor Forward CACAAACCCATAGAGAGGATTAC 
 
 
2.4 MOLECULAR BIOLOGY METHODS 
 
2.4.1 Restriction digestion 
DNA was digested with restriction enzymes to yield suitable DNA fragments for 
further analyses or experiments. The standard reaction setup for a restriction digest is 
listed below in Table 2.4. The mixture was gently mixed and incubated at an 
appropriate temperature, according to manufacturer’s protocol, in a water bath for at 
least 1 hour. Double restriction digests were performed using a reaction buffer 
suitable for both restriction enzymes and the reaction setup were adjusted 
accordingly. If the optimal temperature for the restriction enzymes differed, the 
reaction was incubated at the lower optimal temperature for an hour before 
increasing to the higher optimal temperature for another hour. Digested DNA was 
then subjected to agarose gel electrophoresis, section 2.4.4, for further analysis or 
purification. 
Table 2.4: Reaction mix for restriction digestion 
Component Volume added 
10X Reaction Buffer (suitable for 
particular restriction enzyme(s)) 3μl 
Restriction enzyme 1μl 
Plasmid DNA (1-2 μg) or purified PCR 
product 
As required depending on plasmid 
concentration 






2.4.2 Polymerase Chain Reaction (PCR) DNA amplification 
Desired DNA fragments could be amplified using the technique termed Polymerase 
Chain Reaction (PCR). The standard reaction setup using KOD Hot Start DNA 
polymerase, section 2.3.5, is listed below in Table 2.5. All components listed, except 
primers, DNA template and Milli-Q water, were provided with the enzyme. The 
standard reaction conditions used to carry out PCR amplification are shown in Table 
2.6. Steps 2-4 were repeated 30 times. PCR reactions were performed using a 
Mastercycler personal machine (Eppendorf). 
 
Table 2.5: Reaction condition for PCR DNA amplification 
Component Volume Final Concentration/Amount 
10X Reaction Buffer  5μl 1X 
25mM MgSO4 3μl 1.5mM 
dNTPs (2mM each) 5μl 0.2mM (each) 
Sense (5´) Primer (10μM) 1.5μl 0.3μM 
Anti-sense (3´) Primer (10μM) 1.5μl 0.3μM 
KOD Hot Start DNA polymerase 
(1 Unit/μl) 1μl 0.02 Unit/μl 
DNA template X μl 10ng 
Milli-Q water Y μl To bring volume to 50μl 
Total reaction volume 50μl - 
 
 
Table 2.6: List of steps for typical PCR DNA amplification 
 Step Incubation 
1. KOD Hot Start 
polymerase activation 95ºC for 2 minutes 
2. Denaturation of DNA 95ºC for 20 seconds 
3. Annealing of primers At Tm of primer with lowest Tm for 10 seconds 
4. DNA extension 72ºC for 50 seconds 
 
Note: Primer Melting Temperature (Tm) is defined as the temperature at which half of the DNA 




2.4.3 Agarose gel electrophoresis 
DNA molecules of different lengths can be separated by performing agarose gel 
electrophoresis. 1% (w/v) UltraPureTM Agarose (Invitrogen, 16500) in 1X TAE 
buffer was prepared and heated using a microwave to dissolve the agarose powder. 
The solution was allowed to cool before adding SYBR® Safe DNA Gel Stain 
(Invitrogen, S33102) to a final concentration of 1X. The final solution was poured 
into a casting tray with the comb inserted and allowed to solidify at room 
temperature. Once the gel was ready, the comb was removed and the gel was placed 
into a suitable electrophoresis tank (Bio-Rad). The tank was then filled with 1X TAE 
buffer and DNA samples were prepared. An appropriate volume of 10X BlueJuiceTM 
Gel Loading Buffer (Invitrogen, 10816-105) was added to DNA samples to a final 
concentration of 1X prior to loading into the gel. 7μl of DNA molecular weight 
marker, see section 2.3.4, at 100 ng/μl was loaded into a well on each gel for size 
referencing. Loaded DNA was electrophoresed using a Power Pack 3000 (Bio-Rad) 
at 100V for 60-90 minutes depending on the size of the DNA sample that needed to 
be resolved. Upon completion of electrophoresis, the positions of DNA products 
within the gel were visualised using a GelVue UV Transilluminator (Syngene) and 
imaged using GeneFlash (Syngene) or FluorChemTM System (Alpha Innotech). 
 
2.4.4 DNA Purification from agarose gel 
Upon completion of agarose gel electrophoresis, the gel was viewed using a UV 
transilluminator, UVT-28M (HeroLab), or Safe ImagerTM 2.0 Blue-Light 
Transilluminator (Invitrogen). DNA product with the correct size was extracted 
using a sterile scalpel and weighed. The DNA product was purified from the agarose 
gel using QIAquick® Gel Extraction Kit (Qiagen, 28704) according to 
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manufacturer’s protocol. In the final step, the digested DNA fragments were eluted 
with 30μl of Milli-Q water whereas DNA plasmids were eluted with 50μl of Milli-Q 
water and stored at -20ºC prior to use. 
 
2.4.5 DNA Ligation 
Fragments of purified DNA were ligated together using T4 DNA Ligase (section 
2.3.3). The standard reaction setup is listed in Table 2.7. The reaction was mixed 
gently and incubated overnight at room temperature, prior to use for transformation 
of competent E. coli. 
 
Table 2.7: Reaction conditions for DNA ligation 
Components Requirements 
5X Ligase Reaction Buffer 4μl 
Vector DNA 1-2 μl 
Insert DNA 3-6 μl  
T4 DNA Ligase (1 Unit/μl) 1μl 
Milli-Q water to make mixture up to 20 μl  
Total 20μl 
 
Note:  The volume of Vector DNA, Insert DNA and Milli-Q water varied depending on the 
concentration of the DNAs. However, a molarity ratio of 1:3 Insert:Vector was maintained for all 
ligation reactions. The final total volume of the ligation reaction was made up to 20μl with Milli-Q 
water. 
 
2.4.6 Transformation of competent DH5α cells 
50μl of competent DH5α E. coli cells (section 2.3.6) were taken from storage at -
80ºC and thawed on ice. Cells were mixed by gently tapping before introducing 
DNA. 1-5μl (1-10ng) of plasmid DNA or 1-2μl of ligation product (section 2.4.6) 
was added to cells and mixed gently before incubating on ice for 30 minutes. Cells 
were then heat shocked for 20 seconds in a 42ºC water bath and placed on ice for 
another 2 minutes. Subsequently 950μl of pre-warmed LB broth medium was added 
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to the cells and incubated at 37ºC for 1 hour, with shaking at 50g. Cells were 
centrifuged at 800g for 3 minutes and 700μl of supernatant was discarded. Cells were 
resuspended in the remaining LB broth medium and pipetted onto an LB agar plate 
with ampicillin (section 2.3.1), previously warmed to room temperature. A sterile L-
shaped spreader (Greiner Bio-One, 730190) was used to spread the cells evenly 
across the plate, which was then incubated at 37ºC overnight to allow formation of 
bacterial colonies. 
 
2.4.7 Plasmid DNA amplification 
Plasmid DNA was amplified by inoculating bacteria that carry the correct plasmid 
into a large volume of selective growth medium. All plasmids described in this thesis 
carried an ampicillin resistance gene, allowing ampicillin to be used as the selective 
agent. For a smaller scale of amplification, such as for a DNA miniprep, transformed 
bacterial colonies on LB agar plates (section 2.3.7) were picked into different 30ml 
polypropylene tubes containing 5ml LB broth with ampicillin and incubated 
overnight at 37ºC, with shaking at 200 rpm. Upon completion of incubation, cells 
were ready for plasmid DNA extraction (section 2.4.9) unless a larger scale of 
plasmid DNA amplification was required. For a larger scale amplification, such as 
for a DNA maxiprep, 5ml of overnight bacterial culture was added to a larger 
volume (200-500ml) of LB broth with ampicillin and cultured overnight at 37ºC, 
with shaking at 200 rpm. Bacterial culture was ready for plasmid purification 





2.4.8 Plasmid DNA extraction 
Miniprep 
Plasmid DNA from 5ml of bacterial culture was extracted and purified using a 
QIAprep® Spin Miniprep Kit (Qiagen, 27106), according to manufacturer’s protocol. 




Plasmid DNA from larger volumes of bacterial culture (200-500ml) was extracted 
and purified using a QIAGEN® Plasmid Maxiprep Kit (Qiagen, 12163), according to 
manufacturer’s protocol. In the final step, plasmid DNA was reconstituted with 
500μl of Milli-Q water and transferred to a 1ml microfuge tube to be stored at -20ºC. 
 
2.4.9 DNA Concentration and purity 
The concentration and purity of purified DNA was measured using a ND-1000 
Spectrophotometer (NanoDrop). The concentration of sample DNA was calculated 
by loading 1μl of sample into the device. With regards to DNA purity, the sample 
absorbance at 230nm, 260nm and 280nm were measured. A value of ~1.80 for the 
260/280 ratio and one of 2.0-2.2 for the 260/230 ratio was considered to be indicative 
of a highly pure DNA sample. A ratio that was either higher or lower than the ratios 






2.4.10 DNA Sequencing 
All plasmid DNA along with appropriate sequencing primers were submitted to 
DNA Sequencing and Services Unit, University of Dundee for automated sequencing. 
 
2.5 TISSUE CULTURE MATERIALS 
 
2.5.1 Cell lines and growth conditions 
All reagents and supplements used for cell line culture were purchased from Gibco, 
ThermoFisher Scientific. 
 
Table 2.8: List of cell culture conditions and details of each cell line used 











10% Foetal Bovine Serum 
1X Penicillin-Streptomycin 
Below 1 x 106 
cells/ml at 












FreeStyle™ 293 Expression 
Medium 
1X Penicillin-Streptomycin 
Below 2.5 x 
106 cells/ml at 














1X Sodium Pyruvate 
1X Non-Essential Amino 
Acids 
1X L-Glutamine 
50 μM β-Mercaptoethanol 
(Sigma) 
Below 5 x 105 
cells/ml at 
37ºC, 5% CO2 
 
Note:  1X Penicillin-Streptomycin = 10 Units/ml Penicillin and 10 μg/ml Streptomycin 
1X Kanamycin = 100 μg/ml Kanamycin 
1X Sodium Pyruvate = 1mM Sodium Pyruvate 
1X Non-Essential Amino Acids = A mixture of 7 amino acids, 0.1mM of each amino acid 




25 cm2 (T25), 75 cm2 (T75) and 175 cm2 (T175) tissue culture flasks were purchased 
from Greiner-Bio-One. 125ml Erlenmeyer Flasks were purchased from Corning. 
2.6 TISSUE CULTURE METHODS 
 
2.6.1 Thawing of frozen cells 
A 30ml universal tube containing 5ml of suitable medium, preincubated at 37ºC, was 
prepared for each cell line. A vial containing the desired cells was removed from 
liquid nitrogen storage and thawed with gentle shaking in a 37ºC water bath. After 
spraying the exterior of the vial with 70% (v/v) ethanol, the contents were decanted 
into the universal tube and centrifuged at 500g for 5 minutes. Supernatant was 
discarded and cells were resuspended in 1 ml of suitable medium before seeding 
either a T25 or T75 tissue culture flask filled with suitable medium. 
 
2.6.2 Cell maintenance or expansion 
When cells were approaching the cell maintenance threshold, Table 2.8, they were 
split into similar sized tissue culture flasks for maintenance or larger flasks for cell 
expansion if a high number of cells were required for experiments. 
 
2.6.3 Harvesting cells 
Once the number of cells per ml had been determined using a haemocytometer, the 
desired volume of cell suspension was pipetted into a 30ml universal tube and 
centrifuged for 5 minutes at 500g. Supernatant was discarded and the cell pellet was 
washed 3 times with PBS or medium by resuspending and centrifuging for 5 minutes 
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at 500g each time. Finally, the supernatant was discarded and the cells were 
resuspended in PBS or medium at the desired final cell density. 
 
2.6.4 Freezing cells for storage 
Normally between 1 x106 and 1 x107 cells per vial were frozen. Cells were harvested 
and centrifuged at 500g for 5 minutes. The supernatant was discarded and the cells 
were resuspended at between 1 x106 and 1 x107 cells/ml in suitable freezing medium, 
Table 2.9. 1ml aliquots were added into CryoTube vials (Nunc) and labelled. The 
cryotubes were then placed in a biological freezer (Taylor Wharton) and allowed to 
freeze slowly in the liquid nitrogen vapour phase for ~5 hours or overnight. 
Alternatively, a CoolCell® Cell Freezing Container (Biocision) was used to freeze 
the cells at a controlled rate of -1℃/minute in a -80℃ freezer overnight. All 
cryotubes were transferred into liquid nitrogen freezers for long-term storage. 
 
Table 2.9: Details of the medium used for freezing different cell lines 
Cell line Freezing medium 
THP-1 90% FBS, 10% DMSO 
FreeStyle 293-F 90% FreeStyle™ 293 Expression Medium, 10% DMSO 
B3Z 90% RPMI, 10% DMSO 
 
 
2.7 PROTEIN ANALYSIS MATERIALS 
 
2.7.1 Buffers and solutions 
 
SDS Running buffer 
A 10X stock solution of SDS running buffer (0.25M Tris, 1.92M glycine, 1% SDS, 
pH 8.3) was prepared. This stock solution was diluted to 1X with Milli-Q water prior 
to use. 
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Non-reducing sample buffer (2X) 
Milli-Q water                                 2.8 ml 
Glycerol                                         2.0 ml 
1.0M Tris, pH 6.8                          1.2 ml 
10% SDS                                       4.0 ml 
Bromophenol Blue (Bio-Rad)       0.01% 
 
Reducing sample buffer (2X) 
Milli-Q water                                 1.8 ml 
Glycerol                                         2.0 ml 
1.0M Tris, pH 6.8                          1.2 ml 
10% SDS                                       4.0 ml 
14.3M β-Mercaptoethanol             1.0 ml 
Bromophenol Blue (Bio-Rad)       0.01% 
 
Transfer buffer 
25mM Tris, 192mM glycine, 20% methanol, pH 8.3 
 
2.7.2 Protein molecular weight markers 
Precision Plus Protein™ All Blue Prestained Protein Standards (161-0373) were 
purchased from Bio-Rad. 
 
2.8 PROTEIN ANALYSIS METHODS 
 
2.8.1 Preparation of dialysis tubing 
Dialysis tube (19mm with a molecular weight cut-off at 12-14 kDa), was purchased 
from Scientific Laboratory Supplies Ltd (TUB2008). An appropriate length of tubing 




2.8.2 Preparation of Protein G Sepharose 
Protein G SepharoseTM 4 Fast Flow, 17061801, was purchased from GE Healthcare. 
The protein G Sepharose was mixed gently and 500μl was pipetted into a 30ml 
universal tube. To wash the resin, 5ml binding buffer (a mix of 577ml 20mM 
Na2HPO4 and 424ml 20mM NaH2PO4, pH 7.0 per litre) was added and mixed gently, 
followed by centrifugation at 500g for 5 mins. The liquid was discarded and the 
washing process was repeated 3 times. After the final wash, the protein G Sepharose 
was ready to be used. 
 
2.8.3 Antibody purification on Protein G Sepharose 
25ml transfected FreeStyle 293-F cell suspension was collected into a 30ml universal 
tube. Cells were centrifuged at 500g for 5 minutes. The supernatant was transferred 
to a universal tube containing washed protein G Sepharose (section 2.8.2) and 
incubated overnight on a roller (Spiramix 5 (Dentley)) at 4ºC. The next day, a 5 ml 
disposable polypropylene column (Pierce 29922, Thermo Fisher Scientific), was 
prepared according to manufacturer’s guide. The column was flushed with PBS prior 
to use. The protein G Sepharose mixture was poured into the column and allowed to 
flow by gravity to separate the resin from the liquid. The liquid solution was 
collected and stored at 4ºC. The protein G Sepharose was washed several times with 
binding buffer before adding 10ml elution buffer (0.1M glycine, pH 3.0). The eluted 
antibody was collected into a 30ml universal tube and immediately neutralised with 
neutralising buffer (1M Tris-HCl, pH 8.0) to give a final pH of 7.0-7.5.  
 
2.8.4 Protein dialysis  
Protein preparations such as purified antibody (section 2.8.3) were pipetted into 
	 71	
dialysis tubing (section 2.8.1). After sealing with a clip, the tubing was placed into a 
beaker filled with PBS for dialysis overnight at room temperature or 4ºC with at least 
one change of buffer. 
 
2.8.5 Protein concentration  
Protein concentration was performed using Amicon Ultra-15 Centrifugal Filter Units, 
of 50kDa molecular weight cut off, purchased from Millipore. Upon completion of 
dialysis, protein preparations were centrifuged in filter units at 700g for ~10 minutes 
until a final volume of 300-400μl was retained. The concentrated protein was 
transferred to a 1.5ml microfuge tube and its protein concentration determined. 
 
2.8.6 Antibody and Fc-fusion protein concentration determination 
To minimise loss of protein, a 10X dilution was used for determination of 
absorbance at 280nm, measured using a UV spectrophotometer (Ultrospec 2000, 
Pharmacia Biotech). The concentration of the protein sample was calculated using 
the formula below. 
A = ε c l 
A = Absorbance at 280nm 
 = extinction coefficient (1.5 for IgG)  
c  = protein concentration (mg/ml)  
l  = path length in cm (1 cm in the cuvette used) 
 
With regards to the above formula, a formula to calculate protein concentration could 
be derived where, c in mg/ml = (A/ ε l) x (dilution factor) 
 
2.8.7 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)  
Proteins could be analysed by separating on the basis of molecular weight using 
SDS- PAGE. For antibody and Fc-fusion protein analysis, a 10% separating gel was 
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used. The recipe listed below was used to make one gel. 
 
Stacking gel 
Milli-Q water        2.1 ml 
Acrylamide/ Bis-acrylamide, 37:1 ratio (A6050, Sigma)  0.5 ml 
1.0M Tris, pH 6.8       0.38 ml 
10% (w/v) SDS       30 μl 
10% (w/v) ammonium persulphate (freshly made)   30 μl 
TEMED        3 μl 
 
Separating gel (10%) 
Milli-Q water         4.0 ml 
Acrylamide/ Bis-acrylamide, 37:1 ratio (A6050, Sigma)  3.3 ml 
1.5M Tris, pH 8.8       2.5 ml 
10% SDS        100 μl 
10% ammonium persulphate (freshly made)    100 μl 
TEMED        3 μl 
 
A gel-running apparatus (Bio-Rad Mini Protean II) was set up according to 
manufacturer’s instructions. 8ml of separating gel solution was poured into gel plates 
and overlaid with isopropanol before allowing it to set for 15-20 mins. Once the gel 
had solidified, the isopropanol was discarded and the exposed section of the gel was 
washed with Milli-Q water. Stacking gel solution was poured on top on the 
separating gel and the comb was inserted before allowing the gel to set for 10-15 
minutes. The gel plates, which contained the gel, were then placed into the apparatus 
and the tank was filled with fresh SDS running buffer (section 2.7.1). The comb was 
removed and the gel was ready for protein sample loading. Samples were prepared in 
1.5ml microfuge tubes. About 1-2 μg of protein was required to be loaded into each 
well. Once the appropriate dilutions were made, an equal volume of non-reducing 
sample buffer or reducing sample buffer (section 2.7.1) was added to each prepared 
protein sample to give a final concentration of 1X sample buffer. The protein 
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samples were then incubated in a heat block at 90ºC for 10 minutes to fully denature 
the proteins. Once completed, the protein samples were centrifuged for 5 seconds 
and allowed to cool to room temperature before loading into their respective wells. 
7μl of protein molecular weight marker (section 2.7.2) was loaded for size 
referencing. After protein loading, protein samples were electrophoresed using a 
Power Pack 3000 (Bio-Rad) at 100V for 10-13 minutes to be properly stacked before 
entering the separating gel. The voltage was then increased to 180V and the protein 
samples were run until the bromophenol blue almost reached the end of the gel. The 
gel plates were removed from the tank and dismantled to expose the gel. The gel was 
then ready to proceed to western blotting or Coomassie staining. 
 
2.8.8 Western blotting 
After SDS-PAGE electrophoresis, the proteins embedded in the gel were transferred 
to nitrocellulose membrane for further analysis using a Bio-Rad transfer device. 
Nitrocellulose Blotting Membrane (Protran, 0.45 μm pore size, GE Healthcare) and 
filter paper (Whatman 3MM) cut to the size of the gel, were presoaked along with 
transfer sponges in transfer buffer (section 2.7.1) for at least 5 mins prior to use. The 
nitrocellulose membrane was placed on top of the protein gel and sandwiched 
between filter papers and transfer sponges before placing into the transfer tank. Once 
the apparatus was set up, the transfer tank was filled with transfer buffer and an ice 
block was placed in the tank to prevent overheating. The proteins were transferred at 
100V for 60 minutes. After disassembling, the nitrocellulose membrane was blocked 
with 5% (w/v) non-fat milk in PBS-T (section 2.1.2) for 1 hour at room temperature 
with shaking. The nitrocellulose membrane was then washed three times with PBS-T 
for 5 minutes each wash. The nitrocellulose membrane was then incubated with the 
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desired primary antibody for 1 hour or overnight followed by three 5 mins washes 
with PBS-T. If the primary antibody was unconjugated, the membrane was incubated 
with a suitable secondary antibody for 1 hour followed by three further washes as 
before, and developed using an appropriate substrate. If the primary antibody was 
conjugated, the membrane was ready to be developed using an appropriate substrate. 
Since detecting antibodies were HRP conjugated, TMB Membrane Peroxidase 
Substrate (Kirkegaard & Perry Laboratories Inc.) or Pierce® ECL Western Blotting 
Substrate (Thermo Fisher Scientific) was used to develop the reaction. Developed 
protein bands were imaged using FluorChemTM System (Alpha Innotech), Canon iR-
ADV C5030i or Li-Cor Odyssey Fc (Li-Cor Bioscience UK Ltd). 
 
2.8.9 Coomassie staining and destaining of SDS gels 
After SDS-PAGE, the gel was placed into a suitable container/tray and rinsed once 
with Coomassie destaining solution (25% (v/v) methanol, 7% (v/v) acetic acid). The 
gel was then incubated with Coomassie staining solution (0.25% (w/v) Coomassie 
Brilliant Blue R-250 (Sigma, B-0149), 50% (v/v) methanol, 10% (v/v) acetic acid) 
overnight at room temperature with shaking.  The gel was subsequently incubated in 
Coomassie destaining solution at room temperature on a shaker. Destaining solution 
was changed as frequently as required until the gel was completely destained. The 




All ELISA analyses were carried out using 96 well MaxiSorp ELISA plates (Nunc). 
Appropriate concentrations of proteins (e.g. ~10μg/ml of NIP-BSA) were prepared in 
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freshly made ELISA coating buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6). 100μl 
of final ELISA coating solution was pipetted into wells and incubated overnight at 
4ºC. For control wells, ELISA coating buffer was used alone. When the coating was 
completed, the plate was washed 5 times with tap water. Each well was then blocked 
with 200μl of 5% (v/v) non-fat milk in PBST (section 2.1.2) for 1 hour. After 
repeating the washing process 100μl of selected primary detecting antibody, 
prepared in PBST at a concentration shown in Table 2.1, was added to desired wells. 
The plate was incubated on a shaker at room temperature for 1 hour before being 
washed 5 times as before. If required, 100μl of selected secondary detecting antibody, 
prepared in PBST at a concentration shown in Table 2.1, was added to desired wells, 
and the palate incubated as previously. After washing as before, 200μl SureBlueTM 
TMB Microwell Peroxidase Substrate (Kirkegaard & Perry Laboratories Inc.) was 
added to each well and colour allowed to develop for at least 20 minutes. 


















GENERATION OF ANTI-NIP WILDTYPE 











CHAPTER 3. GENERATION OF ANTI-NIP WILDTYPE HUMAN IgG1 AND 
DIFFERENT HINGE MUTANT ANTIBODIES 
 
3.1 INTRODUCTION 
The length of the hinge region and in particular the distance between the end of the 
CH1 domain and the first inter-heavy chain disulphide bridge varies between 
antibody classes and subclasses (Burton, 1987). As an example, the number of amino 
acids in this particular region of hIgA1 is 20 whilst in hIgG1 it is only 5. The length 
and flexibility of this region is expected to play a role in allowing the Fab arms to 
attain better positioning to achieve efficient antigen binding, as described earlier in 
Figure 1.9B. In brief, a better flexibility at the region between the end of the CH1 
domain and the first inter-heavy chain disulphide bridge would improve the overall 
free movements of the Fab arms to achieve better positioning for antigen binding 
whilst a longer length of this region would distance the Fab arms further away from 
the Fc region to allow better antigenic reach. Exactly how modification of this 
particular region might improve antibody functionality has not been very well 
studied. However, extending the length of this region is expected to improve, at least, 
the antigenic reach of an antibody, as mentioned earlier. In human IgG, this 
particular region is also known as the upper hinge region, as indicated earlier in 
Figure 1.8A. This chapter aimed to generate a range of IgG mutant antibodies with 
different upper hinge lengths which could be tested in various analyses to improve 
understanding of the role of the upper hinge region on antibody functionality. 
 
3.1.1 Bivalent antigenic distance of an antibody 
Bivalent antigenic distance is defined in this thesis as the maximum distance between 
two antigens bound by both the Fab arms of an antibody as shown in Figure 3.1. This 
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distance is expected to depend heavily on the flexibility and length of the hinge 
region, in particular, the distance between the end of the CH1 domain and the first 
inter-heavy chain disulphide bridge which governs the movement of Fab arms. 
hIgG1 and hIgA1 are two good examples to describe the difference in bivalent 
antigenic distance likely to arise as a result of the difference in the number of amino 
acid residues in their hinge regions, as illustrated in Figure 1.8. In brief, the hinge 
region of hIgA1 consists of 20 amino acid residues whereas the upper hinge region 
of hIgG1 consists of 5 amino acid residues. Thus, it is expected that hIgA1 will have 
a greater bivalent antigenic distance than hIgG1. Indeed, observations from the 
derived hIgA1 structure model suggested that the bivalent antigenic distance of 
hIgA1 was 17nm (Boehm et al., 1999) whereas the bivalent antigenic distance of the 
crystallised hIgG1 Kol was  estimated to be 146Å (14.6nm) (Huber et al., 1976).  
 
Previous studies have reported the Fab tip to tip distance of several different 
antibodies. This distance is likely to be closely related to bivalent antigenic distance 
Figure 3.1: A schematic diagram illustrating the bivalent antigenic distance of antibodies. The 
bivalent antigenic distance of an antibody is the maximum distance between two antigens bound by 
both the Fab arms and is expected to be dependent on the length and flexibility of the hinge region. 
The hinge region of human IgA1 consists of 20 amino acid residues whilst the upper hinge region 
of human IgG1 consists of only 5 amino acid residues. Thus, it is expected that IgA1 will have a 
greater bivalent antigenic distance than IgG1. 
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but it can be determined in the absence of antigen whereas bivalent antigenic 
distance cannot. These Fab tip to tip calculations were mainly based on electron 
microscopy, neutron/X-ray scattering and/or crystallography of the relevant 
antibodies (Valentine and Green, 1967; Marquart et al., 1980; Sosnick et al., 1992). 
Valentine and Green incubated bivalent DNP ligands with anti-DNP rabbit IgGs and 
allowed the formation of immune complexes (Valentine and Green, 1967). Using 
electron microscopy, the authors noticed that the majority of the immune complexes 
formed a ring structure consisting of 2-3 antibody molecules (4-6 Fab arms). The 
mean Fab tip to tip distance was reported to be 120Å and did not exceeded 150Å 
(Valentine and Green, 1967). In a different scenario, Sosnick and colleagues used 
neutron and X-ray scattering analysis and deuterated antigen to measure the antigen 
binding distance in solution between the two Fab arms of murine IgG1, IgG2a and 
IgG2b and reported that the mean distance was around 117Å - 134Å for all three 
subclasses (Sosnick et al., 1992). Finally, Marquart and colleagues calculated the 
Fab tip to tip distance of Kol (a human IgG1) from its crystal structure and reported a 
distance of 145Å (Marquart et al., 1980).  In contrast, the average Fab tip to tip 
distance of human IgA1 was reported to be 17nm (170Å) according to molecular 
models build on the basis of small angle X-ray and neutron scattering measurements 
(Boehm et al., 1999). In a different study, Roux and colleagues generated an 
antigenic idiotype (Id) matched set of genetically engineered human IgG1, -2, -3 and 
-4 subclass antibodies to investigate the differences in immune complex formation 
due to hinge-mediated differences in flexibility by incubating the generated IgGs 
with two different anti Id-specific murine monoclonal antibodies (Roux et al., 1997a). 
The authors reported that each IgG subclass exhibited different ranges of Fab-Fab 
angle in which IgG1 was 30º-210º; IgG2 was 60º-190º; IgG3 was 20º-270º and IgG4 
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was 30º-210º and that the hinge mediated flexibility of different human IgG 
subclasses was ranked as lgG3 > lgGl > lgG4 > lgG2 (Roux et al., 1997a). Although 
the Fab tip to tip distances of different generated human IgGs were not calculated in 
the studies of Roux et al. (1997), the authors demonstrated the different ranges of 
Fab-Fab angle distance that each IgG could adopt which in turn contributes to the 
diversity of the Fab tip to tip distance of each different IgG subclass. 
 
The differences in the reported Fab tip to tip distances of different antibodies 
described earlier is hypothesised to be due to the different lengths of their hinge 
regions. However, this hypothesis is yet to be proven. In addition, the distance 
between Fab arms of different antibodies when bound to antigen have not been 
identified. As a result, this chapter aimed to generate novel IgG hinge mutant 
antibodies to investigate if the length of the upper hinge region affected the bivalent 
antigenic distance. Using antibody recombinant technology, the length of the upper 
hinge of wild type human IgG1 (wt hIgG1) was extended by the addition of amino 
acids to generate hIgG1 hinge mutants with different upper hinge lengths, as shown 
in Figure 3.2, so that an antigen binding comparison can be made with wt hIgG1 to 
identify if the length of upper hinge of hIgG1 would affect the overall bivalent 
antigenic distance of hIgG1. Rather than randomly adding different amino acids to 
extend the upper hinge length of IgG, it was decided to utilise the hinge region of 
hIgA1 as a choice of peptide chain extension. One of the main reasons for using 
hIgA1 is because the hinge region of hIgA1 is very long at 20 amino acids, compared 
to other human antibodies. More importantly, it is a naturally evolved hinge region, 
and therefore the generated hinge mutants containing such a hinge insertion should 
be very stable during and after protein production. Secondly, based on the structure  
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of hIgA1 that was modelled based on small angle X-ray and neutron scattering, the 
hinge region of IgA1 had been proposed to adopt an open and extended 
conformation (Boehm et al., 1999), as illustrated in Figure 3.1A. Bonner and 
colleagues later modelled the structure for dimeric hIgA1 based on solution 
scattering studies and proposed a similar conformation in which the Fab arms of the 
antibody were quite extended away from the Fc region, most likely due to the long 
hinge (Bonner et al., 2008). As a result, using the hinge region of hIgA1 for hinge 
extension of IgG1 was reasoned as likely to provide an open and extended 
conformation with a greater bivalent antigenic distance. Further details of the hinge 
region of hIgA1 will be described in another section below. In summary, by 
extending the length of the upper hinge of hIgG1 while retaining identical constant 
domains identical would allow a comparison of the hIgG1 hinge mutants with wt 
hIgG1 to be made. Hence, any significantly different outcomes exhibited by the 
hinge mutants are most likely to be due to the upper hinge extension.  
Figure 3.2: A schematic diagram illustrating the differences in lengths of the upper hinge region of 
different human IgG antibodies. A) Wildtype human IgG1 with normal upper hinge length. B) 
Human IgG1 hinge mutant with extended upper hinge length (shown in red). 
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3.1.2 The disulphide bond between heavy (H) and light (L) chains 
In this project, a previously constructed hinge mutant hIgG1, TAHG (described 
below), was used as a starting point for generation of novel hinge mutants. The 
TAHG mutant carries part of the hinge sequence of human IgA1 but has lost the 8 
amino acid sequence EPKSCDKT which comprises the N-terminal portion of the 
original IgG1 hinge region. This sequence is critical since the cysteine residue which 
it contains is responsible for disulphide bond linkage to the light chain (Liu and May, 
2012; Edelman et al., 1969). As mentioned in Chapter 1, an antibody is composed of 
two light chains and two heavy chains bound together by disulphide bonds. 
Appropriate association of heavy and light chains, stabilized by a disulphide bridge, 
is important so that both the variable domain of the light chain and that of the heavy 
chain come into close contact to form the complete antigen binding site located at the 
tip of the Fab arms. Some antibodies, especially IgA, were secreted onto the mucosal 
lining where extreme pH may be encountered, e.g. in the gastrointestinal tract 
(Mantis et al., 2011). The disulphide bonding between light and heavy chain may 
prove crucial in holding both chains together as the extreme pH within the 
environment may tend to affect the protein structure leading to the disruption of light 
and heavy association.  
 
The heavy chains of the different antibody classes form disulphide bonds with light 
chains at different locations. For human IgG1, the disulphide bond with light chain 
was formed between the fifth cysteine residue of the IgG1 heavy chain (Cys220) and 
the C-terminal cysteine of the light chain (Cys214) (Liu and May, 2012). However, 
for human IgG2, IgG3 and IgG4 the H-L disulphide bond is formed between the 
third cysteine residue (Cys131) of the heavy chain and Cys214 of light chain (Liu 
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and May, 2012). In the case of human IgA1, the disulphide bond to light chain 
involves the third cysteine residue, Cys133, of the a heavy chain constant region 
(Chintalacharuvu and Morrison, 1996). Human IgA2 is slightly different as it lacks a 
Cys at position 133, (it is replaced by an aspartic acid), but at least for the IgA2m(2) 
allotype, it is still capable of forming an H-L disulphide bond (Chintalacharuvu et al., 
2002). The IgA2m(1) allotype is exceptional. An early study reported that there were 
no disulphide bonds found between light and heavy chains in this allotype 
(Tsuzukida et al., 1979). However, further studies have reported H-L disulphide 
bonds in some IgA2m(1) molecules. Seemingly, the efficiency of formation of that 
linkage is greatly reduced (Chintalacharuvu and Morrison, 1996; Chintalacharuvu et 
al., 2002). In contrast, there had been no reports of intact human IgGs that lack H-L 
disulphide bonding. Since an aim of this project was to investigate the impact of 
antibody structure in relation to its function, the restoration of the 8 IgG hinge amino 
acids into the TAHG construct was necessary in order to more closely resemble the 
natural hIgG1 antibodies in terms of H-L assembly. 
 
3.1.3 The benefits of introns and their removal by mRNA splicing  
All the antibody heavy chain constant region DNA sequences used in this project 
aim were not cDNAs but gene sequences that contained both introns and exons. 
Often, expression of protein from cDNA is preferred as it significantly reduces the 
size of the encoding DNA which makes transfection easier. Moreover, the cDNA 
option is often considered less complicated as it removes any concern about correct 
mRNA splicing to remove introns. However, the usage of introns in antibody 
expression systems had several advantages. One of the advantages is the associated 
enhancement in antibody expression. Gaurav and colleagues constructed several 
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antibody expression plasmids to test different types of promoter as well as the 
addition or removal of an intron and found that with the addition of a single intron, 
the antibody expression level increased by almost two fold (Backliwal et al., 2008). 
Increased expression levels of proteins due to the addition of introns have been 
reported by other groups also (Buchman and Berg, 1988; Nott et al., 2003). Thus, it 
has been found beneficial to include introns in order to obtain improved antibody 
expression. Another benefit of the inclusion of introns relates to the possibility to 
introduce useful restriction sites within introns without affecting the actual protein 
transcription and translation. For antibodies, this creates an easy approach for 
domain swapping, addition or deletion, which has proved highly beneficial for 
understanding antibody structure and its functionality. However, the mRNA splicing 
signals encoded in an intron must not be disrupted in order to ensure all introns are 
spliced out and all exons are joined correctly. An intron usually starts with the 
sequence GT at the 5´ end and ends with AG at the 3´ end (Clancy, 2008). These 
consensus sequences, also known as splice sites, are crucial and any changes in their 
sequence would result in splicing failure (Clancy, 2008). Another important 
requirement apart from the splice sites is the branch site which is located upstream of 
the 3´ end splice site (Clancy, 2008). The branch site always contains an adenine and 
usually adopts the sequence YNYYRAY, where Y is a pyrimidine (C or T), N is any 
nucleotide, R is a purine (A or G) and A is adenine (Clancy, 2008).  In this chapter, 
all the antibody constructs used were found to contain an intron deletion, which is 
most likely a PCR artifact, that included a small part of the starting sequences of the 
CH1 domain. The missing 3´ intron splice site located before the start of CH1 
domain coding sequence might cause the CH1 domain exon to be mistakenly 
signaled as an intron and completely spliced out, resulting in the loss of the CH1 
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domain in the mature protein. Therefore, restoration of the lost intron and the CH1 
domain splice site was necessary. 
 
3.1.4 The hinge region of human IgA1 and its O-linked glycans 
As mentioned in section 3.1.1 above, this project developed novel hIgG1 hinge 
mutants with hIgA1 hinge insertions. The structure for hIgA1 has been proposed to 
adopt an open and extended conformation (Boehm et al., 1999; Bonner et al., 2008), 
in which the extra long hinge of hIgA1 may have contributed to this structural 
conformation. Another factor that might contribute to the conformation of the hIgA1 
hinge is the presence of O-linked glycans (Mattu et al., 1998; Baenziger and 
Kornfeld, 1974; Novak et al., 2000). As mentioned in Chapter 1, the hinge region of 
hIgA1 displays a repeated sequence of proline, serine and threonine and the O-linked 
glycosylation on hIgA1 was reported to occur on both serine and threonine residues 
within the hinge region (Baenziger and Kornfeld, 1974). There are a total of nine 
potential sites for O-linked glycosylation at the hinge region of hIgA1 but not all 
sites appear to be glycosylated, as indicated in Figure 3.3. Usually three to five sites 
are glycosylated (Baenziger and Kornfeld, 1974; Mattu et al., 1998), but up to six 
have been described (Tarelli et al., 2004). The presence of glycans at the hinge 
region might create steric hindrance which prevents the Fab arms of hIgA1 from 
coming close in contact, thus, an open conformation might be more optimal for 
hIgA1. The roles of O-linked glycans at the hinge region of hIgA1 are not exactly 
clear yet but some believe that they provide a certain degree of structural rigidity 
which stabilises the long hinge (Arnold et al., 2007). Similarly, hIgD which has a 
longer hinge than hIgA1 is also O-glycosylated at the hinge region (Takahashi et al., 




O-linked glycans. Instead, the structural rigidity is provided by eleven inter-chain 
disulphide bonds between the two hIgG3 heavy chains (Liu and May, 2012). Thus, it 
seems that hIgA1 and hIgD have evolved to be glycosylated in their hinge regions as 
an alternative way to ensure structural integrity whilst attaining a higher degree of 
reach, and possibly flexibility, in antigen binding. In addition to extra hinge length, 
the hIgA1 hinge region displays heterogeneity in its O-linked glycosylation (Novak 
et al., 2000). Royle and colleagues analysed the glycan structures from pooled 
normal human secretory hIgA1 and found that O-linked glycans present at the hinge 
region of secretory hIgA1 had a wide range of interaction sites that could interact 
with bacterial adhesins (Royle et al., 2003). Looking at the proposed model of hIgA1, 
the open conformation that hIgA1 is proposed to adopt actually provides an easy 
access for bacterial adhesins to the hinge O-linked glycans. Therefore, the O-linked 
glycans might have a role in immune system defensive approaches. As a result, the 
present project also aimed to investigate whether the removal of hinge O-linked 
glycans would have any effect on antibody structure and function. To achieve that 
aim, the O-glycosylation of a hinge mutant was prevented by mutating all the serine 
and threonine residues at the hinge region to alanine and/or glycine residues. 
Figure 3.3: A schematic diagram illustrating the nine potential O-linked glycosylation sites located 
at the hinge region of human IgA1. O-linked glycosylation occurs only at serine or threonine 
residues. There are nine potential sites but not all are glycosylated. Blue, most likely glycosylated 
sites; Aqua blue, likely glycosylated sites; Grey, less likely glycosylated sites. 
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3.1.5 Jacalin, an O-linked glycan binding lectin 
Lectins are a class of proteins that bind specifically to different sugars. Among 
different plant lectins, jacalin originates from the seeds of jackfruit (Artocarpus 
heterophyllus) and has a high specificity for the disaccharide galactose (β1, 3) N-
acetylgalactosamine, which is the most common core of O-linked glycans (Kabir, 
1998). Due to such high specificity, jacalin had been used to isolate hIgA1 and hIgD 
from other immunoglobulins because these two immunoglobulins have O-linked 
oligosaccharides at their hinge regions (Kabir, 1998). In this project, jacalin was 
utilised to determine the presence of O-linked glycans on the different recombinant 
antibodies generated. 
 
3.1.6 Anti-NIP variable domain 
The use of matched sets of antibodies featuring identical antigen binding sites 
ensures that antigen binding affinity and epitope recognition is identical across all 
antibodies produced, allowing direct comparison of the impact of different antibody 
heavy chain features on function. In 1978, Reth and colleagues reported a murine 
hybridoma capable of producing antibodies which recognised the hapten 4-hydroxy- 
3-iodo-5-nitrophenyl acetic acid (NIP) (Reth et al., 1978).  The chemical structure of 
NIP is shown in Figure 3.4. In the past, the NIP antigen system has been utilised by 
many groups to investigate antibody function by generating a variety of anti-NIP 
chimeric antibodies and comparing them in different functional analyses (Bindon et 
al., 1988; Garred et al., 1989; Lucisano Valim and Lachmann, 1991). In particular, 
Bindon and colleagues generated anti-NIP human IgG1, IgG2, IgG3, IgG4 and IgE 
and by derivatizing NIP onto the surface of human red blood cells they were able to 
study each antibody’s ability to activate the complement cascade (Bindon et al., 





different antigen densities in order to study the relationship between antigen 
availability and complement activation. Using different anti-NIP human antibodies 
they found that at a lower antigen density IgG3 was the best candidate in 
complement activation followed by IgG1 and IgG2 (Garred et al., 1989). In this 
project, the NIP recognition system was selected to study the impact of hinge length 
on the functionality of different human IgG1 antibodies as the NIP system is very 
well established in the Woof lab. 
 
3.2 AIMS 
This project hypothesised that an increase in the length of the upper hinge region will 
lead to an increase in the bivalent antigenic distance of an antibody. To test this 
hypothesis, this chapter aimed to generate a matched set of anti-NIP hIgG1 mutants 
with different upper hinge lengths by incorporating portions of the hinge region of 
hIgA1 into their upper hinge regions. This project also aimed to study the impact of 
O-linked glycans of an antibody in antigen binding, thus, the generation of an O-








Figure 3.4: Chemical structure of 4-hydroxy-3-iodo-5-nitrophenyl acetic acid (NIP) hapten. 
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Bovine serum albumin derivatised with hapten NIP (NIP-BSA) was available in the 





The pE1001 plasmid encoding the majority of the constant region of the heavy chain 
of wildtype human IgG1 (wt hIgG1) was available in the Woof lab. DNA sequencing 
showed that pE1001 lacked approximately 400 base pairs (bp) comprising part of the 
exon encoding the CH1 domain and the upstream intron. 
 
pTAHG 
The pTAHG plasmid, encoding the heavy chain of an anti-NIP hinge-modified 
human IgG1, was available in the Woof lab. The reason for using pTAHG is because 
pTAHG carried DNA sequence encoding the hinge region of human IgA1 inserted at 
the upper hinge region of wt hIgG1, resulting in an extension of 18 amino acids in 
the encoded heavy chain protein, which would generate a suitable hinge mutant 
candidate for this project. However, DNA sequencing showed that pTAHG lacked 
sequence encoding 8 amino acids, EPKSCDKT, which comprises the N-terminal 
portion of the original IgG1 hinge region. pTAHG also contained the CH1 domain 
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upstream exon deletion as described in pE1001. 
 
pBSK-419bp 
A plasmid, pBSK-419bp, containing a sequence of 419bp that encoded the correct 
intron sequence upstream of the CH1 domain of wt hIgG1 was purchased from 
Dundee Cell Products Ltd. The sequence contained two unique restriction sites that 
could be digested by HindIII and BstEII. 
 
prelLC 
An expression vector encoding a murine anti-NIP lambda light chain was available 
in the Woof lab.  
 
3.3.3 CONSTRUCTION OF ANTI-NIP ANTIBODY PLASMIDS 
 
3.3.3.1 Reintroducing missing sequence EPKSCDKT into the pTAHG 
expression vector 
The procedure for reintroducing the sequence encoding the eight missing amino 
acids is illustrated in Figure 3.5. The PCR procedure was carried as described in 
section 2.4.3 using the appropriate primers and annealing temperatures to obtain the 
final desired DNA products. Primers DS3 and GUHIAS (Table 2.2, No.1 & 2) were 
used to amplify a fragment of approximately 140bp which contained a unique BstEII 
site, using pTAHG as template at an annealing temperature of 63ºC. Using pTAHG 
as template, primers GUHIS and AG3’NEW (Table 2.2, No.3 & 4) were used at an 
annealing temperature of 65ºC to amplify a DNA product of approximately 1100bp 
which contained a unique EcoRI site. PCR products were run on a DNA agarose gel  
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Figure 3.5: A schematic diagram illustrating the procedure to reintroduce sequence encoding the 
missing amino acids. The hinge region of the hinge mutant encoded in pTAHG was PCR amplified 
to reintroduce missing sequence. The missing sequence served as a complementary sequence 
during overlapping PCR. The new insert was inserted into digested pE1001 using the restriction 
enzymes BstEII and EcoRI. pTF1 is a plasmid with just half the hinge region from hIgA1 inserted 
due to primer mismatches during PCR amplification. In contrast, pTF2 is a plasmid with full hIgA1 
hinge region insertion.  
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as described in section 2.4.4 and DNA bands of the correct sizes were extracted as 
described in section 2.4.5. Using a PCR procedure described in section 2.4.3, an 
overlap PCR extension was performed by using a mix of 2μl of each extracted DNA 
fragment as template and DS3 and AG3’NEW as primers (Table 2.2, No.1 & 4) at an 
annealing temperature of 63ºC, to produce a final DNA product of approximately 
1240bp. Gel electrophoresis and DNA gel extraction were carried out subsequently. 
The purified DNA fragment and pE1001 were then digested with restriction enzymes 
BstEII and EcoRI as described in section 2.4.1. Gel electrophoresis and DNA gel 
extraction were performed to purify the digested DNA fragment at 1240bp (insert) 
and digested pE1001 at about 8000bp (vector). Both purified DNA fragments were 
then ligated as described in section 2.4.6 and transformed into competent DH5α E. 
coli as described in section 2.4.7. After purifying the plasmids from positive clones 
as described in section 2.4.9, DNA sequencing was carried out (section 2.4.11) to 
ensure the desired sequence was obtained. Plasmids with the correct DNA sequence 
were named as pTF1 and pTF2. pTF1 is a plasmid with just half the hinge region 
from hIgA1 inserted due to primer mismatches during PCR amplification and the 
reason for using pTF1 will be discussed in section 3.4.1, page 103. In contrast, pTF2 
is a plasmid with full hIgA1 hinge region insertion.  
 
3.3.3.2 Repairing the CH1 region of fixed pE1001, pTF1 and pTF2 
The procedure for repairing the intron upstream to CH1 is illustrated in Figure 3.6. 
Plasmids pE1001, pTF1, pTF2 and pBSK-419bp were individually digested with 
restriction enzyme HindIII and BstEII at 37ºC and at 60ºC for 1 hour respectively as 
described in section 2.4.1. Gel electrophoresis and DNA gel extraction were 
performed to purify digested DNA fragments at about 8000bp (vector) respectively  
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Figure 3.6: A schematic diagram of the repair of the exon upstream to CH1. pBSK-419bp 
was digested with HindIII and BstEII to obtained the insert encoding the correct DNA 
sequence of the upstream exon. pE1001, pTF1 and pTF2 were digested with HindIII and 
BstEII to obtain respective cut vectors and each was ligated with the insert obtained from 
pBSK-419bp. 
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for pE1001, pTF1 and pTF2, and at 419bp (insert) for pBSK-419bp. Purified DNA 
fragments were then ligated as described in section 2.4.6 and transformed into 
competent DH5α E. coli as described in section 2.4.7. After purifying the plasmids 
from positive clones as described in section 2.4.9, DNA sequencing was carried out 
(section 2.4.11) to ensure that the exon had been successfully repaired. Plasmids with 
correct DNA sequence were named respectively as pHCCR, Fixed pTF1 and Fixed 
pTF2. 
 
3.3.3.3 Generation of O-linked negative mutant expression vector 
The procedure for generating an expression vector for the heavy chain of the O-
linked negative mutant is illustrated in Figure 3.7. Using Fixed pTF2 as template, 
primers DS3 and OlinkNegRev (Table 2.2, No.1 & 6) were used at an annealing 
temperature of 60ºC to amplify a DNA product of approximately 190bp which 
contained a unique BstEII site. Similarly, primers OlinkNegForw and AG3’NEW 
primers (Table 2.2, No.5 & 4) were used at an annealing temperature of 63ºC to 
obtain a DNA product of approximately 1100bp which contained a unique EcoRI site. 
These two sets of amplification are designed to mutate the sequence encoding serine 
and threonine amino acids in the hinge region of Fixed pTF2 to that encoding a 
mixture of glycine and alanine, thereby changing the hinge amino acid sequence 
from TPSTPPTPSPSTPPTPSPS to GPAGPPAPAPGAPPGPAPG. After DNA 
electrophoresis, DNA fragments of the correct sizes were extracted and purified. An 
overlap PCR extension was performed as described in section 2.4.3 on a mix of 2μl 
of each extracted DNA fragment for 30 cycles at an annealing temperature of 72ºC 
without the addition of primers. When the procedure ended, primers DS3 and 
AG3’NEW (Table 2.2, No.1 & 4) were added and the same PCR procedure was  
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Figure 3.7: Generation of O-linked negative mutant heavy chain expression vector. The hinge 
region of the hinge mutant encoded in Fixed pTF2 was PCR amplified to introduce several 
mutations as shown above. The amplified DNA fragment was inserted into pHCCR using 
BstEII and EcoRI sites. pNO-ONeg was then digested with HindIII to allow insertion of VNIP 
obtained from pTAHG shown in Figure 3.8. 
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performed at an annealing temperature of 60ºC to obtain a final DNA product of 
approximately 1240bp. Gel electrophoresis and DNA gel extraction were carried out 
subsequently. Purified DNA fragment and plasmid pHCCR were then digested with 
restriction enzymes BstEII and EcoRI as described in section 2.4.1. Gel 
electrophoresis and DNA gel extraction were performed to purify the digested DNA 
fragment of 1240bp (insert) and digested pE1001 of about 8000bp (vector). Both 
purified DNA fragments were then ligated as described in section 2.4.6 and 
transformed into competent DH5α E. coli as described in section 2.4.7. After 
purifying the plasmids from positive clones as described in section 2.4.9, DNA 
sequencing was carried out (section 2.4.11) to ensure that the hinge region had been 
correctly mutated. Plasmid with correct DNA sequence was named as pNO-ONeg. 
 
3.3.3.4 Insertion of sequence encoding murine anti-NIP variable heavy domain 
(VNIP) 
The procedure for VNIP insertion is illustrated in Figure 3.8. pTAHG, pHCCR, 
Fixed pTF1, Fixed pTF2 and pNO-ONeg were digested individually with restriction 
enzyme HindIII at 37ºC for 1 hour as described in section 2.4.1. Gel electrophoresis 
and DNA gel extraction were performed to purify digested DNA fragment at about 
8000bp (vector) for pHCCR, Fixed pTF1, Fixed pTF2 and pNO-ONeg and 750bp 
(VNIP insert) for pTAHG. In each case, purified vector and insert DNA fragments 
were then ligated as described in section 2.4.6 and transformed into competent DH5α 
E. coli as described in section 2.4.7. Due to both ends of the VNIP insert being 
flanked by HindIII sites, it was possible for the VNIP insert to ligate in two different 
orientations. However, the correct orientation could be determined by EcoRI 
digestion because VNIP carried a unique EcoRI restriction site located near 3´ end, 




Figure 3.8: Anti-NIP variable heavy domain (VNIP) insertion. pTAHG was digested with 
HindIII to obtain VNIP insert. pHCCR, Fixed pTF1 and Fixed pTF2 were each digested with 
HindIII to obtain each respective vectors prior to ligation with VNIP insert. 
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for pHCCR and around 1600bp for Fixed pTF1, Fixed pTF2 and pNO-ONeg upon 
EcoRI digestion. After purifying the plasmids from positive clones as described in 
section 2.4.9, DNA sequencing was carried out (section 2.4.11) to verify that the 
VNIP insert was in the correct orientation. Plasmids with correct DNA sequences 
were named as pEIgG1 (derived from pHCCR), pIgG0.5HA (derived from Fixed 
pTF1), pIgG1HA (derived from Fixed pTF2) and pONeg (derived from pNO-ONeg) 
respectively. Amplification of plasmid DNA was then carried out as described in 






3.3.4 PRODUCTION AND CHARACTERISATION OF RECOMBINANT 
ANTIBODIES 
 
3.3.4.1 Antibody production and purification from FreeStyle 293-F cells 
Frozen FreeStyle 293-F cells were thawed and maintained in appropriate growth 
conditions as shown in section 2.6.2. Before the day of transfection, each flask of 
cells were split and seeded in a total volume of 25ml at 5 x 105 cells/ml in 
Erlenmeyer flasks, so that on the day of transfection total cells were 1 x 106 cells/ml 
at a viability of 90% or above. Five antibody plasmids, listed in Table 3.1, were used 
to transfect FreeStyle 293-F cells to generate the desired antibodies. For transfection, 
293Fectin (Invitrogen) and Opti-MEM (1X) (Gibco Life Technologies) were brought  
Figure 3.9: Determination of correct orientation of anti-NIP variable heavy domain (VNIP). 
Both VNIP and the constant region gene carried EcoRI sites near their 3´ termini. When 
digested with EcoRI, the correct VNIP orientation should yield 1929bp for pEIgG1 and around 
1600bp for pIgG0.5HA, pIgG1HA and pONeg. 
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Table 3.1: Amount of DNA required for FreeStyle 293-F cells transfection 
Note:  The total amount of DNA is kept at 25µg. The ratio is for each DNA isHeavy chain:Light 
chain:pAdvantage = 0.5:2.0:0.5. 
 
 
Table 3.2: The type of antibody plasmid required for transfection 
 
 
to room temperature. For a single transfection, two aliquots of 0.833ml of Opti-
MEM (1X) were pipetted into two 30ml Universal tube. In one tube, the amount of 
DNA listed in Table 3.2 were added and mixed gently. In the other tube, 33.25µl of 
293Fectin was added and allowed to incubate for exactly 5 minutes at room 
temperature before the addition of the DNA mixture prepared earlier. Once the DNA 
mixture was added, the solution was gently mixed and allowed to incubate for 20-30 
minutes at room temperature. When completed, the solution was added to the 
FreeStyle 293-F cells and incubated on a shaker at 180rpm in an incubator in 8% 
CO2 at 37ºC. Antibody was ready to be harvested and purified after 4 days as 
described in section 2.8. 
Type of DNA expression vector Amount of DNA 
Heavy chain 4.17µg 
Light chain 16.67µg 
pAdvantage vector (Promega) 4.17µg 
Plasmid Antibody Code Name Encoded Antibody Chain 
pEIgG1 wt hIgG1 Anti-NIP wildtype human IgG1 heavy chain 
pIgG0.5HA 1HA Anti-NIP mutant human IgG1 heavy chain with full hIgA1 hinge inserted 
pIgG1HA 0.5HA Anti-NIP mutant human IgG1 heavy chain with half hIgA1 hinge inserted 
pONeg ONeg 
Anti-NIP O-linked negative mutant human IgG1 
heavy chain with mutated half hIgA1 hinge 
inserted 
prelLC LC Anti-NIP murine lambda light chain 
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3.3.4.2 Characterisation of antibody heavy and light chains 
Antibody purifications were carried out as described in section 2.8. Purified 
antibodies were subjected to SDS-PAGE as described in section 2.8.6. Protein gels 
were stained with Coomassie as described in section 2.8.8 to determine the purity of 
the antibodies generated. To further analyse the purified proteins, they were 
subjected to western blotting as described in section 2.8.7. After the blocking and 
washing procedure, the membranes were incubated with detecting antibodies: 
polyclonal goat anti-mouse lambda light chain HRP conjugated (Table 2.1 No.1) or 
polyclonal rabbit anti-human IgG HRP conjugated (Table 2.1 No.2). All membranes 
were washed and developed with appropriate substrate. 
 
3.3.4.3 Determination of NIP antigen recognition by ELISA 
NIP-binding ELISA was carried out as described in section 2.8.9. Wells of 96 well 
Maxisorp ELISA plates (Nunc) were coated with NIP-BSA at 1-2 μg/ml overnight at 
4°C. For certain control wells, buffer alone was used for coating. After the blocking 
and washing procedure, wells were incubated with 100μl of wt hIgG1, 0.5HA, 1HA 
and ONeg antibodies at 20 μg/ml for 60 minutes. For certain control wells, anti-NIP 
antibodies were replaced with PBST buffer only. The wells were washed as 
described and incubated with 100μl of detecting antibodies: polyclonal goat anti-
mouse lambda light chain HRP conjugated (Table 2.1 No.1) or polyclonal rabbit 
anti-human IgG HRP conjugated (Table 2.1 No.2). All wells were washed and 
developed with appropriate substrate. Absorbance of each well were read at 630nm. 
3.3.4.4 Determination of O-linked glycosylation by ELISA 
NIP-binding ELISA was carried out as described in section 2.8.9. Wells of 96 well 
Maxisorp ELISA plates (Nunc) were coated with NIP-BSA at 1-2 μg/ml overnight at 
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4°C. For certain control wells, buffer alone was used for coating. 1% (w/v) BSA in 
PBST was used as blocking buffer instead of 5% (w/v) milk. After the blocking and 
washing procedure, wells were incubated with 100μl of wt hIgG1, 0.5HA, 1HA and 
ONeg antibodies at 20μg/ml for 60 minutes. 100μl of 20μg/ml human IgA1 
produced from CHO cells (available in the Woof Lab) was used as positive control. 
The plates were washed as described and incubated with 100μl of biotinylated jacalin 
(Table 2.1 No.3) for 1 hour. For certain control wells, biotinylated jacalin were 
replaced with PBST buffer only. All wells were washed and further incubated with 
100μl of streptavidin HRP conjugated (Table 2.1 No.4) for another hour. The wells 
were washed and developed with appropriate substrate.  Absorbance of each well 




3.4.1 Restoration of missing DNA sequences 
Using the primer combinations of DS3 and GUHIAS, and GUHIS and AG3’NEW, 
DNA amplified fragments of the correct sizes of 1100bp and 140bp respectively 
were obtained as shown in Figure 3.10 A. Although there were other non-specific 
bands being amplified, the bands were not at similar sizes when compared to the 
desired ones, thus, allowing an easy purification. The GUHIAS and GUHIS primers 
were specifically designed not only to restore the missing DNA sequence, shown in 
red in Figure 3.5, but also to generate complementary regions to aid overlapping 
PCR. The result of the subsequent overlapping PCR procedure was shown in Figure 
3.10 B. The band obtained of approximately 1200bp indicated that the 1100bp and 




successful amplification. The PCR product and pE1001 vector were ligated together 
after digestion with BstEII and EcoRI restriction enzymes. After transforming the 
plasmids into E.coli, DNA plasmids were purified from positive clones and digested 
with BstEII and EcoRI and the presence of an insert size of 1240bp were confirmed 
as shown in Figure 3. 10 D. Subsequent DNA sequencing also confirmed that the 
previously missing DNA sequences had been successfully restored and the correct 
plasmid was named as pTF2.  
 
Interestingly, the result of DNA sequencing of positive clones also identified another 
mutant that carried only 10 amino acids from the human IgA1 hinge rather than the 
expected 18 amino acids. This mutant was most likely due to a mismatch at the 
region encoding the hinge during the overlapping PCR procedure. The hIgA1 hinge 
region sequence PSTPPTPSPSTPPTPSPS, has a repeated sequence of 8 amino 
acids before ending with a proline and a serine. It was suspected that during the 
Figure 3.10: Results of molecular cloning for heavy chain repair. A) PCR amplifications to 
reintroduce missing DNA sequences. Lane 1100bp shows PCR amplification using DS3 and 
GUHIAS to obtain DNA fragment at 1100bp. Lane 140bp shows PCR amplification using 
GUHIS and AG3’NEW to obtain DNA fragment at 140bp. B) Overlapping PCR. Complementary 
DNA fragments of 1100bp and 140bp from A. were amplified using DS3 and AG3’NEW to to 
produce a fragment of 1240bp. C) Restriction digest of pE1001 to obtain cut vector at 8000bp. D) 
Restriction digests of purified plasmid from positive clones. 
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overlapping PCR procedure, the DNA fragment had misaligned and bound to the 
second PSTPPTPS, skipping the primary repeat of this sequence, thus generating a 
mutant with about half the hIgA1 hinge. This mutant would be a useful comparison 
in this project, therefore, the plasmid was retained and named as pTF1. Finally, to 
repair the CH1 intron, pBSK-419bp was digested using the restriction enzyme 
HindIII and BstEII to obtain an insert of 419bp. The insert was then ligated into 
pTF1, pTF2 and pE1001 after performing a similar digestion to obtain suitably cut 
vectors. After transforming the plasmids into E.coli, DNA plasmids were purified 
from positive clones and subsequent DNA sequencing confirmed that the intron was 
successfully reintroduced (data not shown). 
 
3.4.2 Generation of O-linked negative mutant heavy chain expression plasmid 
Using the primer combinations of DS3 and OlinkedRev, and OlinkedForw and 
AG3’NEW, DNA amplified fragments of the correct sizes of 1100bp and 190bp 
were obtained as shown in Figure 3.11A. This suggested that although there were 
several nucleotide mismatches within the OlinkedRev and OlinkForw primers, the 
remaining complementary base pairs were sufficient for the primers to anneal at the 
targeted site. Overlapping PCR was performed after purifying the required DNA 
fragments and a successful amplification was indicated by generation of a DNA 
fragment with the correct size of 1290bp in Figure 3.11B. Amplified PCR product 
and pHCCR vector were ligated together after digestion with HindIII and BstEII 
restriction enzymes. After transforming the plasmids into E.coli, DNA plasmids were 
purified from positive clones and digested with HindIII and BstEII. The presence of 




confirmed that the mutations shown in Figure 3.7 had been successfully incorporated 
(data not shown). 
 
3.4.3 VNIP insertion 
VNIP insert was successfully obtained from pTAHG by performing a restriction 
digest using HindIII enzyme. Suitable cut vectors were obtained by digesting 
pHCCR, Fixed pTF-1, Fixed pTF-2 and pNO-ONeg with EcoRI enzyme. Since 
VNIP was flanked by HindIII sites, it was able to ligate in two different orientations. 
Initially, it was observed that many of the obtained clones lacked VNIP insertions. 
After several ligation attempts, plasmid that carried VNIP insertion with the correct 
orientation was obtained and subsequent DNA sequencing confirmed the presence 
and orientation of VNIP. Figure 3.12 shows a representative result with pONeg of a 
correct VNIP insertion whereby the size of the insert was around 1600bp, as 
described in Figure 3.9. 
Figure 3.11: Results of molecular cloning for generating O-Linked negative mutant heavy 
chain expression plasmid. A) PCR amplifications to introduce several mutations using 
designated primers. Four repeat experiments (190bp) of PCR amplification using DS3 and 
OlinkRev primers. Four repeat experiments (1100bp) of PCR amplification using OlinkForw 
and AG3’NEW primers. The correct sized product is seen in the third and fourth repeats. B) 
Two repeat experiments (1290bp) of an overlapping PCR amplification using the DNA 




3.4.4 Amino acid sequence of the hinge region of different antibodies 
The DNA sequencing result and the encoded amino acid sequence of the hinge 
region of each different hIgG1 antibody were shown in Table 3.3. In summary, wt 
hIgG1 has 5 amino acids, 0.5HA which incorporated only half the hinge region from 
hIgA1 has 13 amino acids, 1HA with the full hinge region from hIgA1 inserted has 
21 amino acids, and ONeg which is similar to 1HA has 21 amino acids in their hinge 
regions respectively. Although having similar hinge length, the difference between 
1HA and ONeg was that the residues corresponding to serine and threonine residues 
in the hinge region of 1HA were mutated to a mixture of glycine and alanine in 
ONeg, as shown in Table 3.3.  
 
3.4.5 Production and characterisation of recombinant antibodies 
Four antibody heavy chain constructs, pEIgG1, pIgG0.5HA, pIgG1HA and pONeg, 
were each transfected together with the light chain vector prelLC into FreeStyle 
293-F cells. After 4 days, supernatants of the cell cultures were incubated with 
Protein G-Sepharose and the antibodies expressed were efficiently purified. The 
amount of antibody obtained from a single 25ml transfection was around 200-250µg 
Figure 3.12: A representative result for 
determination of VNIP orientation. pONeg 
was digested with EcoRI enzyme and yielded 
an insert at around 1600bp which showed a 
correct orientation of the VNIP insert. 
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Table 3.3: DNA sequencing results and the translated protein sequences of the hinge region of different antibodies 
The number of amino acids in the hinge is indicated. Cys residues involved in H-L and the most N-terminal H-H interchain disulphide bonds and 






for all antibodies. Purified antibodies were subjected to SDS-PAGE, as described in 
Section 2.8.6. Figure 3.13 shows the results of the SDS-PAGE under both non-
reducing and reducing condition after Coomassie staining, and Figure 3.14 shows the 
western blotting results obtained when probing with anti-human IgG heavy chain 
HRP and anti-murine lambda light chain HRP detecting antibodies. As seen in 
Figure 3.13, the antibody preparations appear highly pure, with no obvious 
contamination with other proteins. There were some other faint bands below 150kDa 
seen under non-reducing conditions as shown in Figures 3.13A, 3.14A and 3.14C. 
However, under reducing conditions there were no bands observed other than the 
heavy chain band at 50-60kDa (Figures 3.13B and 3.14B) and the lambda light chain 
band at 25kDa (Figures (3.13B and 3.14D). This suggests that the faint bands seen 
under non-reducing conditions might be due to the presence of half molecules (HL or 
H-H), but these represent only a very minor proportion of the total antibody.  
 
Figure 3.13: Coomassie staining of purified antibodies after SDS-PAGE. A) Antibodies run 
under non-reducing conditions. B) Antibodies run under reducing conditions. Molecular 
weight markers were run in the left hand lane in both cases. Wt hIgG1, wildtype human IgG1; 
0.5HA, half hinge mutant; 1HA, represents full hinge mutant; ONeg, represents O-linked 




Figure 3.14: Western blotting of purified antibodies. A) Purified antibodies run under non-
reducing conditions probed with anti-human IgG heavy chain detecting antibodies. B) Purified 
antibodies run under reducing conditions probed with anti-human IgG heavy chain detecting 
antibodies. C) Purified antibodies run under non-reducing conditions probed with anti-murine 
lambda light chain detecting antibodies. D) Purified antibodies run under reducing conditions 
probed with anti-murine lambda light chain detecting antibodies. Molecular weight markers 
were run in the left hand lane in each case. Wt hIgG1, wildtype human IgG1; 0.5HA, half 
hinge mutant; 1HA, full hinge mutant; ONeg, O-linked negative full hinge mutant.	
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The absence of protein bands below 50kDa under non-reducing conditions (Figure 
3.13A) leads to the conclusion that the light chain formed the expected disulphide 
bonds with heavy chain and the restoration of the required cysteine residue had been 
successful. Although there were faint bands seen under non-reducing conditions with 
masses around 20-25kDa in blots probed with anti-heavy chain antibody (Figure 
3.14A), these bands were absent under reducing conditions (Figure 3.14B). 
Therefore, the hypothesis that these bands were free light chain could be neglected. 
In addition, the presence of only the predicted light and heavy chain bands under 
reducing conditions (Figure 3.13 B), suggested that the mRNA splicing mechanism 
was working correctly and there were no alternative splice variants being produced. 
Hence it could be concluded that the restoration of the lost intron had been successful. 
Under reducing conditions, there were noticeable differences in the molecular 
weights of the heavy chain of each of the antibodies, as seen in Figure 3.13B and 
Figure 3.14B. With the longest hinge, the heavy chain of IHA had the highest 
molecular weight of these antibodies. The heavy chain of ONeg demonstrated a 
lower molecular weight than than that of 1HA even though they had the same 
numberof amino acids in their hinge region. This finding suggests the presence of O-
linked glycosylation within the hinge regions of 0.5HA and 1HA but not that of 
ONeg, as anticipated.  
 
3.4.6 NIP antigen recognition 
In order to be able to directly compare the function of each antibody, all antibodies 
under test should have identical antigen recognition properties.  This approach is 
designed to ensure that any differences observed can be attributed to structural 




that were expected to be able to specifically recognise NIP. To confirm such antigen 
recognition, NIP-BSA was coated onto ELISA plate wells and purified antibodies 
were incubated to allow antigen binding. Bound antibodies were then detected using 
suitable detecting antibodies. Figure 3.15 shows the results of NIP antigen 
recognition based on ELISA. As seen in Figure 3.15, all antibodies produced were 
able to recognise NIP antigen as expected. The detection levels for all antibodies 
were very similar, suggesting that the antigen recognition was similar for all 
antibodies, as might be expected given their identical variable domains. Results from 
Figure 3.15 also suggest that the incorporation of longer hinge regions had no or 
minimal impact on antigen recognition, thus, allowing comparison between each 
antibody in subsequent analyses. 
 
 
Figure 3.15: NIP binding ELISA. 10µg/ml of NIP-BSA was coated onto ELISA plate wells and 
different antibodies were added at 20µg/ml. Wells were then developed using suitable substrate 
after probing with anti-human IgG heavy chain HRP (blue) or anti-murine lambda light chain 
HRP (green). Buffer represents PBST only (negative control). Wt hIgG1, wildtype human IgG1; 
0.5HA, half hinge mutant; 1HA, full hinge mutant; ONeg, O-linked negative full hinge mutant. 





3.4.7 Determination of O-linked glycosylation 
Due to the difference in the molecular weight observed between the heavy chains of 
1HA and ONeg in Figure 3.13 B and Figure 3.13 B, the presence of O-linked glycans 
was investigated using the lectin jacalin which has a high specificity for a common 
core structure of O-linked glycans, as mentioned in section 3.1.5. When used to 
probe blots of purified antibodies the biotinylated jacalin was found to react with 
both the light and heavy chains of all antibodies including wt hIgG1 which had no O-
linked glycans (data not shown). To resolve this issue of sensitivity, ELISA was 
applied because the antibodies were considered likely to retain their intact structure, 
rather than being denatured as in SDS-PAGE. Since it had been determined that all 
antibodies were able to recognise NIP when derivatised on BSA (Figure 3.15), a 
similar format was used to detect O-linked glycans using biotinylated jacalin. The 
Figure 3.16: ELISA result of O-linked glycans detection using jacalin. 10µg/ml of NIP-BSA was 
coated onto ELISA plate wells and different antibodies were added at 20µg/ml. Biotinylated 
jacalin at 0.2µg/ml was then used as an O-linked glycans detecting agent. Wells were then 
developed using suitable substrate after incubation with streptavidin-HRP at 0.2µg/ml. Bars in 
blue represent the tests without jacalin (as negative control). Bars in green represent the tests 
with jacalin addition. Wt hIgG1, wildtype human IgG1; 0.5HA, half hinge mutant; 1HA, full 
hinge mutant; ONeg, O-linked negative full hinge mutant; IgA1 (CHO), human IgA1 produced 
from CHO cells used as a positive control. The results show the mean of triplicate measurements. 
Bars represent standard deviation measurements.		
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results of the investigation are shown in Figure 3.16. Using hIgA1 and wt hIgG1 as 
positive and negative control respectively, the investigation showed that 0.5HA and 
1HA were indeed O-linked glycosylated and ONeg did not contain any O-linked 
glycans. It was noticed that there was a difference in the level of absorbance between 
0.5HA and 1HA in which 1HA had a higher absorbance level, suggesting that more 
jacalin had bound to 1HA compared to 0.5HA. The reason for such observation was 
most likely due to a lower level of O-linked glycosylation in 0.5HA compared to 
1HA because 0.5HA only contained half the hinge region of hIgA1, resulting in a 
fewer potential sites for O-linked glycosylation than 1HA which had the entire hinge 
region of hIgA1 incorporated. The absorbance level of ONeg was not significantly 
different from that of wt hIgG1, suggesting that the mutations of hinge region serines 
and threonines to alanines and glycines had indeed abolished O-linked glycosylation 
in the hinge region of ONeg. The low absorbance level of both wt hIgG1and ONeg 
also confirmed the specificity of jacalin for O-linked glycans and not N-linked 
glycans, since all antibodies were assumed to be similarly N-glycosylated. 
 
3.5 DISCUSSION 
The aim of this chapter was to generate upper hinge extended mutant hIgG1 
antibodies with identical antigen recognition capabilities as tools to investigate the 
role of the upper hinge region in IgG structure and function. Rather than randomly 
adding different amino acids to extend the upper hinge length of hIgG1, this project 
had chosen to incorporate the naturally evolved hinge region from hIgA1 into the 
upper hinge of wt hIgG1. The process ensured that the IgG cysteines that were 
required for inter-heavy chain disulphide bonding were not disturbed, thus, all 
antibodies generated should retain the normal antibody structure of two heavy and 
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two light chains as described in Chapter 1. Using a naturally occurring hinge 
sequence is less likely to be immunogenic, should such a construct ever be 
considered for therapeutic application. However, one concern regarding the hinge 
mutants is the possibility of the generation of neoepitopes at the points where the 
hIgG1 and hIgA1 sequences meet. Anti-hinge antibodies that recognises protease-
restricted neoepitopes located at the hinge region of human IgG or antiglycans 
antibodies specific to hIgA1 O-linked glycans had been found to be present in the 
serum of healthy individuals and patients suffering from various inflammatory 
diseases such as RA, SLE and IgA nephropathy respectively (Falkenburg et al., 2017; 
Ryan et al., 2008; Falkenburg et al., 2016; Tomana et al., 1999). For this project, the 
concern regarding immunogenicity can be neglected because the generated hinge 
mutants were not used for therapeutic purposes. 
 
Modifying the hinge region of hIgG1 required care as the area around the hinge 
region, especially the lower hinge region, is crucial for antibody effector function 
through Fcg receptor binding (Klein et al., 1981; Idusogie et al., 2000; Duncan et al., 
1988; Sondermann et al., 2000; Radaev and Sun, 2001; Lu et al., 2015; Kiyoshi et al., 
2015). In addition, since the CH2 domain is critical for binding of C1q and 
subsequent activation of the classical pathway of complement, structural changes to 
the hinge may also impact on complement activation. Hinge deleted mutants such as 
Dob, a human IgG1 cryoglobulin (Silverton et al., 1977), Mcg, a human IgG1 
(Guddat et al., 1993) and Lec, a human IgG1 (Rivat et al., 1976) were unable to 
activate complement protein C1q or bind Fcg receptors (Klein et al., 1981). The 
reason for this was because Dob, Mcg and Lec have a 15 amino acid hinge deletion 
which starts after Valine 216 resulting in a complete lack of the middle hinge (Rivat 
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et al., 1976; Guddat et al., 1993; Steiner and Lopes, 1979). Access to the binding 
sites for C1q and Fcg receptors, the latter located in the lower hinge region (Idusogie 
et al., 2000; Duncan et al., 1988), were blocked presumably as a result of the Fab 
arms coming into close contact with the Fc region due to the hinge deletion (Guddat 
et al., 1993; Silverton et al., 1977). In marked contrast, all three hinge mutants 
generated in this project have a hinge extension. Thus, it was expected that the 
binding sites of C1q and Fcg receptors were unlikely to be disrupted and to remain 
accessible, allowing studies into the role of hinge region on antibody effector 
function to be conducted. 
 
Using recombinant antibody technology, several groups had generated different 
antibody hinge mutants to study the impact of the hinge region on antibody function 
(Roux et al., 1998; Klein et al., 2014; Sandlie et al., 1989; Horgan et al., 1993; 
Michaelsen et al., 1992). In particular, Horgan and colleagues generated different 
hIgG1 and hIgG4 molecules (with and without hinges) and demonstrated that there 
were no significant differences in antigen binding in both solution and solid phase 
antigen binding assays between the mutants of the same isotype (Horgan et al., 1993). 
In agreement with this finding, the mutant antibodies generated in this project 
demonstrated that hinge region modification did not appear to affect the antigen 
binding ability of the antibodies in the solid phase antigen binding assay as shown by 
the NIP-BSA ELISA result. In a different scenario, Roux and colleagues reported the 
generation of several human IgG3 hinge mutants that had reduced hinge lengths, in 
order to investigate the role of the hinge on antibody flexibility (Roux et al., 1998). It 
was found that hIgG3 mutants with hinge regions containing more prolines were able 
to form higher order immune complexes such as tetramers rather than dimers that 
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were preferred by wt hIgG3 (Roux et al., 1998), indicating the impact of the 
flexibility of the hinge. The hIgA1 hinge region incorporated into different hIgG1 
mutants in this project contained several proline residues, leading to speculation that 
the hinge region of these hinge mutants may display a higher degree of flexibility 
compared to wt hIgG1.  
 
Interestingly, other workers have reported expression of several hIgG1 hinge mutants 
with hIgA1 hinge region insertions, but with additional mutations, in HEK-6E cells. 
These mutants were used to investigate different linker flexibilities using dynamic 
light scattering (Klein et al., 2014). Their studies found that mutants with extra hinge 
incorporated from hIgA1 had a higher hydrodynamic radius when compared to wt 
hIgG1 (Klein et al., 2014), suggesting that the hinge mutants adopted a more open 
conformation compared to hIgG1. Although the same hIgA1 hinge region was used, 
the hinge mutants produced by Klein and colleagues were different from the hinge 
mutants generated in this project. Klein and colleagues had introduced several 
mutations including a single or several asparagine residues or a linker peptide to the 
hIgA1 hinge region (Klein et al., 2014). In contrast, this project inserted wt hIgA1 
hinge region without any other mutations to generate the 1HA mutant. It would be 
interesting to investigate if the hinge mutants in this project behave in a similar way 
in dynamic light scattering studies to that reported by Klein and colleagues.  
 
While there have been numerous hinge mutants generated with various hinge lengths 
as mentioned earlier, the ONeg mutant in this project is the first mutant antibody to 
have a hinge length more than 20 amino acids long synthesised de novo without the 
presence of any O- or N-linked glycans or disulphide bonds at the hinge region. In 
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the past, Gala and Morrison had used benzyl 2-acetamido-2-deoxy-a-D-galacto- 
pyranoside (BADG), which blocks the formation of O-linked glycans after the 
addition of first GalNac to serine of threonine residues, to inhibit the complete O-
linked glycosylations of hIgA1 and hIgD (Gala and Morrison, 2002). The authors 
showed that the truncation of O-linked glycans did not inhibit the production and the 
secretion of hIgA1 and hIgD antibodies (Gala and Morrison, 2002). The successful 
production of the ONeg mutant in this chapter further improved the understanding on 
the role of O-linked glycans at the hinge region of antibodies by indicated that the 
presence of O-linked glycans of the hinge region is not an essential factor for 
antibody synthesis and secretion. As a result, whether the presence of the O-linked 
glycans on the hinge regions of hIgA1 and hIgD is evolved to maintain an open 
conformational structure for better antigen reach and to present lectin binding 
epitopes for trapping bacteria remains an open question. Nevertheless, the successful 
generation of different hinge mutants, 0.5HA, 1HA and ONeg, has opened up the 
possibility for further investigation in order to shed more light on the role of upper 
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As mentioned in the previous chapter, the Fab arms of an antibody are able to adopt 
a variety of positions at different times as suggested by the reported Fab-Fab angles 
exhibited by different IgG subclasses (Roux et al., 1997b; Saphire et al., 2002; Kilár 
et al., 1985). For example the observed Fab-Fab angles for antibodies studied by EM 
were 30º-210º for human IgG1; 60º-190º for IgG2; 20º-270º for IgG3 and 30º-210º 
for IgG4 (Roux et al., 1997b). In addition, different solved IgG crystal structures 
have exhibited different Fab-Fab angles, such as 148º by B12 (hIgG1), 132º by Kol 
(hIgG1), 185º by Mcg (hinge-deleted hIgG1), 172º by 231 (murine IgG2a) and 115º 
by 61.1.3 (murine IgG1) (Saphire et al., 2002).  
 
It might be argued that within the antibody molecule, the Fab arms use the most N-
terminal hinge disulphide bond as an anchor point to freely move around for better 
antigen binding, as described earlier in Chapter 1. Antigen binding occurs at the tips 
of the Fab arms, thus, the positioning of Fab arms is expected to have a direct effect 
on the bivalent antigenic distance of an antibody. For IgG, the length and flexibility 
of the upper hinge region is hypothesised to have a role in regulating the bivalent 
antigenic distance, as explained earlier. If this is true, one of the important features 
governed by the upper hinge of IgG would be the maximum bivalent antigenic 
distance. The maximum bivalent antigenic distance is a key feature of the antibody 
since it affects the monovalent and bivalent binding activity. However, this distance 
has rarely, if ever, been directly investigated. The importance of monovalent and 
bivalent binding of an antibody will be further described below in section 4.1.1. 
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Some Fab tip to tip distances of IgG antibodies have been reported in the past, such 
as that of rabbit IgG at around 120Å (Valentine and Green, 1967), those of murine 
IgG1, IgG2a and IgG2b at around 117Å - 134Å (Sosnick et al., 1992), that of human 
IgG1 (Kol) at 145Å (Marquart et al., 1980), and that of human IgA1 at 170Å 
(Boehm et al., 1999). However, these findings were derived from solved crystal 
structures or molecular models generated based on X-ray and neutron scattering and 
were not the actual functional bivalent antigenic distance of the antibodies. As a 
result, this thesis hopes to study the impact of the length of upper hinge on the 
functional bivalent antigenic distance of an IgG antibody.  
 
This project hypothesised that the longer the region of amino acids at the upper hinge 
of IgG the greater the bivalent antigenic distance was likely to be. The generated 
hIgG1 hinge mutant antibodies with different upper hinge lengths, described in the 
previous chapter, are suitable candidates for testing this hypothesis. However, in 
order to test this hypothesis molecular “rulers” of known length are required. This 
chapter sought to test whether dsDNA might serve as a suitable framework for 
molecular “rulers”. dsDNA offers the advantages that its length can be readily 
calculated and molecules of different length can be easily generated which will be 
further described in section 4.1.2.  
 
4.1.1 Antibody maximum bivalent antigenic distance 
Since all antibody molecules have two Fab arms, each antibody could bind 
monovalently or bivalently to a pathogen depending on the density of the target 
antigen on the surface of the pathogen. One of the important features of an antibody 
that regulates monovalent/bivalent antigen binding activity is the bivalent antigenic 
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distance. An antibody that has a greater bivalent antigenic distance is expected to be 
better able to achieve bivalent binding and remain associated with targeted antigen 
for a longer period of time compared to an antibody with a shorter bivalent antigenic 
distance, as shown in Figure 4.1. The reason for this phenomenon, as described in 
Figure 4.1, is because when the targeted antigen is at a low density and individual 
antigen molecules are spaced at relatively further apart, an antibody with a greater 
bivalent antigenic distance has the ability to reach two antigens simultaneously. Thus, 
such antibody will increase in overall avidity. In contrast, an antibody with a shorter 
bivalent antigenic distance would only be able to bind monovalently, hence, showing 
a lower avidity. In addition, when an antigenic dissociation occurs at one of the Fab 
arms of an antibody that is binding bivalently, the antibody remains localised at the 
area due to the association of the remaining Fab arm bound to target antigen. Such 
maintained association may allow the initiation of effector mechanisms or the 
dissociated Fab arm to rebind antigen. In constrast, when an antigenic dissociation 
occurs at the Fab arm of an antibody that is binding monovalently, the antibody is 
more likely to diffuse away from its targeted antigen and the antigen-antibody 
complex is lost. Obviously, the antigen binding affinity plays a major role as well. 
The disadvantage of monovalent binding described above will not be a major 
problem if the antigen binding affinity of the antibody is high because the rate of 
dissociation will be significantly reduced by high affinity binding. However, if the 
binding affinity is low then an antibody with a greater bivalent antigenic distance 
will have the advantage to bind bivalently to target antigens, improving overall 
binding avidity and reducing the rate of dissociation. As a result, it would be a great 
advantage if the bivalent antigenic distance of an antibody could be modified and 




In the past, Tang and colleagues had generated different hIgG1 antibodies capable of 
recognising an identical epitope on the extracellular domain (ECD) of HER2/neu 
receptor (CD340) but with different antigen binding affinities. These were tested on 
different tumour cells, which had different expression levels of HER2/neu receptor, 
Figure 4.1: A diagram illustrating the advantage of an antibody which has a greater bivalent 
antigenic distance when the targeted antigen density is low and individual antigen molecules 
are spaced relatively far apart. A) An antibody with shorter bivalent antigenic distance will 
only bind monovalently to antigen. Upon a single Fab arm dissociation, the antibody would 
lose the association with target antigen and diffuse away. B) An antibody with greater bivalent 
antigenic distance will bind bivalently to antigen. Upon a single Fab arm dissociation, the 
antibody remains localised due the remaining Fab arm which may allow the dissociated Fab 
arm to regain antigen binding. Red triangle represents targeted antigen. 
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to investigate the role of antigen binding affinity and antigen density on ADCC 
activation (Tang et al., 2007). The authors reported that the antibody variants C6.5 
and H3B1 exhibited a different tumour surface retention profile in which C6.5 was 
lower than that of H3B1 after incubation with cells that expressed high levels of 
surface antigen. The authors suggested that this difference was due to differing 
antigen intrinsic binding affinity, in which C6.5 had a Kd = 2.3x10-8M whereas H3B1 
had a Kd = 5.6x10-10M. It was proposed that the higher intrinsic binding affinity of 
H3B1 allowed it a higher likelihood of bivalent binding due to slower dissociation 
rate and, in contrast, C6.5 was mainly monovalent binding because either one of the 
Fab arms was dissociating from its target antigen at a faster rate (Tang et al., 2007). 
Similarly, Velders and colleagues had compared the ADCC activity of two different 
murine monoclonal antibodies, 17-1A and 323/A3, which could recognise 
overlapping epitopes on epithelial cell adhesion molecule (Ep-CAM) (Velders et al., 
1998). Interestingly, 323/A3 had a binding affinity 40-fold higher than 17-1A and by 
regulating the expression level of Ep-CAM on transfected cells and that the authors 
reported that 323/A3 outperformed 17-1A in all ADCC assays. It is very likely that 
the higher binding affinity of 323/A3 increased the antibody surface retention time 
and maximised antibody effector functions. From a different point of view, the 
antibody surface retention time could also be increased with improved bivalent 
binding activity. As a result, structural modifications which could increase the 
bivalent antigenic distance of an antibody may be highly beneficial. 
 
4.1.2 dsDNA as a molecular “ruler” to measure antibody bivalent antigenic 
distance 
As mentioned above, dsDNA was selected as the molecular “ruler”. The reason for 
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this decision was that in order to accurately measure the bivalent antigenic distance 
of an antibody, the length of this ruler should be known and it should be possible to 
manipulate this length. Fortunately, the structure of dsDNA was solved by Watson 
and Crick in 1953 (Watson and Crick, 1953). Based on the solved structure of DNA, 
a single complete turn which consists of 10 nucleotides, was determined to have a 
length of 34Å (3.4nm) (Watson and Crick, 1953). Thus, in a stretch of DNA a single 
nucleotide would contribute a distance of 0.34nm. This information allows the 
calculation of the length of any DNA fragment provided the number of basepairs 
(nucleotides) is known. Since oligonucleotide synthesis can generate short DNA 
fragments of desired numbers of nucleotides, the length of the dsDNA molecules can 
be easily manipulated in order to obtain a desired length. dsDNA of short lengths is 
very stable and rigid in structure. A previous study reported that dsDNA has a 
persistence length of 50nm (Smith et al., 1992). The persistence length of dsDNA is 
defined as the maximum length of the dsDNA to maintain a rigid linear 
conformation (Smith et al., 1992; Hagerman, 1988). Since this distance was at least 3 
fold longer than the reported bivalent antigenic distance of human IgG, dsDNA 
appears to have the potential as a suitable molecular “ruler” to measure antibody 
bivalent antigenic distance. Besides the advantage of ease of length modification, 
dsDNA also offers the capacity to conjugate the 5¢ end of both the sense and 
antisense strands to different compounds such as fluorescent labels or antigens 
(Zearfoss and Ryder, 2012). In this project, this advantage allowed NIP hapten to be 
covalently conjugated to the 5¢ end of each DNA strand, therefore, generating a 
bivalent ligand, as shown in Figure 4.2A. Such ligand should facilitate the binding of 







Figure 4.2: The concept of using dsDNA as a molecular “ruler” to measure the bivalent 
antigenic distance of an antibody. A) A bivalent ligand composed of biotinylated dsDNA with 
NIP antigen covalently attached to both 5´ ends. B) Anti-NIP antibody can bind bivalently to 
short dsDNA bivalent ligand. However, when the length of the dsDNA bivalent ligand is 
increased beyond the bivalent antigenic distance of the antibody, the binding will change from 
bivalent to monovalent, which will be an indication of the bivalent antigenic distance of the 
antibody. 
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hence, through the use of dsDNA molecules of differing lengths allow the 
measurement of the bivalent antigenic distance of an antibody by observing the 
dsDNA length at which binding was monovalent rather than bivalent, as described in 
Figure 4.2B. This approach gives us a chance to measure the actual functional 
bivalent antigenic distance which is distinctively different from, and more 
physiologically relevant than, the reported Fab tip to tip distances which were 
derived from crystal structures or molecular models. 
 
Once produced, NIP-derivatized dsDNA fragments of desired length could be used 
in surface plasmon resonance (SPR) analysis (details are described in Chapter 5) that 
would require the dsDNA to be anchored onto sensor chips. It can be very difficult to 
immobilise dsDNA onto different surfaces due to its highly negative charge (Watson 
and Crick, 1953). In order for dsDNA molecules to be anchored in a controlled 
fashion onto sensor chips, incorporation of a biotinylated deoxythymidine nucleotide 
was required, shown in Figure 4.2A. The incorporated biotin molecule was designed 
to allow tight association with streptavidin immobilised onto different surfaces 
including sensor chips for SPR analysis (Liu and Wilson, 2010). The biotinylated 
deoxythymidine was positioned in the middle of the dsDNA molecule to minimise 
any disturbance to the antigen binding sites which were located at both ends of the 
dsDNA molecule.  
 
4.1.3 Monovalent streptavidin and biotin association 
Steptavidin and biotin association is a very tight interaction with a dissociation 
constant (KD) in the femtomolar range (Howarth et al., 2006). One streptavidin 
protein can bind up to 4 biotin molecules (Howarth et al., 2006). As mentioned 
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above, the approach taken was to use streptavidin to anchor the dsDNA to SPR 
sensor chip surfaces after streptavidin/biotin association. However, having 4 
dsDNAs anchored to each streptavidin molecule would not be ideal and would 
preclude the function as a molecular “ruler” because it would likely result in multiple 
antigens in close proximity, rendering any measurement of the bivalent antigenic 
distance inaccurate. Fortunately, Howarth and colleagues had generated a mutant 
streptavidin with only one biotin binding site per molecule, named monovalent 
streptavidin (Mono-Strep) (Howarth et al., 2006). Mono-Strep is similar to wildtype 
streptavidin but 3 of the 4 biotin binding sites had been mutated to abolish their 
association with biotin (Howarth et al., 2006). More importantly, the remaining 
biotin binding site retains the femtomolar binding affinity towards biotin (Howarth et 
al., 2006). With just one binding site for biotin yet retaining a strong association with 
biotin, Mono-Strep was the best candidate to be used to anchor the dsDNAs since it 
would overcome all the difficulties mentioned previously. However, whether the NIP 
antigens on dsDNA molecules remained accessible for antibody binding after 
associating with Mono-Strep had yet to be investigated. 
 
4.2 AIMS 
This project hypothesised that the longer the upper hinge region the greater the 
bivalent antigenic distance of an antibody was likely to be. To test this hypothesis, 
this chapter aimed to evaluate whether dsDNA might be a suitable molecular “ruler”. 
The approach chosen was to generate several dsDNA molecules of different lengths 
with NIP antigen conjugated to each end and determine whether the NIP antigen 
could then be recognised by anti-NIP antibody after biotin incorporation and Mono-
Strep association. 
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4.3 MATERIALS AND METHODS 
 
4.3.1 MATERIALS AND BUFFERS 
 
NIP-OSu 
4-Hydroxy-3-iodo-5-nitrophenylacetic acid succinimidyl ester (NIP-OSu) was 
purchased from Cambridge Research Biochemicals. 
 
DNA Annealing buffer 
An annealing buffer of 10mM Tris, 50mM sodium chloride, 1mM EDTA, pH 7.5-8.0 
was prepared and autoclaved. 
 
5X TBE 
A 5X TBE (89mM Tris, 89mM boric Acid, 2mM EDTA) stock was prepared. This 
stock solution was diluted to 1X with Milli-Q water prior to use. 
 
Molecular weight marker 
A suitable molecular weight marker comprising 0.02% (w/v) bromophenol blue and 
0.02% (w/v) xylene cyanol in Milli-Q water was prepared. 
 
20bp NIP-DNA oligonucleotides 
Two DNA oligonucleotides listed in Table 4.1 were purchased from Biosearch 
Technologies. Both oligonucleotides were reconstituted at 1mM with Milli-Q water 





Table 4.1: DNA sequence and modifications of purchased oligonucleotides 
 Oligonucleotide DNA sequence and modifications 
1. 20bp NIP-C6-ATCTCGGTGACGGGCAGGAC 3¢ 
2. 20bp Biotin NIP-C6-GTCCTGCCCGTCACCGAGAT 3¢ 
 




45bp and 55bp DNA oligonucleotides 
Four DNA oligonucleotides listed in Table 4.2 were synthesised by the 
Oligonucleotide Synthesis Service (University of Dundee) at a scale of 1μM. 
 
 
Table 4.2: DNA sequence and modifications of synthesised oligonucleotides 
 Oligonucleotide DNA sequence and modifications 
1. 45bp C6-ATCTCGGTGATCTACTATCGGCATGGCTTACAG 
TGCGGGCAGGAC 3¢ 
2. 45bp-Biotin C6-GTCCTGCCCGCACTGTAAGCCATGCCGATAGT 
AGATCACCGAGAT 3¢ 
3. 55bp C6-GTCTCGGTGCTCGATCGTACTATCGGCATGGCT 
TACAGTGCGGGTGAATCAGGAC 3¢ 
4. 55bp-Biotin C6-GTCCTGATTCACCCGCACTGTAAGCCATGCCG 
ATAGTACGATCGAGCACCGAGAC 3¢ 
 










4.3.2 GENERATION OF NIP-CONJUGATED DNA OLIGONUCLEOTIDES 
(45bp AND 55bp) 
 
4.3.2.1 Cleavage of DNA oligonucleotide and deprotection of 5¢ amino modifiers  
Four DNA oligonucleotides listed in Table 4.2 were synthesised by the 
Oligonucleotide Synthesis Service (University of Dundee). Upon completion of a 
single DNA oligonucleotide synthesis, two sterile 2ml syringes, one filled with 2ml 
of 20% diethylamine (Sigma) in acetonitrile (Sigma), were attached to both ends of 
the synthesis column. The synthesis column was washed by performing a “push-pull” 
technique for 10 times and allowed to incubate at room temperature for 5 minutes to 
remove the cyanoethyl group that could react with the free amino group at the 5¢ end 
of the DNA oligonucleotide during the subsequent deprotection procedure. The 
solution was then discarded and the synthesis column was washed with 2ml of 
acetonitrile using the same procedure. When done, the solution was discarded and 
the same procedure was repeated with 2ml volume of air to dry the synthesis column. 
Using a new pair of sterile 2ml syringes, subsequent cleavage of the DNA 
oligonucleotide and deprotection of the 5¢ amino modifier was carried out 
simultaneously by performing the “push-pull” technique for 10 times with 2ml of 
ammonium hydroxide (Sigma) every hour for 3 hours and the synthesis column was 
kept in the dark at room temperature during the process. Upon completion, the DNA 
oligonucleotide-containing ammonium hydroxide solution was transferred to a 4ml 
glass vial (Wheaton®, 224802) and sealed with a cap (Sigma, Z106429). The glass 
vial was labeled and incubated at 65ºC using a heat block for 2 hours. The vial was 
then cooled on ice for 10 minutes before transferring the solution into a 2ml 
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microfuge tube and dried overnight using a SpeedVac Concentrator (SPD111V, 
ThermoFisher Scientific).  
 
4.3.2.2 NIP hapten coupling 
Dried DNA oligonucleotides were resuspended in 200μl of Milli-Q water and the 
concentration of each was measured using a NanoDrop machine (section 2.4.10). 
20nmol of DNA oligonucleotide and 200nmol of NIP-OSu (a ratio of 1:10 
DNA/Hapten) were used for the coupling reaction. Each reaction mixture, shown in 
Table 4.3, was set up in a 1.5ml microfuge tube and incubated overnight at room 
temperature with shaking at 200rpm on a shaker, Thermomixer F1.5 (Eppendorf). 
 
Table 4.3: Reaction conditions for NIP hapten coupling 
Reagent Volume 
Hapten NIP-OSu in DMSO (200nmol) 42 μl 
0.1M Sodium tetraborate, pH 8.5 225 μl 
DNA Oligonucleotide (20nmol) 12 μl 
Milli-Q water 21 μl 
Total 300 μl 
 
4.3.2.3 DNA acrylamide gel electrophoresis purification 
Due to the low molecular weight of the DNA oligonucleotides, a 14% acrylamide gel 
was used for purification after the coupling procedure. The recipe listed below was 
used to make one gel. 
 
14% acrylamide gel  
Denature gel stock (20% Acrylamide/Bis, 7M Urea in TBE)           42 ml 
7M Urea in 1X TBE                                                                          18 ml 
10% Ammonium persulfate                                                             500 μl 
TEMED                                                                                              25 μl 
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A vertical slab gel apparatus (C.B.S. Scientific, SG-250-02) was set up according to 
the manufacturer’s instructions. Acrylamide gel solution was poured between the gel 
plates and a comb was inserted before allowing it to set overnight. Once the gel was 
ready, the gel plates, which contained the gel, were placed into the apparatus and the 
tank was filled with fresh 1X TBE buffer. The comb was removed and the apparatus 
was run without any samples at 650V for 10 minutes to slightly warm up the gel. 
DNA samples was prepared by adding an equal volume (300μl) of formamide 
(Sigma) to the DNA oligonucleotide-hapten reaction mixture before being heated to 
95ºC for 5 minutes in a heat block, then cooled on ice for 2 minutes. Samples were 
loaded into respective wells at a maximum volume of 150μl per well. 100μl of 
molecular weight marker (section 4.3.1) was loaded for size referencing. Samples 
were run at 650V until the sample marker xylene cyanol reached the bottom of the 
gel, in about 2.5-3 hours. When the electrophoresis process was completed, the gel 
plates were removed from the tank and dismantled to expose the gel.  
 
4.3.2.4 DNA oligonucleotide extraction from acrylamide gel 
After electrophoresis, the gel was placed on top of a glass TLC plate coated with 
fluorescent indicator (TLC Silica gel 60 F254, Merck Millipore). The DNA 
oligonucleotide bands were then viewed using a compact UV lamp (UVGL-25, UVP) 
and cut out using sterile scalpels. In order to extract the DNA oligonucleotide from 
the excised gel piece, a Unidirectional Electroelutor (International Biotechnologies, 
Inc) was set up according to the manufacturer’s instructions. The tank was filled with 
1X TBE buffer while the reservoir for DNA collection was filled with 140μl of 8M 
ammonium acetate. The gel pieces containing DNA were placed onto their respective 
wells and the device was run at 150V for 45 minutes. Upon completion, DNA-
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containing 8M ammonium acetate was recovered and transferred into a 1.5ml 
microfuge tube. 1ml of 100% ethanol was added to each tube and incubated at -20ºC 
for at least 1 hour to precipitate the oligonucleotide before being dried overnight 
using a SpeedVac Concentrator (SPD111V, ThermoFisher Scientific). 
 
4.3.2.5 Purification of DNA using High Performance Liquid Chromatography 
(HPLC) 
Dried DNA oligonucleotides were reconstituted in 200μl of 5% acetonitrile in 0.1M 
Triethylammonium acetate (TEAA). High Performance Liquid Chromatography 
(HPLC) was performed to separate the NIP-conjugated DNA oligonucleotides from 
the unconjugated ones. Details of the HPLC apparatus were listed in Table 4.4. 5% 
acetonitrile in 0.1M TEAA was used as the initial running buffer and 200μl of DNA 
sample was injected into the system and binding allowed to occur before being 
eluted with an increasing gradient of acetonitrile. The absorbance of the DNA 
sample was measured at 260nm. The fractions of DNA oligonucleotide that had 
successfully been conjugated to NIP hapten were collected into a 1.5ml microfuge 
tube. The tubes were then placed into a SpeedVac Concentrator (SPD111V, 
ThermoFisher Scientific) and allowed to dry overnight. Dried NIP-DNA 
oligonucleotides were reconstituted in 15μl of Milli-Q water and the concentration 
for each was determined using a NanoDrop machine (section 2.4.10). 
 
Table 4.4: Details of the HPLC devices used 
HPLC Components Product details 
Pump Dionex P680 HPLC Pump 
Detector Dionex PDA-100 Photodiode Array Detector 
Column Ace 10 C18-300 
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4.3.3 CHARACTERISATION OF NIP-CONJUGATED DNA 
 
4.3.3.1 Formation of dsDNA 
To ensure that all biotin-derivatised ssDNA would form dsDNA, the unbiotinylated 
ssDNA strand was added in slight excess during the generation of dsDNA. In each 
case, 55μl of 20μM unbiotinylated oligonucleotide strand and 50μl of 20μM 
biotinylated DNA strand were prepared in DNA annealing buffer (section 4.2.1) in 
0.5ml microfuge tubes respectively. Each strand was then mixed with its 
complementary strand to produce a final volume of 105μl of approximately 10μM 
DNA. To generate dsDNA, the DNA mixtures were then heated to 95ºC for 5 
minutes, in a Mastercycler personal PCR machine (Eppendorf), and allowed to cool 
to room temperature for 1 hour. The tubes were then briefly centrifuged and were 
ready for analysis or to be stored at -20ºC. 
 
4.3.3.2 DNA polyacrylamide gel electrophoresis 
A Bio-Rad Mini Protean II apparatus was set up according to the manufacturer’s 
instructions. 20% polyacrylamide gel solution, shown in Table 4.5, was poured into 
gel plates and a comb was inserted before allowing the solution to solidify. Once the 
gel had solidified, the gel plates were placed into the apparatus and the tank was 
filled with fresh 1X TBE buffer and the comb removed. An appropriate volume of 
10X BlueJuiceTM Gel Loading Buffer (Invitrogen, 10816-105) was added to 200ng of 
each prepared DNA sample to a final 1X concentration prior to loading into the gel. 
10μl of molecular weight marker (section 4.3.1) was loaded for size referencing. The 




Table 4.5: Recipe for 20% DNA polyacrylamide gel 
Components Volume required for 20% Gel 
1X TBE 4.85 ml 
Acrylamide/bis (30%) 10 ml 
10% Ammonium persulfate 150 μl 
TEMED 6 μl 
 
4.3.3.3 Staining of DNA gel 
When the electrophoresis process was completed, the gel plates were removed from 
the tank and dismantled to expose the gel. The gel was then incubated in 50ml 1X 
SYBR® Safe DNA gel stain (Invitrogen, S33102) for 1 hour before viewed using a 
GelVue UV Transilluminator (Syngene). 
 
4.3.3.4 ELISA analysis 
Different concentrations (0.0-1.0μM and 2.0μM) of 20bp NIP-dsDNA and Mono-
Strep were prepared in ELISA coating buffer (section 2.7.1). For a single well, 50μl 
of 20bp NIP-dsDNA and 50μl of Mono-Strep were mixed together at the same 
molarity and allowed to associate for 1 hour at room temperature. When completed, 
the mixture was coated onto a well of a 96 well Maxisorp ELISA plates (Nunc) as 
described in section 2.8.9. ELISA coating buffer alone and 1μM Mono-Strep 
(without DNA) were used in control wells. ELISA analysis was carried out as 
described in section 2.8.9. 20μg/ml of anti-NIP wildtype hIgG1 was used as primary 
detecting antibody and anti-mouse lambda light chain HRP (Table 2.1, No.1) was 







4.4.1 Conjugation of NIP-hapten to DNA and purification of NIP-DNA 
The separation of NIP-conjugated and unconjugated DNA oligonucleotides during 
purification using HPLC might be anticipated to be challenging due to the small 
molecular weight of NIP, which was around 420Da, when compared to those of the 
45bp and 55bp DNA oligonucleotides, which were around 14kDa and 17kDa 
respectively. To resolve this, both unconjugated and NIP-conjugated 45bp DNA 
oligonucleotide samples were injected to the HPLC system for a test run and the 
results of DNA sample elution were compared to determine if the HPLC system 
would be suitable for the DNA purification. The result of the DNA elution 
comparison from HPLC for unconjugated and NIP-conjugated 45bp DNA 
oligonucleotides is shown in Figure 4.3. Surprisingly, the elution times for the 
unconjugated and NIP-conjugated 45bp DNA oligonucleotides were significantly 
different, as shown in Figure 4.3, allowing for easy purification. Two defined peaks 
were observed for the NIP-conjugated sample indicating the presence of both 
residual unconjugated DNA and the major NIP-conjugated DNA product. As 
indicated in Figure 4.3, the DNA peak eluting at 12 minutes has the same elution 
time as the control unconjugated 45bp DNA oligonucleotide, confirming that the 
DNA eluted at this timepoint was unconjugated DNA. In comparison, the DNA peak 
that was eluted at 15 minutes had a higher molecular weight, consistent with the 
identity of this particular fraction being NIP-conjugated DNA. 
 
After determining that the separation and purification of the NIP DNA samples was 




Biotin DNA, 55bp NIP DNA and 55bp NIP Biotin DNA, was carried out. The 
elution profiles of each DNA sample purified using HPLC chromatography is shown 
in Figure 4.4. The results obtained for all DNA samples were very similar to that 
shown in Figure 4.3 where two major peaks were seen. The DNA fractions 
comprising the second peak were collected as the NIP-conjugated fraction. These 
samples were then dried and reconstituted in Millipore water. The concentration of 
the recovered NIP-conjugated DNA was around 14-16 nmol in each case, suggesting 
that around 75% of each initial DNA sample became conjugated with NIP hapten. 
Some minor peaks were also evident during the purification as shown in Figure 4.4. 
However, these were most likely degraded DNA fragments or other minor 
contaminations.  
 
4.4.2 Formation of double stranded DNA  
After formation of dsDNA, samples were analysed on 20% polyacrylamide gels 
 Figure 4.3: A comparison of HPLC elution profiles of unconjugated and NIP-conjugated 45bp 








Figure 4.4: HPLC chromatography profiles of different DNA samples. Red arrow indicates 
the fractions that were purified. A) 45bp NIP-DNA. B) 45bp NIP-DNA Biotin. C) 55bp 




(Figure 4.5). dsDNA of 20bp, 45bp and 55bp was seen to have been successfully 
generated as demonstrated by the products having significantly larger molecular 
weights than either of their respective parent ssDNAs. The difference in the 
molecular weight between the parent 55bp ssDNA and the product 55bp dsDNA, 
shown in Figure 4.5, was less marked but still apparent. A 14% polyacrylamide gel 
had been attempted to provide a more distinctive separation between these species. 
However, the result was not ideal as severe smearing was observed for both 45bp 
and 55bp dsDNA. Due to the limited amount of NIP-conjugated DNA further 
attempts were not attempted. In addition, the success of dsDNA formation was also 
supported by the fluorescent intensity of the dsDNA bands, shown in Figure 4.5 lane 
ds20bp, ds45bp and ds55bp, which were stronger than those of the corresponding 
ssDNA bands, since the staining reagent is reported by the manufacturer to exhibit 
higher binding to dsDNA than ssDNA. The result from Figure 4.5 also indicated that 
the DNA staining reagent bound less well to biotinylated ssDNA as shown by the 
Figure 4.5: Polyacrylamide DNA electrophoresis. DNA was stained with SYBR Safe DNA Gel 
Stain. Marker; DNA molecular weight markers. 20bp, 20bp ssDNA; 20bp Biotin, biotinylated 20bp 
ssDNA; ds20bp, 20bp dsDNA; 45bp, 45bp ssDNA; 45bp Biotin, biotinylated 45bp ssDNA; ds45bp, 
45bp dsDNA; 55bp, 55bp ssDNA; 55bp Biotin, biotinylated 55bp ssDNA; ds55bp, 55bp dsDNA.	
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significantly weak fluorescent intensity, especially in lane 20bp Biotin which was 
barely visible. The reason for this may be due to the presence of biotin, positioned at 
the middle of the ssDNA, which might have caused some disturbance to the binding 
of the staining reagent. Nonetheless, the successful formation of dsDNA indicated 
that the generation of a bivalent molecular “ruler” could be achieved. The subsequent 
step would be to determine if the NIP conjugated to DNA could be recognised by 
anti-NIP antibodies. 
 
4.4.3 The estimated length of each of the DNA fragment  
The length of each DNA fragment was calculated based on the solved DNA structure 
where a single complete turn, consisting of 10 nucleotides, was determined to have a 
length of 34Å (3.4nm) (Watson and Crick, 1953) and the length of the 6 carbon 
linker chain based on a Carbon-Carbon bond length reported to be 1.54Å (0.154nm) 
(Pauling and Brockway, 1937) and the result is shown in Table 4.6. The overall 
estimated length of 20bp NIP-dsDNA was 7.57nm, 45bp NIP-dsDNA was 16.06nm 
and 55bp NIP-dsDNA was 19.47nm.  
 
Table 4.6: Estimated length of each DNA fragment 
Note: A The estimated overall length of dsDNA not including C6 or NIP antigen, based on 0.34nm 
per nucleotide (Watson and Crick, 1953). 
B The estimated length of the 6 carbon atom linker, based on a C-C distance of 0.154nm i.e. 5 








One 6 Carbon 




20 6.8 0.77 7.57 
45 15.3 0.77 16.07 
55 18.7 0.77 19.47 
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4.4.4 NIP-dsDNA antigen recognition 
In order for the NIP-dsDNA to be used as a molecular “ruler”, the NIP antigens 
covalently conjugated to the DNA have to be able to be bound by an anti-NIP 
antibody. Generated 20bp NIP-dsDNA antigen recognition was analysed using 
ELISA and the result is shown in Figure 4.6. Anti-NIP wt hIgG1 appeared to be able 
to bind to NIP antigen conjugated to 20bp dsDNA that had formed a complex with 
Mono-Strep (NIP-dsDNA/Strep) as evidenced by the significant difference (almost 
two-fold) in absorbance level between sample wells coated with 0.5μM, 1.0μM and 
2.0μM 20bp NIP-dsDNA/Strep and the control wells. The anti-NIP wt hIgG1 was 
specific for NIP antigen and had no or very little non-specific binding to monovalent 
streptavidin as shown by the low absorbance level of control wells coated with 
1.0μM monovalent streptavidin alone. It was noticed that coating of different 
concentrations of 20bp NIP-dsDNA/Strep resulted in very similar absorbance levels, 
as seen in Figure 4.6. This finding suggested that the sample wells might have been 
saturated with 20bp NIP-dsDNA/Strep at all concentrations, limiting the amount of 
antibody able to bind. To resolve this issue, a similar ELISA analysis but with lower 
concentrations of 20bp NIP-dsDNA/Strep was carried out to check if a ‘dose-
response’ curve could be achieved. The result of this analysis is shown in Figure 4.7. 
Surprisingly, a maximum absorbance level was achieved when coating 20bp NIP- 
dsDNA/Strep at a concentration of around 0.4μM, and increasing concentrations of 
coating material beyond this point did not appear to result in higher levels of anti-
NIP antibody binding. This result suggested that the sample well may be saturated at 
a concentration of 0.4μM 20bp NIP-dsDNA/Strep and due to the limited availability 
of NIP antigen molecules (only two per complex) the corresponding low levels of 




successful detection of bound anti-NIP wt hIgG1 confirmed that the recognition site 
of NIP antigen was not hindered by the structure of the dsDNA and Mono-Strep and 
that the generation of a molecular “ruler” for measuring an antibody bivalent 
antigenic distance had been successful.  
 
4.5 DISCUSSION 
As mentioned previously, the free movements of the Fab arms to conduct better 
positioning for antigen binding are mainly governed by the length and flexibility of 
the region between the end of the CH1 domain and the first inter-heavy chain 
disulphide bridge, i.e. the upper hinge region for IgG. Therefore, the maximum 
Figure 4.6: ELISA result of antigen recognition of 20bp NIP-dsDNA/Strep by anti-NIP wt hIgG1. 
Either different concentrations of 20bp NIP-dsDNA/Strep (0.5μM, 1.0μM and 2.0μM), 1.0 mM 
Strep alone, or buffer only were coated onto sample wells and 20μg/ml of anti-NIP wildtype 
hIgG1 was incubated to allow binding. Anti-mouse lambda light chain-HRP was used to detect 
antibody binding. +/- represented the addition or absence of particular protein. The results shown 
are the average of duplicate determinations, and the bars represent standard deviation 




distance of antigen binding between two Fab arms of an IgG antibody would be 
expected to be dependent on the length and flexibility of the upper hinge region. It 
was hypothesised that the longer the upper hinge region of an IgG the further the Fab 
arms may be spaced away from the Fc region, thus granting a greater bivalent 
antigenic distance. To test this hypothesis, a molecular “ruler” is required in order to 
be able to accurately determine the bivalent antigenic distance of IgG antibodies with 
different upper hinge lengths. This chapter aimed to test whether dsDNA might serve 
as a suitable molecular “ruler” and has successfully confirmed that dsDNA is a 
reasonable choice for this role because the length of dsDNA can be easily 
manipulated and calculated and, more importantly, the target antigen can be 
conjugated to the 5¢ ends of the dsDNA, thus, producing a bivalent ligand. 
 
Figure 4.7: ELISA result of antigen recognition of 20bp NIP-dsDNA/Strep by anti-NIP wt hIgG1. 
Different concentrations of 20bp NIP-dsDNA/Strep (0.0-1.0μM) were coated onto sample wells 
and 20μg/ml of anti-NIP wildtype hIgG1 was incubated to allow binding. Anti-mouse lambda light 
chain-HRP was used to detect antibody binding. The results shown are the average of duplicate 
determinations, and the bars represent standard deviation measurements. A representative 




As mentioned in the Introduction (section 4.1), the Fab tip to tip distance of hIgA1 
was reported to be 17nm (Boehm et al., 1999). This project has generated new 
mutant hIgG1 antibodies with either the whole or partial hIgA1 hinge region 
incorporated. Hence, the length of the molecular “rulers” had to be carefully 
designed in order to be suitable for sensing differences in the bivalent binding of 
these antibodies to antigen. This project produced three different dsDNA products 
with lengths of 20bp, 45bp and 55bp, each with NIP hapten covalently conjugated to 
the 5¢ end of each strand. Given the double stranded nature of DNA, there should be 
two NIP haptens attached to each DNA product, representing a bivalent molecular 
“ruler”. The overall estimated length of 20bp NIP-dsDNA was 7.57nm, that of 45bp 
NIP-dsDNA was 16.06nm, and that of 55bp NIP-dsDNA was 19.47nm. The lengths 
of all three dsDNA products were well below the reported dsDNA persistence length 
of 50nm (Smith et al., 1992; Hagerman, 1988). Therefore, all three should maintain a 
rigid linear structure, suitable for providing an accurate length measurement.  
 
20bp NIP-dsDNA with an estimated length of 7.57nm was designed so that all the 
antibodies generated in this project, especially wt hIgG1 which has the shortest 
predicted hinge length, would be able to bind bivalently. In contrast, the longer NIP-
dsDNAs were designed with the hope that they might serve to distinguish between 
the bivalent binding abilities of the different antibodies, such that we might 
encounter a condition where some of the antibodies were only able to bind 
monovalently. In particular, 55bp NIP-dsDNA (19.47nm) was designed with length 
surpassing the estimated bivalent antigenic distance of hIgA1 (~17nm) so that, at 
least wt hIgG1 antibody would not be able to bind bivalently to this ligand. This 
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allows an easier approach in the interpretation of monovalent binding in subsequent 
analyses.  
 
Antibody binding to antigens conjugated to dsDNA had been reported in the past 
(Paar et al., 2002). Paar and colleagues generated several DNP-dsDNA molecules 
ranging from 3.1nm to 10.2nm in length and showed that bivalent DNP-dsDNA of 
length around 4.4-5.1nm were able to stimulate mast cell degranulation, via binding 
of anti-DNP human IgE. In constrast, bivalent ligands of length above 6.8nm were 
unable to do so (Paar et al., 2002). The NIP-dsDNA molecules generated in this 
chapter share similar features to the DNP-dsDNA mentioned in the previous 
investigation except for the differing antigens, the additional biotin incorporation and 
the Mono-Strep association. Fortunately, the NIP antigen conjugated to dsDNA was 
shown to be recognisable by anti-NIP wt hIgG1 after incorporation of the biotin 
molecule and complex formation with Mono-Strep. This finding paved the way for 
the usage of these NIP-dsDNA molecules for subsequent SPR analyses in Chapter 5. 
 
One possible alternative approach to measure the bivalent antigenic distance of an 
antibody would be the use of molecular printing, which transfers molecules or 
materials to a suitable surface in molecular scale, ranging from sub-50-nm to µm 
(Braunschweig et al., 2009). The advance technology of molecular printing has 
allowed the transfer of DNA proteins, peptides, polymers, and metal ions onto many 
types of surfaces (Braunschweig et al., 2009; Torres et al., 2011). As a result, 
molecular printing might be able to “print” targeted antigen at defined distances to 
investigate the bivalent antigenic distance of an antibody. Orth and colleagues had 
used a molecular printing technique to generate a patterned lipid bilayer containing 
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2,4-dinitrophenyl (DNP) antigens, distanced from 1.5µm to 60µm apart, and showed 
that anti-DNP IgE could bind these patterned antigens through fluorescence imaging 
(Orth et al., 2003).  One concern of using molecular imaging would be the cost of 
production and the availability of the involved machineries. In addition, whether the 
antigen could be printed at a distance of 5-20nm has to be confirmed as the bivalent 
antigenic distance of IgG would be expected to fall within this range. In contrast, the 
dsDNA used in this project is very cost-effective compared to the materials used in 
molecular printing and the distance between two adjacent antigens could start as 
short as 3.4nm, which is 10bp, up to 50nm, which is the limit of the reported DNA 
persistent length. Therefore, using DNA is definitely an ideal approach. 
 
Another approach to tackle the measurement of the bivalent antigenic distance of an 
antibody would be to adapt the model used by Sosnick et al (1992) in which X-ray 
and neutron scattering was performed on antibodies that had formed a complex with 
deuterated antigens (Sosnick et al., 1992). Due to the differing neutron scattering 
length of hydrogen and deuterium, the bivalent antigenic distance of an antigen 
bound antibody could be determined (Sosnick et al., 1992). In this case, we could 
generate a similar dsDNA bivalent ligand of differing lengths with deuterated 
antigen covalently attached and subject the generated antigen-antibody complex to 
X-ray and neutron scattering analyses to determine the bivalent antigenic distance of 
the antibody. However, the dissociations of antibody from antigen has to be taken 
into consideration, but this obstacle might be overcome by using antigens with high 
binding affinity with specific antibodies to reduce overall dissociation rate. Another 
concern of this approach would be the generation of an antibody binding with two 
individual bivalent ligands or polymeric immune complexes consisting of multiple 
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antigen-antibody linked to each other. Both formations would cause the 
measurement to be inaccurate. Nonetheless, having alternative options is always 
































The previous chapter described the role of NIP-dsDNA molecules as molecular 
“rulers” to estimate the bivalent antigenic distances of different antibodies. This 
chapter will describe utilisation of the generated dsDNA molecules for such 
measurement. The procedure involves the association of the generated NIP-dsDNA 
molecules with Mono-Strep, which had been previously immobilised onto sensor 
chips, to form a protein complex for surface plasmon resonance (SPR) analyses, 
which is capable of detecting real-time antibody-antigen association and dissociation 
(Nguyen et al., 2015; Torreri et al., 2005; Homola et al., 1999; Adamczyk et al., 
2000; MacKenzie et al., 1996). As described previously, it was expected that an 
antibody molecule capable of binding bivalently to immobilised antigens should 
have a longer dissociation time compared to an antibody molecule bound 
monovalently to a single antigen molecule. Applying the same principle to NIP-
dsDNA, it might be predicted that if the NIP-dsDNA was too long (i.e. the NIP 
molecules are spaced too far apart) for an antibody molecule to bind bivalently, the 
antibody molecule would tend to dissociate much more readily than when bound to a 
shorter NIP-dsDNA since it will be binding predominantly in a monovalent fashion. 
Therefore, by observing the association and dissociation of antibody binding to 
different lengths of NIP-dsDNA via SPR, estimates of the range of bivalent antigenic 
distance of each generated antibody may be determined. If the NIP-dsDNA 
molecular ruler model was proven to be successful, this would allow the 
determination of the range of bivalent antigenic distances of several different 
wildtype antibodies, such as IgM, IgE, IgA, IgD and IgG, in future investigations. In 
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addition, it should be possible to use similar antigen-dsDNA models to determine the 
optimal antigen binding distance to achieve maximum effector effect from bispecific 
antibodies and BiTE molecules, as described in Chapter 1, which interact with two 
different target antigens bound at close proximity. 
 
Target cell-effector cell bridging by antibody molecules is likely to be exceptionally 
important for pathogen clearance. When invading pathogens are opsonised by 
antibodies they may be efficiently cleared by Fc-bearing effector cells, such as 
macrophages, natural killer cells and neutrophils, through ADCC (Schroeder Jr and 
Cavacini, 2010; Desjarlais and Lazar, 2011; Lazar et al., 2006; Tang et al., 2007). 
However, these antibody effector mechanisms required the Fc region of the antibody 
to interact with corresponding Fc receptors (Dilillo and Ravetch, 2015; Lazar et al., 
2006; Lu et al., 2015; Schroeder Jr and Cavacini, 2010). As a result, having a better 
target cell-effector cell bridging efficiency would improve pathogen clearance by the 
immune system.  
 
There were several Fcg receptors expressed by immune cells, as described in Chapter 
1. Each has its own antibody binding profile (Woof and Burton, 2004; Bruhns et al., 
2009). For example, the relative binding affinity of human FcgRI for the human IgG 
subclasses is IgG1 = IgG3 > IgG4 >> IgG2 (Woof and Burton, 2004). Interestingly, 
Redpath and colleagues generated a mutant human IgG3 with a shortened hinge and 
showed that it had reduced binding to FcgRI compared to wt IgG3 (Redpath et al., 
1998), which suggested that the length of the hinge region might play a role in 
enabling optimal FcgRI interaction. In addition, Goh and colleagues generated a 
matched set of human IgG antibodies of different subclasses and compared their 
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ability to induce phagocytosis by THP-1 cells (Goh et al., 2011). The authors 
reported that IgG3 elicited a higher bacterial uptake by phagocytosis after bacterial 
opsonisation than IgG1 (Goh et al., 2011). IgG3 has the longest hinge region among 
all human IgGs, therefore, it is possible that the extra hinge length allowed IgG3 to 
better adopt a favourable conformation for optimal FcgR binding to induce 
phagocytosis. However, the argument regarding the difference in the amino acid 
composition of the constant regions between the IgG subclasses remained valid. The 
constant regions of different IgG subclasses do not share identical amino acid 
sequences (Burton, 1987) and, more importantly, variable region structure and 
function has been reported to be affected by the constant domains of different IgG 
subclasses (Janda et al., 2012; Janda et al., 2016). Therefore, keeping identical 
constant regions of antibody might be crucial in certain structural investigations. The 
hinge mutants generated in this project have identical constant domains, therefore, it 
is reasonable to seek to determine whether the structural modification of upper hinge 
extension in IgG might have an effect on target cell-effector cell bridging. The 
approach in investigating target cell-effector cell bridging by antibody molecules will 
be further described below. 
 
5.1.1 Surface plasmon resonance (SPR) analyses 
SPR utilises an optical technique to measure the refractive index changes in the 
vicinity of a thin metal layer resulting from changes in the mass of molecules 
associated with the layer (Nguyen et al., 2015; Homola et al., 1999; Torreri et al., 
2005). Therefore, when an association occurs any changes are immediately recorded. 
SPR had been used in a variety of applications to determine the interactions and 
binding affinities of different ligands and analytes including protein-protein, protein-
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DNA, receptor-drug, and virus-protein interactions (Homola et al., 1999; Nguyen et 
al., 2015; Torreri et al., 2005). In this chapter, NIP-dsDNA could not be immobilised 
directly onto the sensor chip due to DNA and the sensor chip surface being highly 
negatively charged, thus, repulsion will occur. Therefore, Mono-Strep was firstly 
immobilised onto the CM5 sensor chip at a low density. NIP-dsDNA was then 
introduced to allow association with Mono-Strep via the incorporated biotin 
molecule. The rationale for immobilising Mono-Strep at a low density was to ensure 
that on average each Mono-Strep molecule is likely to be positioned at some distance 
away from each other so that the likelihood of an antibody molecules being able to 
bind to two adjacent immobilised NIP-dsDNA molecules could be kept very low. 
Such an incidence is illustrated in Figure 5.1. As mentioned previously, the length of 
each NIP-dsDNA molecule, at either 20bp, 45bp or 55bp, was designed according to 
the previously reported Fab tip to tip distances of immunoglobulins. In brief, 20bp 
NIP-dsDNA was designed in order to enable all the antibodies under test to bind 
bivalently, 45bp NIP-dsDNA was designed in order to enable antibodies with longer 
reach to bind bivalently, and 55bp NIP-dsDNA was designed such that none of the 
antibodies would be likely to bind bivalently. Monovalent binding and bivalent 
binding should be differentiated from SPR analysis by monitoring the dissociation 
curve. It was expected that bivalent binding would present a slower dissociation rate 
due to longer antigen association time, as mentioned earlier. In contrast, monovalent 
binding should present a faster dissociation rate compared to bivalent binding due to 
shorter antigen association time. Therefore, SPR should enable investigation of the 






5.1.2 Rosette Test 
This chapter hypothesised that an increase in the upper hinge length of IgG1 would 
tend to also increase the target cell-effector cell bridging efficiency of an IgG1 
antibody due to the extra reach and possibly flexibility granted through the upper 
hinge extension. To investigate this hypothesis, a rosette test was performed. The 
surface of sheep red blood cells were derivatised with NIP-hapten and coated with 
different concentrations of anti-NIP antibodies before being incubated with THP-1, a 
human monocytic cell line, that expresses both FcgRI and FcgRII (Fleit and 
Kobasiuk, 1991) to generate rosettes. The association between sheep red blood cells 
and Fab arms, via NIP antigen binding, and between the Fc region and Fcg receptors, 
expressed on the surface of THP-1, would hold both cells closely associated to 
Figure 5.1: A schematic diagram of different scenarios following monovalent streptavidin 
immobilisation on a CM5 sensor chip. A. A scenario where monovalent streptavidin is 
immobilised at close proximity to each other (high density) allowing an anti-NIP antibody to bind 
to two adjacent NIP-dsDNA molecules. B. A scenario where monovalent streptavidin was 
immobilised at positions more distance to each other (low density), such that an anti-NIP 
antibody is able to bind to only one NIP-dsDNA molecule. Scenario B is that which the 




each other, thus, generating a phenomenon known as rosettes, as indicated in Figure 
5.2. This system creates a scenario resembling pathogen clearance in which red 
blood cells are considered as target cells and THP-1 cells as effector cells. Michel 
and colleagues used a rosette inhibition assay to determine the binding affinity of Fc 
receptors for the antibodies Dob and Lec (both were hinge-deleted hIgG1 mutants) 
compared to that of wt hIgG1. They showed that Dob and Lec displayed very 
reduced rosette formation capability with THP-1 cells (Klein et al., 1981). In a 
different scenario, Walker and colleagues generated a matched set of chimeric anti-
NIP human IgG1, IgG2, IgG3 and IgG4 molecules and investigated their interactions 
with human FcgRI and FcgRII via a rosetting assay (Walker et al., 1989). The 
Figure 5.2: A schematic diagram illustrating the rosette formation. Sheep red blood cell (RBC) 
was derivatised with NIP antigen and incubated with anti-NIP IgG1 antibodies before being 
further incubated with effector cell, THP-1, which expresses Fcg receptors. The taret cell-
effector cell bridging is formed by the interactions between an antibody binding to target antigen 
on the surface of RBC via Fab arms and the Fc region associating with Fcg receptor on the 
surface of THP-1. 
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authors showed that among all subclasses of hIgGs, hIgG1 and hIgG3 were the best 
performers in rosette assays with U937, K562 and Daudi cells (Walker et al., 1989). 
Based on these earlier successes, the rosetting assay was chosen as a suitable assay to 
allow comparison of the target cell-effector cell bridging efficiency of a matched set 
of IgG antibodies. An antibody displaying enhanced rosette formation would suggest 
improved performance at pathogen clearance, since it would model close interaction 




This chapter hypothesised that a longer upper hinge length would increase the 
bivalent antigenic distance and improve the overall antigenic reach of an antibody. In 
addition, this chapter also hypothesised that dsDNA might be a suitable “molecular 
ruler” to measure the bivalent antigenic distance of an antibody. As a result, the aims 
of this chapter were to  
 
1) determine if upper hinge extension is able to increase the maximum bivalent 
antigenic distance of an IgG1 molecule. 
 
2) determine if the NIP-dsDNA model would function as a suitable model for 
measuring the bivalent antigenic distance of an antibody.  
 
3) investigate if upper hinge extension is able to increase the target cell-effector cell 
bridging efficiency of an IgG1 antibody. 
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5.3 MATERIALS AND METHODS 
 
5.3.1 MATERIALS AND BUFFERS 
 
CM4 and CM5 Sensor chips 
CM4 and CM5 Sensor chips purchased from GE Healthcare Life Sciences were 
stored at 4ºC, and brought to room temperature before use. 
 
HBS-EP Buffer 
HBS-EP Buffer (0.01M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v 
Surfactant P20) purchased from GE Healthcare Life Sciences was stored at 4ºC and 
brought to room temperature before use. 
 
Sheep red blood cells (RBC) 
Sheep blood in Alsever’s solution was purchased from TCS Bioscience Ltd. and 
stored at 4ºC. 
 
Isotonic borate buffer 
100mM boric acid, 25mM borax, 75mM NaCl was prepared in Millipore water and 
stored at 4ºC. 
 
NIP hapten 
NIP-caproic acid-OSuccinimide (NIP-cap-OSu) was purchased from Biosearch 
Technologies. An appropriate amount of NIP-cap-OSu was dissolved in dimethyl 
formamide to give a final concentration of 10mg/ml prior to use. 
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5.3.2 SURFACE PLASMON RESONANCE ANALYSIS 
 
5.3.2.1 Immobilisation of NIP-dsDNA on CM4/CM5 sensor chip 
Immobilisation of NIP-dsDNA on CM4/CM5 sensor chip was performed using the 
protocol described by Liu and Wilson (2010) with some modifications as described 
below. Due to lower degree of carboxylation, the immobilisation level of CM4 
sensor chip is about 30% of CM5 sensor chip according to manufacturer guidance. 
 
Immobilisation of monovalent streptavidin (Mono-Strep) 
A CM4/CM5 sensor chip was inserted into a Biacore® X machine (GE Healthcare 
Life Sciences) and primed several times with HBS-EP buffer. A sensorgram was 
initiated and both flow cell 1 (FC1) and flow cell 2 (FC2) of the sensor chip was run 
at a flow rate of 5µl/min to allow the temperature to stabilise to room temperature. 
100µl of 1µM Mono-Strep was prepared in 10mM Sodium Acetate pH4.5 (GE 
Healthcare Life Sciences) in a 1.5ml microfuge tube. At pH4.5, the overall net 
charge of Mono-Strep becomes positive, facilitating the association of Mono-Strep 
with the dextran of the sensor chips which is negatively charged. 50µl of 0.1M N-
hydroxysuccinimide (NHS) and 50µl 0.4M 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) (both freshly prepared) were mix gently together 
in a microfuge tube. 50µl of NHS/EDC mixture were then injected to activate the 
sensor chip surface (for 10 minutes). Subsequently 100µl of 1µM of Mono-Strep was 
injected into the system. Using “Manual Injection”, 25µl of 1µM of Mono-Strep was 
injected each time until the monitored Response Unit (RU) showed a reading of 
around 2500-3000RU for a CM4 sensor chip or 1500-2000RU for a CM5 sensor 
chip. When the desired RU reading was achieved, the injection procedure was 
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stopped and the sensor chip surface was deactivated with 50µl of ethanolamine-
hydrochloride (10 minutes). The sensorgram was stopped and the sensor chip was 
then primed several times with HBS-EP buffer. 
 
Immobilisation of NIP-dsDNA 
After the immobilisation of Mono-Strep, a new sensorgram was initiated in which 
the flow was only over FC2 at a flow rate of 2µl/min. FC1 would serve as a control, 
thus, no NIP-dsDNA would be immobilised on it. On separate chips, 50µl of either 
10µM 20bp NIP-dsDNA, 45bp NIP-dsDNA or 55bp NIP-dsDNA was prepared in 
HBS-EP buffer in a 0.5ml microfuge tube. 20µl of the particular NIP-dsDNA was 
injected into the system to allow binding to Mono-Strep on FC2 to occur (10 
minutes). Subsequently the flow rate was increased to 10µl/ml and 10µl of 50mM 
sodium hydroxide (GE Healthcare Life Sciences) was injected to wash and remove 
any loosely bound NIP-dsDNA from the surface of the sensor chip (1 minute). The 
sensor chip was primed several times with HBS-EP buffer, and was then ready for 
investigations to proceed. 
 
5.3.2.2 Determination of binding of anti-NIP antibodies to immobilized NIP-
dsDNA 
A CM4 sensor chip with an immobilisation level of approximately 2300RU of 20bp 
NIP-dsDNA was generated by the above procedure and inserted into the Biacore® X 
system. A sensorgram was initiated at a flow rate of 15µl/min over both FC1 and 
FC2. FC1 was the reference control. Anti-NIP wt hIgG1, 0.5HA, 1HA and ONeg 
antibodies at molar concentrations ranging from 2nM to 28nM were prepared in 
HBS-EP buffer. 20µl of each concentration was injected into the system to allow 
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antigen binding and held for 300 seconds with the same flow rate, 15µl/min, to 
resemble a washing process before the unchangeable programmed washing process, 
(high flow rate) was initiated. Subsequently the sensor chip surface was regenerated 
by injecting 10µl of 50mM sodium hydroxide (GE Healthcare Life Sciences) to 
remove all bound antibodies and enable subsequent analyses on the same chip. The 
same procedure was repeated with each concentration of the different antibodies. 
 
5.3.2.3 Investigation of bivalent antigenic distance in SPR experiments 
Different CM5 sensor chips on which either 20bp NIP-dsDNA, 45bp NIP-dsDNA 
and 55bp NIP-dsDNA was immobilised were generated in the above procedure.  
 
Investigation using high antibody saturation level  
For each different CM5 sensor chip, following insertion in the Biacore® X machine, 
a sensorgram was initiated at a flow rate of 10µl/min over both FC1 and FC2, and 
FC1 was selected as the reference control. Anti-NIP wt hIgG1, 0.5HA, 1HA and 
ONeg antibodies were each prepared at 20nM in HBS-EP buffer respectively. 30µl 
of antibody was injected into the system each time to allow antigen binding and held 
for 300 seconds before the washing process was initiated. Subsequently the sensor 
chip surface was regenerated by injecting 10µl of 50mM sodium hydroxide (GE 
Healthcare Life Sciences) to remove all bound antibody. The same procedure was 
repeated for the investigation of each of the different antibodies. 
 
Investigation using low antibody saturation level (100RU) 
For each different CM5 sensor chip, a sensorgram was initiated at a flow rate of 
10µl/min over both FC1 and FC2, and FC1 was selected as the reference control.  
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Anti-NIP wt hIgG1, 0.5HA, 1HA and ONeg antibodies were each prepared at 2nM 
in HBS-EP buffer. Using “Manual injection”, 100µl of antibody was injected into the 
system each time to allow antigen binding and the RU of the sensorgram was 
monitored. The injection was stopped when the antibody-antigen binding reached 
100RU and held for 300 seconds before the washing process was initiated. 
Subsequently the sensor chip surface was regenerated by injecting 10µl of 50mM 
sodium hydroxide (GE Heathcare Life Sciences) for 60 seconds to remove all bound 
antibodies. The same procedure was repeated for the investigation of each of the 
different antibodies. 
 
5.3.3 ROSETTING ASSAY 
 
5.3.3.1 Analysis of Fcg receptor expression on THP-1 cells using flow cytometry 
Each test was done in duplicate and required 3 x 106 cells. An appropriate number of 
THP-1 cells were harvested as described in section 2.6.3 and resuspended in cold 
PBN buffer (0.1% (w/v) BSA, 0.01% NaN3, in PBS) at a density of 3 x 106 
cells/100µl. 100µl aliquots were pipetted into 1.5ml microfuge tube. For 
investigation of FcgRI expression, THP-1 cells were incubated with 100µl FITC-
conjugated mouse anti-human CD64 antibody (Table 2.1 No.5) for 1 hour on ice, in 
the dark. For analysis of FcgRII expression, THP-1 cells were incubated with 100µl 
FITC-conjugated mouse anti-human CD32 antibody (Table 2.1 No.6) for 1 hour on 
ice and kept in the dark. When the incubations were completed, cells were washed 
three times with 500µl cold PBN buffer by centrifuging for 5 minutes at 250g. Cells 
were resuspended in 500µl of PBN buffer and transferred to 5ml polystyrene round-
bottom tubes (BD Bioscience) for subsequent flow cytometry analyses. Cells were 
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analysed on a BD FACSCanto II machine (BD Biosciences). 
 
5.3.3.2 Derivatisation of RBC with NIP 
2ml sheep RBC was pipetted into a 30ml Universal tube. 8ml of isotonic borate 
buffer was added to wash the RBC before centrifuging for 5 minutes at 250g. The 
supernatant was discarded and the washing process was repeated twice. After the 
final wash, the cell pellet was resuspended in 5ml of isotonic borate buffer and 
centrifuged for 5 minutes at 300g to pack the RBC cell pellet. The supernatant was 
discarded and the volume of RBC cell pellet was measured using a 1ml pipette after 
0.5ml resuspension of cell pellet with isotonic borate buffer. When the volume of 
RBC had been determined, an appropriate volume of isotonic borate buffer was 
added to the cells to make a 10% (v/v) RBC suspension. An appropriate volume of 
10mg/ml NIP-cap-OSu (1μl for every ml of 10% RBC suspension) was added and 
incubated at room temperature for 1 hour on a roller. After the incubation period, the 
cells were washed 3 times with 5ml of PBS and centrifuging for 5 minutes at 250g 
each time. The supernatant was discarded and the cell pellet was resuspended in PBS 
to give a 10% (v/v) RBC suspension.  
 
5.3.3.3 Coating of NIP-derivatised RBC with anti-NIP antibodies 
wt hIgG1, 0.5HA, 1HA and ONeg anti NIP antibodies were each prepared at various 
concentrations up to14μg/ml in PBS. 6μl of each concentration was pipetted into a 
1.5ml microfuge tube. 12μl 10% NIP-derivatised RBC was added to each microfuge 
tube and gently mixed. All tubes were incubated for 1 hour at 37ºC in an incubator. 
Subsequently the cells were washed 3 times with 100μl of PBS, centrifuging for 5 
minutes at 250g each time. The supernatant was discarded and the cell pellet was 
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resuspended in 108μl PBS to make a 1% (v/v) RBC suspension.  
 
5.3.3.4 Rosetting assay 
Each test was done in duplicate and required 25μl effector cells at a density of 2 x 
106 cells/ml. An appropriate number of THP-1 cells were harvested as described in 
section 2.6.3 and resuspended in PBS at 2 x 106 cells/ml. 25μl THP-1 cells were 
pipetted into each well of a 96 well U-bottom plate (Falcon®, Corning Inc.). 25μl of a 
1% suspension of RBC coated with each antibody was pipetted into duplicate sample 
wells. 50μl PBS was then added to each well producing a final volume of 100μl in 
each well. The plate was allowed to stand at room temperature for 15 minutes before 
being centrifuged at 50g for 1 minute to enhance cell interaction. The plate was then 
transferred to an incubator at 37ºC for 90 minutes. After the incubation period, cells 
were briefly mixed by gently pipetting up and down. Cells were transferred to a 
haemocytometer to be examined under a microscope and the percentage rosette 
formation was determined. In this assay, a rosette was defined as an effector cell 
having three or more RBC attached. The minimum number of effector cells counted 
for each test was at least 100 cells. The average percentage rosette formation were 
determined for different antibodies and normalised against wt hIgG1 by setting the 




5.4.1 The success of different immobilisations 
Immobilisation of high levels of Mono-Strep onto CM4 sensor chips was found to be 
challenging. In some attempts, a Mono-Strep immobilisation level of less than 
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600RU was achieved, which was considered to be a very low level since it is 
reportedly possible to exceed 4000RU in immobilisations on CM4, according to the 
manufacturer’s guidance. In an attempt to resolve this issue, the concentration of 
Mono-Strep was doubled to 2µM during the immobilisation step but the RU obtained 
was similar and failed to exceed 600RU. After introducing 20bp NIP-dsDNA to 
these CM4 sensor chips with low Mono-Strep immobilisation, the resultant binding 
lead to an increase of about 50-80RU. These low immobilisation CM4 sensor chips 
were then tested with anti-NIP wt hIgG1 but showed insignificant antibody binding. 
Therefore, it was concluded that these sensor chips were unsuitable for the proposed 
investigations.  
 
Fortunately, there was one CM4 sensor chip that had an immobilisation level of 
Mono-Strep of around 2300RU. After the introduction of 20bp NIP-dsDNA, the 
overall RU increased to approximately 2500RU. The reason as to why one CM4 
sensor chip could be immobilised up to 2300RU with 1µM of Mono-Strep but not 
the others was not known because the immobilising procedure was carried out 
identically. As a result of this seeming variability, CM5 sensor chips were selected as 
an alternative because they have a higher capacity for immobilisation than CM4 
sensor chips (see section 5.3.2.1 for the difference between CM4 and CM5). All 
generated sensor chips used in this chapter are listed in Table 5.1. Although the 
immobilisation level of Mono-Strep on the CM5 sensor chip was still considered low, 
since immobilization can reportedly exceed 6000RU on CM5 sensor chips according 




Table 5.1: Details of generated CM4/CM5 sensor chips 
Type of sensor chip Type of dsDNA Final approximate RU 
CM4 20bp NIP-dsDNA 2500 RU 
CM5 20bp NIP-dsDNA 1900RU 
CM5 45bp NIP-dsDNA 2000RU (High) 
CM5 45bp NIP-dsDNA 1000RU (Low) 
CM5 55bp NIP-dsDNA 1500RU 
Note: There were two CM5 sensor chips on which 45bp dsDNA was immobilised, thus, they were 
designated either high or low, on the basis of their RU values. 
 
5.4.2 Binding to NIP-dsDNA assessed by SPR analysis 
All four antibodies tested, wt hIgG1, 0.5HA, 1HA and ONeg, were able to bind to 
the NIP antigen on 20bp NIP-dsDNA as shown in Figure 5.3. The maximum RU 
obtained by all antibodies were around 600RU which indicated that all the antibodies 
reached a similar saturation level. As presented in Figure 5.3, all the hinge mutants, 
0.5HA, 1HA and ONeg, showed similar association and dissociation patterns to 
those of wt hIGg1, suggesting that hinge extension had no significant impact on 
antigen recognition when the antigens are interposed by a stretch of 20 bp of DNA. 
In addition, at low concentrations, for example 2nM - 6nM, all antibodies seemed to 
show very slow dissociation as seen in Figure 5.3, consistent with the relatively high 
binding affinity the anti-NIP antibody is known to have for NIP.  
 
5.4.3 Estimation of the bivalent antigenic distance of the different antibodies 
In this study the determination of the bivalent antigenic distances of different 











Figure 5.3: Results of SPR analyses of different anti-NIP IgG antibodies binding to 20bp 
NIP-dsDNA at different concentrations between 2nM and 28nM. A. wt hIgG1; B. 0.5HA; C. 
1HA; D. ONeg. 20µl antibody was injected for every test at a flow rate of 15µl/min and 
continued for 300 seconds before washing. The starting point of antibody injection of all 
curves had been superimposed so that the RU value and time were identical for all curves. 
Different antibody concentration injections are represented by different colours. A 
representative experiment of two is shown. 
	 166	
discussed previously. Antibody molecules which have bound bivalently are expected 
to have a slower rate of dissociation when compared to antibody molecules which 
have only bound monovalently. Two different concentrations, 20nM and 2nM, of 
antibodies were used for this investigation. The 20nM option was used to estimate 
the maximum RU that could be obtained for each sensor chip and to confirm that all 
the antibodies were behaving similarly, as previously determined using the CM4 
sensor chip. In addition, the 20nM option was used to study the monovalent/bivalent 
binding activity of each antibody at saturation. However, one limitation to the 
determination of monovalent/bivalent binding at 20nM was that at saturation level 
there is likely to be a mixture of antibody binding modes, with some molecules being 
bound monovalently and others bivalently to the target NIP antigen. Therefore, the 
interpretation of the results obtained requires care, and should be further verified. To 
further strengthen the findings from the studies using 20nM, a lower concentration of 
2nM was used and the injection was stopped when the antigen binding had reached a 
value of 100RU. The reason for such a procedure was that using 2nM antibody gave 
a better control over the level of binding during antibody-antigen association and 
stopping the injections at 100RU would create a situation in which the amount of 
antibody injected into the system was insufficient to bind all available antigen. Thus, 
there would be no competition for antigen binding and the antibodies would be free 
to bind to their target antigen with minimal steric hindrance. As a result, the 












Figure 5.4: A comparison of SPR profiles of 20nM and 2nM concentrations of different 
antibodies binding to the 20bp NIP-dsDNA surface. A) SPR profile of different antibodies 
binding to 20bp NIP-dsDNA. B) Dissociation of different antibodies from the 20bp NIP-
dsDNA surface. For 20nM, 30µl antibody was injected and continued for 300 seconds before 
washing whereas for 2nM 100µl of antibody was injected and the injection stopped when 
100RU was reached. Each test was performed at a flow rate of 10µl/min. The starting point of 
antibody injection (A) or the end of antibody injection (B) of all curves had been superimposed 
so that the RU value and time were identical for all curves. Blue, wt hIgG1; Pink, 0.5HA; 
Green, 1HA; Red, ONeg. Black arrow, antibody injection; Red arrow, injection stopped; Blue 
arrow, washing began. A representative experiment of 2 is shown. 
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Association and dissociation with 20bp NIP-dsDNA 
As presented in Figure 5.4, at a concentration of 20nM a similar pattern of antibody-
antigen association and dissociation was observed when compared to the earlier 
results obtained from CM4 sensor chip, Figure 5.3. This result indicated that there 
were no significant differences in antigen binding activity between the 20bp NIP-
dsDNA immobilised on CM5 and CM4 sensor chips. When a concentration of 20nM 
was used, all antibodies seems to reach saturation level approximately 45 seconds 
after injection and the maximum RU obtained were around 450-550RU. With a 
maximum RU of 450RU, it was reasoned that a reading of 100RU would be likely to 
reflect a situation where only about 20% of the available antigen molecules were 
bound. All the tested antibodies at 2nM concentration required around 20 seconds 
after injection to achieve 100RU, as indicated in Figure 5.4. 
 
When the dissociation curves of each antibody at different concentrations were 
compared as shown in Figure 5.4 B, the dissociation curves of all antibodies at 2nM 
(100RU) were significantly different from those obtained at 20nM (saturated). 
Noticeably, at 2nM (100RU) the dissociation curve resembled a virtually linear trace 
whereas at 20nM (saturated) a clear dissociation curve was apparent. The reason for 
this phenomenon was predicted to be due to the difference between monovalent and 
bivalent binding. As mentioned previously, a concentration of 20nM would likely 
saturate the sensor chip, and thus there would be a mixture of monovalently bound 
and bivalently bound molecules. Monovalently bound antibodies would tend to 
dissociate at a faster rate than bivalently binding antibodies. Hence a faster decrease 
in RU would tend to result for the 20nM concentration than the 2nM one. In contrast, 
the almost linear dissociation trace observed with 2nM (100RU), Figure 5.4B, 
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strongly suggests the presence of mainly bivalently bound molecules resulting in a 
slower rate of dissociation. This reasoning was supported by the predicted length of 
20bp NIP-dsDNA of 7.57nm which was well within the reported 14.5 nm Fab tip to 
tip distance from hIgG1 (Kol). Therefore, bivalent binding to the 20bp NIP-dsDNA 
was highly feasible for all the IgG variants. 
 
As seen in Figure 5.4B, there were no significant differences in the rates of 
dissociation between the different antibodies at 2nM(100RU). However, at 
20nM(saturated) the antibodies showed slight differences in their rates of 
dissociation. ONeg appeared to have the slowest dissociation rate followed by wt 
hIgG1, then 0.5HA and finally 1HA with the quickest dissociation rate. One possible 
explanation for this observation was that the combination of longer upper hinge and 
the absence of O-linked glycans at the hinge region of ONeg probably allowed a 
better positioning of the Fab arms of ONeg to conduct antigen binding, thus, 
allowing more efficient bivalent binding activity. Although 1HA has the same upper 
hinge length as ONeg (both have 21 amino acids), 1HA appears to have some O-
linked glycans at the upper hinge region which arguably might tend to increase 
overall steric hindrance between the two Fab arms when they come close to together 
to bind the two NIP antigens of 20bp-dsDNA which is separated about 7.57nm away 
from each other. Thus, maintaining bivalent binding was less efficient for 1HA. 
0.5HA has a shorter upper hinge length and presumably lesser O-linked glycans 
when compared to 1HA. Therefore, the overall steric hindrance may be lower than 
that of 1HA but higher than that of wt hIgG1, meaning that 0.5HA had a slower 
dissociation rate when compared to 1HA but a faster dissociation rate when 
compared to wt hIgG1, as observed in Figure 5.4B. These results suggested that the 
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upper hinge length and the presence of O-linked glycans at the upper hinge region 
may play some role in the overall positioning of the Fab arms of an antibody with 
regards to antigen binding. 
 
In summary, the study using 20bp NIP-dsDNA showed that dsDNA has a high 
potential as molecular ruler as different antibodies are able to bind to the targeted 
antigen covalently attached to dsDNA in SPR analyses. The results using 2nM of 
antibodies demonstrated that bivalent binding produced a tight association between 
antibody and antigen in the context of NIP antigen recognition. Further analyses 
would be require to determine if there is a difference in the dissociation rate between 
bivalent and monovalent binding in the context of NIP antigen recognition in order 
to validate the potential of dsDNA as molecular ruler to measure the bivalent 
antigenic distance of an antibody. 
 
Association and dissociation with 45bp NIP-dsDNA 
As presented in Figure 5.5, at a concentration of 20nM (saturated) all tested 
antibodies appeared to reach saturation levels approximately 45 seconds after 
injection and the maximum RU obtained were around 150-200RU. When the 
dissociation curves for each antibody were compared, as shown in Figure 5.5B, 
ONeg appeared to have a slower dissociation rate than the other antibodies. This 
difference in dissociation rate was more noticeable at a concentration of 20nM 
(saturated) than at 2nM (100RU). Such a result suggests that ONeg may be more 
capable of binding bivalently to 45bp NIP-dsDNA molecules than the other 
antibodies tested. Although apparently binding bivalently, ONeg did not produce a 










Figure 5.5: A comparison of SPR profiles of 20nM and 2nM concentrations of 
 different antibodies binding to 45bp NIP-dsDNA surface. A) SPR analyses at 20nM and 
2nM concentrations of different antibodies binding to 45bp NIP-dsDNA. B) Dissociation of 
different antibodies from the 45bp NIP-dsDNA surface. For 20 nm, 30µl antibody was 
injected whereas for 2nM 100µl was injected and the injection stopped when 100RU was 
reached. Each test was performed at a flow rate of 10µl/min and held for 300 seconds before 
washing. The starting point of antibody injection (A.) or the end of antibody injection (B.) of 
all curves had been superimposed so that the RU value and time were identical for all 
curves. Blue, wt hIgG1; Pink, 0.5HA; Green, 1HA; Red, ONeg. Black arrow, antibody 
injection; Red arrow, injection stopped; Blue arrow, washing began. A representative 
experiment of 2 is shown. 
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both occasions. With 20bp NIP-dsDNA (2nM), there was almost no significant 
changes in RU during the expected ONeg dissociation period, as seen in Figure 5.4B. 
However, with 45bp NIP-dsDNA (2nM) a decrease in RU was noticed during the 
expected ONeg dissociation period, as indicated in Figure 5.5B. One possible 
explanation for this finding is that the length of 45bp NIP-dsDNA at 16.07nm, was 
very close to the maximum bivalent antigenic distance of ONeg. Hence, although 
ONeg was perhaps capable of binding bivalently, the binding tension exerted on the 
Fab arms to do this was too great for ONeg to maintain bivalent binding for a long 
period of time. Thus, bivalent binding was abolished. This reasoning seems to be 
supported by the faster dissociation rate of 1HA, which had the same hinge length as 
ONeg, to 45bp NIP-dsDNA. Such behaviour may possibly be due to 1HA having O-
linked glycans present at the hinge region resulting in an overall reduction in Fab 
arm reach or flexibility, thus, abolished the bivalent binding activity. 
 
The result obtained from 45bp NIP-dsDNA strongly suggested that the combination 
of NIP-dsDNA and SPR could provide a platform to estimate the maximum bivalent 
antigenic distance of antibody. However, there was a concern that the results 
obtained in Figure 5.5B might be due to a phenomenon where ONeg was binding to 
two adjacent 45bp-NIP-dsDNA molecules as previously described in Figure 5.1. To 
minimise the likelihood of an antibody molecule binding to two adjacent 45bp NIP-
dsDNA molecules, a different CM5 sensor chip was generated using a lower 
concentration of Mono-Strep in the immobilisation step (0.5µM instead of 1µM), to 
create a sensor chip with a lower density of 45bp NIP-dsDNA than the original 
sensor chip with readings of about 1000RU instead of 2000RU recorded at the 










Figure 5.6: A comparison of SPR profiles of 20nM concentrations of 
 different antibodies binding to different concentration of 45bp-dsDNA immobilised surface. 
A) SPR analyses of both 20nM and 2nM concentrations of different antibodies binding to 
45bp NIP-dsDNA. B) Dissociation of different antibodies from 45bp NIP-dsDNA surfaces. 
For 20nm, 30µl antibody was injected whereas for 2 nM 100µl antibody injection was 
stopped when 100RU was reached. Each test was performed at a flow rate of 10µl/min and 
held for 300 seconds before washing. Blue, wt hIgG1; pink, 0.5HA; green, 1HA; red, ONeg. 
The starting point of antibody injection (A.) or the end of antibody injection (B.) of all 
curves had been superimposed so that the RU value and time were identical for all curves. 
Blue, wt hIgG1; Pink, 0.5HA; Green, 1HA; Red, ONeg. Black arrow, antibody injection; 




were very similar to the results obtained with the higher density chip, as shown in 
Figure 5.6. Again ONeg was shown to display the slowest dissociation rate when 
compared to wt hIgG1, 0.5HA and 1HA. Therefore, both results confirmed the 
slower dissociation rate of ONeg on 45bp NIP-dsDNA which was consistent with it 
possibly having a greater capability for bivalent binding to the 45 bp NIP-dsDNA. In 
summary, the results obtained from the study using 45bp NIP-dsDNA suggested that 
the bivalent antigenic distance could potentially be evaluated using the combination 
of dsDNA and SPR analyses as observed from the result of the binding activity of 
ONeg on 45bp-dsDNA. Furthermore, the results suggested that wt hIgG1, 0.5HA 
and 1HA may have bivalent antigenic distances less than 16.07nm whereas ONeg 
may have had a bivalent antigenic distance around 16.07nm or more. 
 
Association and dissociation with 55bp NIP-dsDNA 
As presented in Figure 5.7, at a concentration of 20nM (saturated) all antibodies 
seemed to reach saturation level approximately 45 seconds after injection and the 
maximum RU obtained were around 100-120RU. When the dissociation traces of 
each antibody were compared, as shown in Figure 5.7B, there seemed to be no 
significant difference between the dissociation rates from 55bp NIP-dsDNA. Due to 
the maximum RU of this sensor chip being around 100RU, the investigation using 
2nM of each antibody was modified to stop when the reflective index reached 60RU 
instead of 100RU. The observation of similar dissociation curves for all antibodies at 
both 20nM (saturated) and 2nM (60RU) concentrations suggested that all antibodies 
had a similar binding pattern to 55bp NIP-dsDNA, which is most likely monovalent 
binding. It was noticed that in the investigation using at 2nM of 0.5HA, 0.5HA 






Figure 5.7: A comparison of SPR profiles of 20nM and 2nM concentrations of 
 different antibodies binding to 55bp NIP-dsDNA surface. A) SPR analyses of 20nM and 
2nM concentrations of different antibodies binding to 55bp NIP-dsDNA. B) Dissociation of 
different antibodies from the 55bp NIP-dsDNA surface. For 20 nm, 30µl antibody was 
injected whereas for 2 nM, 100µl antibody injection was stopped when 100RU was reached. 
Each test was performed at a flow rate of 10µl/min and held for 300 seconds before 
washing. Blue, wt hIgG1; pink, 0.5HA; green, 1HA; red, ONeg. The starting point of 
antibody injection (A.) or the end of antibody injection (B.) of all curves had been 
superimposed so that the RU value and time were identical for all curves. Blue, wt hIgG1; 
Pink, 0.5HA; Green, 1HA; Red, ONeg. Black arrow, antibody injection; Red arrow, 




in Figure 5.7 A. The exact reason for this phenomenon was not known, however, it 
was noticed that the maximum RU that the can be achieved by anti-NIP antibodies 
reduced slightly after each regeneration process which involved the use of 10µl of 
50mM sodium hydroxide. Therefore, it was reasonable to suggest that the 0.5HA 
antigen binding phenomenon noticed in Figure 5.7 A might be due to the instability 
or the overall reduction in the amount of immobilised Mono-Strep/55bp NIP-dsDNA 
on the relevant sensor chip after several usages. Nonetheless, the results obtained 
indicated that 55bp-dsDNA, which had a predicted length of 19.47nm, may have 
exceeded the maximum bivalent antigenic distance of all the antibodies tested, 
including ONeg. 
 
In summary, wt hIgG1, 0.5HA and 1HA appear to have a bivalent antigenic distance 
of less than 16.07nm. In contrast, ONeg may have a bivalent antigenic distance of 
between 16.07nm and 19.47nm, as indicated from the binding to 45bp NIP-dsDNA 
and 55bp NIP-dsDNA.  
 
5.4.4 Determination of Fcg receptor expression on THP-1 cells 
To carry out target cell-effector cell bridging analysis, the expression of Fcg 
receptors on the surface of the effector cells first had to be confirmed. In addition, 
the type of Fcg receptors expressed should be identified because of their differing 
antibody binding affinity as described in Chapter 1, which might affect the 
interpretation of results obtained. As indicated in Figure 5.8, THP-1 cells expressed 
both FcgRI and FcgRII, as evidenced by the fluorescence observed in the flow 
cytometry analysis. This confirmation of Fcg receptor expression allowed THP-1 to 








 5.4.4 Rosetting assay 
A rosetting assay was performed to investigate whether upper hinge extension was 
able to impact on the target cell-effector cell bridging efficiency of an engineered 
IgG antibody. The results of rosette formation with each antibody is shown in Figure 
5.9. Two hinge mutants, 0.5HA and 1HA, displayed very slightly increased levels of 
rosette formation compared to wt hIgG1. 0.5HA, which had half the hIgA1 hinge 
inserted, gave maximal rosette formation at the lowest concentrations, followed by 
1HA which had the longest hinge insertion. One possible explanation for these minor 
differences is that both 1HA and 0.5HA have O-linked glycans within the hinge 
region which may impact to a small extent on the conformation of the hinge. Thus, it 
may be hypothesised that 0.5HA and 1HA may have a more open conformational 
structure, resulting in a slightly better reach to target antigens between target and  
Figure 5.8: Result of flow cytometry analysis of FcgRI and FcgRII expression on THP-1 
cells. A. Detection of FcgRI expression by probing THP-1 cells with anti-human CD64 
FITC conjugated antibody. B. Detection of FcgRII expression by probing THP-1 cells with 
anti-human CD32 FITC conjugated antibody. In control, THP-1 was incubated with buffer 
only. Black line, control; red line, test with specific antibody. A representative experiment of 








effector cell when compared to wt hIgG1 and ONeg, which both lack the O-linked 
glycans. It was perhaps surprising that ONeg behaved similarly to wt hIgG1 in 
rosette formation despite ONeg having a longer hinge and seemingly being able to 
bind bivalently to 45bp-dsDNA, whilst the other antibodies could not. The major 
difference between ONeg and 1HA is the presence of O-linked glycans within the 
hinge region. Therefore, the result in Figure 5.9 suggested that possibly a slightly 
more open conformational structure of antibody at the hinge region resulting from O-
linked glycosylation may influence target cell-effector cell bridging efficiency to a 
small extent. However, further experimentation would be required to verify any 
differences in hinge conformation resulting from variation in glycosylation.  
Moreover, the differences observed are very minor indeed, since half-maximal 
rosette formation lies in all cases between 2 μg/ml and 6 μg/ml. The similar 
percentage rosette formation observed for ONeg and wt hIgG1 suggest that hinge 
Figure 5.9: Formation of rosettes with THP-1 cells and NIP-derivatized red blood cells 
coated with different concentrations of anti-NIP antibodies. Results were normalised by 
setting the maximal rosette formation achieved with wildtype hIgG1 as 100%. Blue, wt 
hIgG; green, 1HA; yellow, 0.5HA; brown ONeg. Inset lower right shows the appearance of 
typical rosettes. The results shown are the amassed results of 3 experiments. The bars 
represent standard deviation measurements. 
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length may not be the only factor influencing target cell-effector cell bridging 
efficiency. Rather, a combination of hinge length and conformational structure, or 
other factors, may influence the outcome of rosetting assays to a small extent. 
 
5.5 DISCUSSION 
The structure of immunoglobulin molecules has been very well studied over the 
years. However, the functional bivalent antigenic distance between the antigen 
binding sites of the two Fab arms of different antibody molecules has not been fully 
determined to date. Previous studies had described attempts to estimate the Fab tip to 
tip distances based on the results from electron microscopy, neutron/X-ray scattering 
and crystallography of the antibodies. Using such techniques estimates of 120Å for 
rabbit IgGs (Valentine and Green, 1967), 117Å - 134Å for murine IgGs (Sosnick et 
al., 1992), 145Å for KOL (human IgG1) (Marquart et al., 1980) and 17nm (170Å) 
for human IgA1 (Boehm et al., 1999) have been reported. However, these reported 
calculations were estimations based on the conformational structure that the relevant 
antibodies adopted at the particular moment of analysis or crystallisation and were 
not the actual functional bivalent antigenic distance of the antibodies. In contrast, the 
model presented in this chapter utilised NIP-coupled dsDNA of different lengths as 
molecular rulers and the combination with SPR analysis as a means to estimate the 
bivalent antigenic distance. This approach was considered to be more accurate as it 
required the antibody to actually bind to target antigens that were spaced at different 
distances apart. The determination of the bivalent antigenic distance of an antibody 
was based on the theory regarding the difference in the rate of dissociation from 
antigen of monovalently bound antibody molecules and bivalently bound antibody 
molecules. 
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This project had hypothesised that upper hinge extension might increase the bivalent 
antigenic distance of an IgG1 antibody and in this chapter evidence has been 
presented in support of this hypothesis. Of particular note is the apparent bivalent 
binding activity of ONeg to 45bp NIP-dsDNA. In summary, three different NIP-
dsDNA molecules, 20bp NIP-dsDNA, 45bp NIP-dsDNA and 55bp NIP-dsDNA, 
which differed in overall estimated length were generated for the investigation. The 
estimated length of 20bp NIP-dsDNA at 7.57nm, was well within the reported Fab 
tip to tip distance of Kol (145Å) (Marquart et al., 1980). Therefore, it was expected 
that all the tested antibodies would be able to bind bivalently to 20bp NIP-dsDNA. 
Indeed, this expectation was validated by the observed low dissociation rates of all 
antibodies at 2nM (100RU) from 20bp NIP-dsDNA, which suggested that the mode 
of binding was chiefly bivalent in nature. Subsequently, the hypothesis was 
supported by the binding of the generated antibodies to 45bp NIP-dsDNA. With an 
estimated length of 16.06nm, 45bp NIP-dsDNA was designed to differentiate the 
monovalent and bivalent binding capabilities of the matched set of anti-NIP 
antibodies. The slower rate of dissociation of ONeg from 45bp NIP-dsDNA, 
compared to those of wt hIgG1, 0.5HA and 1HA, suggested that ONeg was the only 
recombinant antibody tested to be more capable of bind bivalently to 45bp NIP-
dsDNA. Finally, 55bp NIP-dsDNA with an estimated length of 19.47nm was 
designed to exceed the reported Fab tip to tip distance of hIgA1, estimated to be 
17nm (Boehm et al., 1999), with the expectation that no bivalent binding activity 
would be possible for the antibodies tested. Indeed, all antibodies showed similar 
rates of dissociation, suggesting that all could only bind monovalently to 55bp NIP-
dsDNA. The proposed binding activity of each different antibody to 20bp NIP-








The results from the SPR analyses have shown that the NIP-dsDNA/SPR 
measurement model to be a feasible model for such determinations. More 
importantly, 1HA which has an insertion of the same number of amino acids as 
ONeg was less capable to bind bivalently to 45bp NIP-dsDNA unlike ONeg. This 
finding suggested that this measuring model may be highly sensitive and suitable to 
Figure 5.10: A diagram illustrating the proposed binding activity of different anti-NIP hinge 
mutant antibodies (wt hIgG1, 0.5HA, 1HA and ONeg) to different NIP-dsDNA bivalent 
ligands. A) All antibodies appear to bind bivalently to 20bp NIP-dsDNA which was 
predicted to be 7.57nm. B) wt hIgG1, 0.5HA and 1HA appeared to be less capable or unable 
to bind bivalently to 45bp NIP-dsDNA, which was predicted to be 16.07nm, whilst ONeg 
demonstarted some potential of bivalent binding. C) All antibodies appeared to bind 
monovalently to 55bp NIP-dsDNA which was predicted to be 19.4nm. wt hIgG1, wild type 
human IgG1; 0.5HA, half hinge hIgG1 mutant; 1HA full hinge hIgG1 mutant; ONeg, O-
linked glycosylation negative full hinge hIgG1 mutant. 
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accurately determine the bivalent antigenic distance of an antibody. In the future, this 
measuring model should allow the determination of the bivalent antigenic distance of 
other anti-NIP antibodies, such as wildtype IgG (of any subclass), IgA (of either 
subclass), IgM, IgE, and IgD. Moreover, bispecific antibodies and also other 
antibody formats like BiTE, might be amenable to future investigation by such 
means. Since the dsDNA bivalent ligand is formed by the association of two 
independent ssDNA, it should be possible to covalently conjugate different antigens 
to each ssDNA respectively in order to generate a dsDNA bivalent ligand consisting 
of two different antigens for the bivalent antigenic distance investigation of 
bispecific antibodies. 
 
This project also hypothesised that an increase in upper hinge length would increase 
the target cell-effector cell bridging efficiency of an IgG antibody by improving the 
overall antigenic reach of Fab arms. This chapter took advantage of a rosetting assay 
as a model to compare the target cell-effector cell bridging efficiency of the different 
antibodies under test. An earlier study had demonstrated that THP-1 expressed both 
FcgRI and FcgRII (Fleit and Kobasiuk, 1991) and our findings confirmed this result. 
Due to the presence of FcgRI, which has the highest affinity for IgG and is able to 
bind monomer IgG at high affinity (Woof and Burton, 2004; Bruhns et al., 2009; 
Kiyoshi et al., 2015), it was predicted that majority of the target cell-effector cell 
bridging during rosetting would be mediated through FcgRI, although FcgRII may 
contribute to some extent. In a previous study, Walker and colleagues treated U937 
and Daudi cell with bromelin which cleaved surface glycoproteins and reduced the 
net surface charge of cells and demonstrated an increase in rosette formation with 
both U937 and Daudi when hIgG1 and hIgG3 was used to coat RBCs (Walker et al., 
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1989). More importantly, Daudi cells which expressed FcgRII but not FcgRI 
displayed better rosette formation after such treatment (Walker et al., 1989), 
suggesting that overcoming the repulsion forces between cells aided antibody 
bridging. With that reasoning, an increase in hinge length would be beneficial as it 
would extend the Fab arms of an antibody, allowing bridges to form between target 
cell and effector cell without such close approach, thereby avoiding mutual repulsion 
and resulting in more efficient binding. This reasoning was in agreement with the 
observation that the hinge mutants 0.5HA and 1HA elicited very slightly higher 
levels of rosette formation that wt hIgG1 when used at the same coating 
concentration. However, the slightly lower rosette formation of ONeg despite having 
a longer hinge than wt hIgG1 suggested that an increase in hinge length may not be 
the only factor in target cell-effector cell bridging efficiency. As a result, it was 
hypothesised that an open conformational structure of the hinge region may also be 
necessary. The main difference between ONeg and other hinge mutants is the 
absence of O-linked glycosylation. As described in Chapter 3, both 0.5HA and 1HA 
were proposed to adopt a more open hinge conformation due to the presence of O-
linked glycosylation at the incorporated hinge region of hIgA1. It is possible that the 
presence of O-linked glycans help to maintain an open hinge conformation in 0.5HA 
and 1HA and maintain the Fab arms away from Fc region, thus, keeping the 
repulsion forces, mentioned above, to a minimum. 
 
Finally, target cell-effector cell bridging is likely to also depend on the availability 
and geometry of the targeted antigen. In the context of the NIP antigen rosetting 
assay, NIP antigen was used in an excessive amount which would derivatise all 
available reactive sites of the surface of RBC. However, in reality, the availability of 
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target antigen on the surface of a pathogen may vary extensively and might be 
separated by significant distances from neighbouring molecules. In addition, the 
geometry of the targeted antigen might be a factor in governing the accessibility of 
the targeted epitope to Fab arms. Recently, Giuntini and colleagues compared the 
bactericidal activity, via complement activation, of chimeric IgG antibodies against 
two outer membrane meningococcal vaccine antigens and reported that IgG1 was the 
best performer in CDC activation against PorA (an abundant antigen) but IgG3 was 
better against FHbp (a limited and variably distributed antigen) (Giuntini et al., 
2016). The superior performance of IgG3 against sparse antigens was most likely 
due to a longer and probably better flexibility of the upper hinge region which 
allowed the Fab arms to gain a better reach against target antigen. Such findings 
would further support the idea of upper hinge extension of IgG antibody contributing 
to a longer bivalent antigenic distance as well as better flexibility to bind to hidden or 
inaccessible epitopes. 
 
Previously, Redpath and colleagues had generated a hIgG3 hinge deleted mutant, 
hIgG3m15, consisting of only 15 amino acids at the hinge region rather than the 
usual 63 amino acids, and showed that when compared to wt hIgG3, hIgG3m15 had 
a comparable binding to FcgRI but reduced binding to FcgRIIa. However, hIgG3m15 
was more potent in mediating ADCC (Redpath et al., 1998). On the other hand, Tan 
and colleagues generated several hIgG3 hinge mutants, by duplication or removal of 
hIgG3 hinge exons, with different hinge lengths ranging from 17-107 amino acids 
and compared their proficiency in complement activation (Tan et al., 1990). Due to a 
similar complement binding and activation level exhibited by different antibodies, 
except hIgG3 mutant with a hinge length of 107 amino acids that showed reduced 
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complement fixing, the authors reported that the hinge length of hIgG3 is not 
sufficient to affect complement binding and activation. The exact reason for the 
reduced complement fixation by the mutant hIgG3 with the longest hinge length, 107 
amino acids, was not known (Tan et al., 1990). However, these findings were not in 
agreement with the findings reported by Norderhaug and colleagues (1991). 
Norderhaug and colleagues similarly generated several hIgG3 hinge mutants with 
shortened hinge lengths (around 15 amino acids) and a hIgG3 mutant that carried the 
hinge region of hIgG4 to investigate the role of hinge length in complement 
activation (Norderhaug et al., 1991). The authors reported that hIgG3s with reduced 
hinge length were more efficient at complement activation than wt hIgG3. 
Unfortunately, this project did not manage to study both the ADCC and complement 
activation of the generated hIgG1 hinge mutants, therefore, it is not possible to 
comment on the role of upper hinge length of IgG1 in ADCC and complement 
activation. However, such studies are worth investigating to improve our 
understanding of the impact of structural features on antibody functionality. 
 
In summary, the NIP-dsDNA model coupled with SPR analysis would be useful in 
determining the bivalent antigenic distance of different antibodies including 
bispecific antibodies. In addition, upper hinge extension was shown to most likely 
improve the reach of the Fab arms and increase the maximum bivalent antigenic 
distance of an IgG antibody. Finally, to improve overall target cell-effector cell 
bridging efficiency of IgG, it is suggested that upper hinge extension should be 
accompanied by certain requirements which could contribute to the maintenance of 




























Fc fusion proteins are an expanding class of proteins in which a variety of proteins 
are fused with the Fc region of an immunoglobulin in order to impart novel function. 
Some of them, such as etanercept, aflibercept, rilonacept, belatacept and abatacept, 
are used in clinical therapies (Czajkowsky et al., 2012). For example, etanercept is a 
Fc fusion protein that was engineered to comprise tumour necrosis factor receptor 
(TNFR) fused to the Fc region of human IgG1, in order to function as a TNF 
inhibitor by acting as a decoy receptor (Haraoui and Bykerk, 2007). The creation of 
etanercept greatly benefited the treatment of several inflammatory diseases 
especially rheumatoid arthritis (RA) (Haraoui and Bykerk, 2007).  
 
One of the major advantages of the Fc fusion protein format is the ability to utilise 
the long plasma half-life of immunoglobulins which is regulated by interaction with 
a unique Fc receptor called FcRn (Roopenian and Akilesh, 2007). FcRn binds 
specifically to the Fc region of IgGhowever, it only interacts with IgG Fc at acidic 
pH 4.5-6.5 but not at physiological pH 7.4 (Roopenian and Akilesh, 2007). As 
described in Chapter 1 Figure 1.7B, when an IgG monomer is phagocytosed by a 
phagocytic cell through interaction with FcgR, the resultant phagocytic vacuole fuses 
with an endosome which contains FcRn, and is gradually acidified. When the 
vacuole reaches pH 4.5-6.5, FcRn is able to bind to the Fc region of the IgG and 
prevent the antibody from entering the degradation pathway. The IgG may then be 
recycled back to the extracellular environment and on reaching the extracellular  
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space with a pH of 7.4, the IgG will dissociate form FcRn and be released to carry 
out its immunological function again (Roopenian and Akilesh, 2007). More recently, 
FcRn was shown to be capable of promoting antigen cross presentation in dendritic 
cells, which resulted in presentation of digested exogenous antigens on MHC-I 
molecules and subsequent activation of cytotoxic T cells (Liu et al., 2011; Baker et 
al., 2011). The process of antigen cross presentation is briefly described in Figure 6.1. 
Figure 6.1: A schematic diagram illustrating the process of antigen cross presentation mediated by 
FcRn in a dendritic cell. 1) Antigen immune complex bound to Fcg receptors. 2) Fcg receptor 
activation induces phagocytosis of the immune complex. 3) FcRn binding to Fc region of IgG 
antibodies in acidified endosome. 4, 5 and 6) Antigen is digested into small peptides and loaded 
onto MHC class I for antigen presentation to activate cytotoxic T cells. 
	 189	
Baker and colleagues showed that dendritic cells that expressed FcRn were able to 
initiate a cytotoxic T cell response with a 100-fold lower antigen concentration than 
that required for dendritic cells that did not express FcRn (Baker et al., 2011). In 
addition, the authors also showed that a mutant hIgG1, known as IHH-IgG, which 
was unable to bind to FcRn provided a confirmatory result. Thus, immune complexes 
formed by IHH-IgG were unable to effectively activate a cytotoxic T cells response 
(Baker et al., 2011). In a further study, Baker and colleagues used adoptive transfer 
of wildtype dendritic cells into Fcgrt-/- mice (i.e. mice lacking FcRn expression) that 
were suffering from induced colorectal cancer. They found that transfer of the 
wildtype FcRn-positive dendritic cells greatly improved the infiltration of cytotoxic 
T cells into the tumour environment and provided protective immunity to the mice 
that lacked FcRn expression, whereas transfer of DC lacking FcRn expression did 
not (Baker et al., 2013). An interpretation of these findings is that the enhanced T 
cell cytotoxic response was due to antigen cross presentation that occurred within 
newly transferred dendritic cells that expressed FcRn. As a result, the engagement of 
antibodies with FcRn seems to be crucial for the induction of antigen cross 
presentation to obtained an enhanced cytotoxic T cell activity against exogenous 
antigens. In a different study, Ye and colleagues fused the herpes simplex virus type-
2 (HSV-2) glycoprotein gD to the Fc region of murine IgG2a and vaccinated both wt 
mouse expressing FcRn and Fcgrt-/- mouse with the generated Fc fusion protein 
before subjecting them to HSV challenge (Ye et al., 2011). The authors reported that 
the wt mice displayed complete protection against the viral challenge and had 
stronger T cell and antibody responses when compared to the FcRn knockout mice 
(Ye et al., 2011). Again, this result supports the idea that FcRn is capable of 
promoting antigen cross presentation by dendritic cells. These findings in antigen 
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cross presentation studies raise the possibility of using FcRn antigen presentation as 
a means to induce effective anti-tumour immune responses. It can be hypothesised 
that one might generate a potential cancer vaccine by fusing a protein which is highly 
expressed by cancer cells to the Fc region of IgG. Such a vaccine might induce 
effective antigen cross presentation of the fused protein and thereby activate relevant 
cytotoxic T cells to kill cancer cells.  
 
One major obstacle in this Fc-fusion protein approach is the selection of a suitable 
protein to be fused with the Fc region of wt hIgG1, since the majority of proteins 
expressed by cancer cells are also found in normal cells. T cells and B cells undergo 
selection in the thymus and bone marrow respectively, whereby self-epitopes are 
presented to naïve T cells and B cells and any self-reactive cells are eliminated. 
Therefore, this defensive mechanism should prevent any immune response against 
self-expressed proteins. As a result, the selection of a protein expressed by cancer 
cells but not on normal cells has proven to be difficult. Fortunately, a group of 
proteins known as cancer testis antigens (CTA) have been shown to be expressed 
only by cancer cells but not normal cells other than testis, ovary and placenta 
(Scanlan et al., 2002). This CTA appear suitable as candidate proteins for Fc-fusion 
cancer vaccines. Although CTA are expressed in testis, ovary and placenta, these 
sites are immune privileged sites in which the activation of an immune response is 
greatly reduced or well tolerated (Hong and Van Kaer, 1999; Li et al., 2012). 
Therefore, if an immune response was initiated against cancer cells by an CTA-Fc 
fusion vaccine it might be expected that no severe damage would occur to CTA-
expressing normal tissues, such as testis, ovary and placenta, in the body. With such 
reasoning, CTA proteins may serve as suitable candidates to be fused to the Fc 
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region of wt hIgG1 to generate potential cancer vaccines. By fusing CTA protein to 
the Fc region of IgG, the resultant Fc fusion protein would benefit from long plasma 
half-life due to FcRn binding, thus, increasing the chances of the Fc fusion protein to 
elicit host antibodies directed against CTA protein and form immune complexes via 
antigen binding. As a result, this could induce antigen cross presentation of the CTA 
protein to activate cytotoxic T cells which might serve to eliminate CTA expressing 
cancer cells. The concept of using such vaccine will be further described below. 
 
6.1.1 Melanoma-associated antigen (MAGE) A protein family  
As mentioned above, CTA are a unique class of proteins that were highly expressed 
by cancer cells but expression on normal tissues is restricted to testis, ovary and 
placenta (Scanlan et al., 2002). Several protein classes have been categorised as CTA 
over the years, including melanoma-associated antigens (MAGE), NY-ESO-1, and 
synovial sarcoma X (SSX) antigens (Scanlan et al., 2002). Amongst these protein 
classes, MAGE have been well studied and found to be expressed by a wide range of 
different cancers, such as those of ovary, lung, breast and bladder (Müller-Richter et 
al., 2009; Figueiredo et al., 2011; Schultz-Thater et al., 2011; Meek and Marcar, 
2012). MAGE-1 (now renamed to MAGE-A1) was the first member to be identified 
after isolating the corresponding cytotoxic T cell from an autologous melanoma 
patient (van der Bruggen et al., 1991). Many more family members had been 
identified subsequently and currently MAGE were categorised into three subfamilies 
known as MAGE-A, MAGE-B and MAGE-C (Meek and Marcar, 2012; Sang et al., 
2011). MAGE-A have been well studied and consists of twelve family members, 
named MAGE-A1 to MAGE-A12 (Meek and Marcar, 2012; Sang et al., 2011). The 
actual function of each MAGE-A proteins is still unknown but it was identified that  
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all MAGE-A proteins share a conserved domain consisting of around 165-171 amino 
acids termed MAGE Homology Domain (MHD), as shown in Figure 6.2 (Sang et al., 
2011). MAGE A proteins have been reported to be expressed by a variety of 
different cancers (Müller-Richter et al., 2009; Figueiredo et al., 2011; Schultz-Thater 
et al., 2011; Meek and Marcar, 2012). Figueiredo and colleagues reported the 
expression of MAGE-A1, -A3 and -A4 in patients suffering from laryngeal 
Figure 6.2: A schematic diagram illustrating the MAGE-A protein family members aligned 
based on the MAGE Homology Domain (MHD) (purple). MAGE-A7 is a pseudo-gene 
therefore not shown. The numbering above each protein family member represents amino 
acid residues. Image adapted from (Meek and Marcar, 2012). 
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squamous cell carcinoma based on an immunohistochemistry technique (Figueiredo 
et al., 2011). On the other hand, Müller-Richter and colleagues reported the 
expression of MAGE-A2, -A3, -A4, -A6 and -A10 in five oral squamous cell 
carcinoma cell lines (Müller-Richter et al., 2009). In a more detailed investigation, 
Schultz-Thater and colleagues generated a monoclonal antibody against MAGE-A10 
and investigated the expression of MAGE-A10 in a variety of cancers (Schultz-
Thater et al., 2011). The authors reported that MAGE-A10 was highly expressed in 
breast, oesophagus, lung and skin cancers (Schultz-Thater et al., 2011). MAGE-A 
proteins are highly expressed in various cancer diseases as mentioned above. More 
importantly, all MAGE-A proteins share a conserved MAGE Homology Domain 
(MHD). Therefore, if a cytotoxic T cell immune response is initiated against an 
epitope belonging to the MHD it may be expected that the relevant cytotoxic T cell 
immune response would be effective against all cancer cells that express MAGE-A 
proteins. 
 
In this study, MAGE-A2 was selected as the protein to be fused with the Fc region of 
wt hIgG1 to generate a potential cancer vaccine. The exact role of MAGE-A2 is as 
yet unknown. However, investigations have shown that MAGE-A2 can directly bind 
to p53 core and recruit transcription repressors to repress p53 activity (Monte et al., 
2006). Such activity might be expected to result in the initiation of an uncontrollable 
cell proliferation thus causing the development of cancer. In an immunotherapeutic  
view, Graff-Dubois and colleagues had identified a few HLA-A*0201 restricted 
MAGE-A peptides which were able to stimulate specific cytotoxic T cells to kill 
human cancer cells that expressed different MAGE-A proteins, including MAGE-A2 
(Graff-Dubois et al., 2002). In addition, Tanzarella and colleagues identified a HLA-
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B*3701 restricted MAGE-A peptide, which was expressed by MAGE-1, -2, -3 and -6 
(MAGE-A1, -A2, -A3, -A6), that could induce a cytotoxic T cell immune response 
against COS-7 cells which were co-transfected with HLA-B*3701 and MAGE-1, -2, 
-3 and -6 respectively (Tanzarella et al., 1999). Based on such findings, MAGE-A2 
was considered a reasonable candidate for a generation of an Fc-fusion protein 
vaccine. 
 
6.1.2 Fusion of MAGE-A2 with IgG1 Fc 
The antigen cross presentation assays carried out in previous studies involved the 
activation of Fcg receptors on the surface of dendritic cells to induce phagocytosis of 
immune complexes (Baker et al., 2013; Baker et al., 2011). It is not known if a 
monomeric MAGE-A2-Fc (MFc) molecule would induce antigen cross presentation 
by itself. Therefore, as a precaution the binding site for Fcg receptors on any MFc 
should not be disturbed to examine the characteristic of monomeric MFc. The 
binding site on IgG for Fcg receptors has been localised to the lower hinge region 
(Woof and Burton, 2004). In addition, the crystal structure of MAGE-A2 protein has 
not been solved. Therefore, it is not known if the structure of the MAGE-A2 protein 
would be likely to cause any steric hindrance to the Fc region. As a result, it was 
decided that a 13 amino acid peptide linker, GSSGGGSSGGSSS, should be 
introduced to the C-terminal of the MAGE-A2 protein and fused to the N-terminal of 
the hinge region of IgG. It was hoped that the linker might help to keep the MAGE-
A2 protein distanced apart from IgG Fc region and minimise any possible steric 
hindrance. By keeping the hinge region of the IgG intact, the cysteine residues that 
were responsible for interchain disulphide bonding would be undisturbed. Therefore, 
it was expected that two MFc polypeptide chains would associate and link together 
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just as in an immunoglobulin molecule. A diagram illustrating the expected general 
structure of MFc is shown in Figure 6.3. 
 
6.1.3 The role of FcRn in the concept of MAGE-A2-Fc (MFc) fusion protein as 
cancer vaccine  
MAGE-A2-Fc fusion cancer vaccine protein (MFc) was designed with the aim of 
utilising the antigen cross presentation ability of FcRn to induce a suitable cytotoxic 
Figure 6.3: A schematic diagram illustrating the general structure of MAGE-A2-Fc fusion 
protein (MFc). A) The expected general structure of a MFc polypeptide which consists of the 
IgG Fc region, IgG hinge region, peptide linker and human MAGE-A2 protein. Cys226 and 
Cys229 (EU numbering) form the interchain disulphide bond with another single chain MFc. B) 
The predicted general structure of MFc protein in which interchain disulphide bonding had been 
formed between two MFc polypeptides. 
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T cell immune response against cancer cells. In addition, the inclusion of the Fc 
region of IgG in MFc was designed to take advantage of the long plasma half-life of 
associated with FcRn engagement. The concept of MFc as a potential cancer vaccine 
is illustrated in Figure 6.4. In brief, when MFc is injected into the patient, MFc 
would encounter host antibodies that would specifically recognise MAGE-A2 as 
foreign protein thereby forming immune complexes. Subsequently these immune 
complexes would be taken up by phagocytic cells, in particular dendritic cells, via 
FcgR engagement. The phagocytic vacuole would fuse with endosomes, which 
contained FcRn, and become gradually acidified to initiate protein degradation. 
When the pH of the endosome reached pH 4.5-6.5, the histidine residues of the Fc 
region would be protonated and association with FcRn would occur (Roopenian and 
Akilesh, 2007). The late endosomes would fuse with lysosomes and MFc would be 
degraded and digested into appropriate short peptides to be loaded onto MHC class I 
and MHC class II molecules. Baker and colleagues had demonstrated that IgG 
immune complexes remain bound to FcRn within the intracellular compartment after 
60 minutes whereas IHH-IgG immune complexes were not found after 
internalisation beyond 60 minutes (Baker et al., 2011). The authors suggested that 
the longer period of time that immune complexes were retained by FcRn allowed for 
proper digestion of antigens in order to be presented on MHC class I molecules 
(Baker et al., 2011). The exact mechanism of antigen cross presentation to MHC 
class I molecules was still unknown and remains under investigation. However, 
antigen presentation on MHC class I molecules would activate corresponding 
cytotoxic T cells to induce an immune response against cancer cells that expressed 
MAGE-A2 or other MAGE-A proteins that contained similar peptide sequences. In a 






Figure 6.4: A schematic diagram illustrating the concept of MAGE-A2-Fc (MFc) fusion protein 
as a cancer vaccine. 1, 2, 3, 4, and 5 highlight the key mechanisms of antigen cross presentation 
pathway and A, B, C, D, E highlight the key mechanisms of the recycling pathway. 1 and A) 
MFc immune complex or monomer bound to FcgRI. 2 and B) FcgRI activation induced 
phagocytosis of MFc. 3 and C) FcRn binding to MFc in acidified endosome. 4, 5 and 6) MFc is 
digested into small peptides and loaded onto MHC class I for antigen presentation to activate 
cytotoxic T cells. D and E) FcRn-bound MFc is transported to the extracellular space and 
released at pH 7 to encounter host antibodies. 
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cells before an immune complex was formed. The Fc region of MFc was derived 
from wt hIgG1, thus, it would have a high affinity for FcgRI and could bind to FcgRI 
as a monomer. In such cases, upon FcgRI engagement MFc might be expected to be 
internalised via FcgRI binding and the resultant vacuole would fuse with an 
endosome that contained FcRn. The endosome would be gradually acidified and 
when the pH reached pH 4.5-6.5 FcRn would bind to the Fc region of MFc, therefore, 
protecting MFc from protein degradation. Ward and colleagues had demonstrated 
that IgG molecules that are unable to bind to FcRn proceed into the lysosomal 
pathway in which are degraded whereas IgG that are able to bind FcRn are recycled 
back to the extracellular space (Ward et al., 2003). As a result, MFc might be 
expected to be recycled back to the extracellular environment and the association 
with FcRn would be abolished at pH 7, thus, resulting in the release of MFc back 
into the blood stream, allowing MFc to encounter circulating host antibodies. 
 
6.2 AIMS 
This chapter hypothesised that a potential cancer vaccine could be generated by 
fusing human MAGE-A2 to the Fc region of IgG antibody to stimulate a strong 
cytotoxic T cells immune response against MAGE-A2 expressing cancer cells. As a 
result, the aim of this chapter was to generate MFc fusion proteins using both murine 
IgG2a or wt hIgG1 Fc regions. This chapter also aimed to investigate whether such 
MFc fusion proteins could be successfully produced in mammalian cells using 










A plasmid, pMAGE-A2, encoding wildtype human MAGE-A2 was a gift from 
Bianca Ihrig and Dr David Meek (University of Dundee). 
 
pFUSEN-mG2AFc 
A plasmid, pFUSEN-mG2AFc, encoding the hinge region and the CH2 and CH3 
constant domains of the murine IgG2a heavy chain, was purchased from InvivoGen. 
 
pHCCR 
The pHCCR plasmid encoding the majority of the constant region of the heavy chain 
of wildtype human IgG1 (wt hIgG1) was described in Chapter 2.  
 
6.3.2 CONSTRUCTION OF Kz-hMFc AND Kz-mMFc PLASMIDS 
 
6.3.2.1 Generation of hMFc (MAGE-A2 fused with wt hIgG1 Fc) expression 
plasmid 
The procedure for fusing sequence encoding human MAGE-A2 to that encoding the 







Figure 6.5: A schematic diagram illustrating the generation of the MAGE-A2-hFc 
expression vector. A) MAGE-A2 amplification procedure. pMAGE-A2 was digested with 
BamHI and AflIII to obtain the insert containing MAGE-A2 DNA sequence which was 
amplified with specific primers to introduce sequence encoding an immunoglobulin 
secretion signal peptide (purple) at the 5´ end and one encoding a linker peptide (yellow) at 
the 3´ end. B) hIgG1 Fc amplification procedure. pHCCR was digested with PstI and EcoRI 
to obtain the insert containing hIgG1 Fc DNA sequence which was amplified with specific 
primers to introduce sequence encoding a linker peptide (yellow) at the 5´ end. C) 
Generation of hMFc expression vector. An overlap PCR was performed to fuse the PCR 
products from A and B together using specific primers and the final product was digested 
with HindIII and EcoRI. pHCCR was digested with HindIII and EcoRI to obtain an open 
vector to ligate with the previously digested insert. 
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Amplification of sequence encoding MAGE-A2 
pMAGE-A2 was digested with restriction enzymes Afl III and BamHI at 37ºC for 1 
hour as described in section 2.4.1. Gel electrophoresis and DNA gel extraction were 
performed to purify digested a DNA fragment of about 965bp, containing the DNA 
sequence of MAGE-A2 (insert). Primers MAGEForwLong and MAGERev (Table 
2.2, No. 9 & 8) were used at an annealing temperature of 50ºC to amplify the 
purified DNA insert to obtain a DNA product of approximately 1050bp, which 
contained a HindIII site at the 5' end. Primers MAGEForwLong and MAGERev 
were designed to introduce sequence encoding an immunoglobulin secretion signal 
peptide, MGWSCIILFLVATATGVHS, at the 5´ end and sequence encoding a 13 
amino acid peptide linker, GSSGGGSSGGSSS, at the 3´ end of the amplified 
MAGE-A2 DNA sequence. PCR products were run on a DNA agarose gel as 
described in section 2.4.4 and DNA bands of the correct sizes were extracted as 
described in section 2.4.5. 
 
Amplification of sequence encoding wt hIgG1 Fc region 
pHCCR was digested with restriction enzymes EcoRI and PstI at 37ºC for 1 hour as 
described in section 2.4.1. Gel electrophoresis and DNA gel extraction were 
performed to purify a digested DNA fragment of about 1031bp, containing sequence 
encoding the Fc region of wt hIgG1 (insert). Primers IgGForw and AG3´NEW 
(Table 2.2, No. 10 & 4) were used at an annealing temperature of 40ºC to amplify the 
purified DNA insert to obtain a DNA product of approximately 1034bp, which 
contained an EcoRI site at the 3´ end. PCR products were run on a DNA agarose gel 
as described in section 2.4.4 and DNA bands of the correct sizes were extracted as 
described in section 2.4.5. 
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Fusion of MAGE-A2 with wt hIgG1 Fc region and generation of plasmid construct 
Using a PCR procedure described in section 2.4.3, an overlap PCR extension was 
performed by using a mix of 2μl of extracted MAGE-A2 and 2μl of extracted wt 
hIgG1 Fc DNA fragments as templates and MAGEForwShort and AG3´NEW as 
primers (Table 2.2, No. 7 & 4) at an annealing temperature of 50ºC, to produce a 
final DNA product of approximately 2056bp. Gel electrophoresis and DNA gel 
extraction were carried out subsequently. Purified DNA fragment and plasmid 
pHCCR were then digested with restriction enzymes HindIII and EcoRI as described 
in section 2.4.1. Gel electrophoresis and DNA gel extraction were performed to 
purify the digested DNA fragment of 2044bp (insert) and digested pHCCR of about 
8000bp (vector). Both purified DNA fragments were then ligated as described in 
section 2.4.6 and transformed into competent DH5α E. coli as described in section 
2.4.7. After purifying the plasmids from positive clones as described in section 2.4.9, 
DNA sequencing was carried out (section 2.4.11) to ensure that sequence encoding 
MAGE-A2 had been correctly fused with that encoding the Fc region of wt hIgG1. A 
plasmid with the correct DNA sequence was named as phMFc. 
 
6.3.2.2 Generation of Kz-hMFc expression plasmid 
It was later realised that the phMFc expression vector did not contain the Kozak 
consensus sequence which is important for efficient protein expression (Lida and 
Masuda, 1996). Therefore, incorporation of the required Kozak sequence was carried 
out. The process for introduction of the Kozak consensus sequence is illustrated in 
Figure 6.6. phMFc was digested with restriction enzymes HindIII and EcoRI as 






Figure 6.6: A schematic diagram illustrating the incorporation of the Kozak consensus 
sequence into the hMFc expression vector. phMFc was digested with HindIII and EcoRI to 
obtain the insert containing hMFc DNA sequence and an open vector. The hMFc insert was 
amplified with specific primers to introduce the Kozak consensus sequence and ligated with 
the purified vector. 
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performed to purify a digested DNA fragment of about 2044bp, containing the DNA 
sequence of hMFc. Primers MAGE-FcKosak and AG3´NEW (Table 2.2, No. 11 & 4) 
were used at an annealing temperature of 60ºC to amplify the purified DNA insert to 
obtain a DNA product of approximately 2061bp, which contained sequence encoding 
a HindIII site at the 5´ end and an EcoRI site at the 3´ end. Gel electrophoresis and 
DNA gel extraction were carried out subsequently. Purified DNA fragment and 
plasmid pHCCR were then digested with restriction enzymes HindIII and EcoRI as 
described in section 2.4.1. Gel electrophoresis and DNA gel extraction were 
performed to purify the digested DNA fragment of 2049bp (insert) and digested 
pHCCR of about 8000bp (vector). Both purified DNA fragments were then ligated as 
described in section 2.4.6 and transformed into competent DH5α E. coli as described 
in section 2.4.7. After purifying the plasmids from positive clones as described in 
section 2.4.9, DNA sequencing was carried out (section 2.4.11) to ensure that the 
Kozak consensus sequence had been incorporated. A plasmid with the correct DNA 
sequence was named as pKz-hMFc. 
 
6.3.2.3 Amplification of sequence encoding the murine IgG2a Fc region 
The procedure for fusing sequence encoding human MAGE-A2 to that encoding the 
Fc region of murine IgG2a is illustrated in Figure 6.7. 
 
Amplification of sequence encoding murine IgG2a Fc region 
pFUSEN-mG2AFc was digested with restriction enzymes EcoRI and HpaI at 37ºC 
for 1 hour as described in section 2.4.1. Gel electrophoresis and DNA gel extraction 
were performed to purify a digested DNA fragment at about 1031bp, containing 








Figure 6.7: A schematic diagram illustrating the generation of MAGE-A2-mFc Fc-fusion protein 
expression vector. A) MAGE-A2 amplification procedure. pKz-hMFc was digested with HindIII 
and EcoRI to obtain the insert containing MAGE-A2-hFc DNA sequence which was amplified 
with specific primers to obtain a suitable MAGE-A2 insert. B) Murine IgG2a Fc amplification 
procedure. pFUSEN-mG2A-Fc was digested with EcoRI and HpaI to obtain the insert containing 
mIgG2a Fc DNA sequence which was amplified with specific primers to introduce sequence 
encoding a linker peptide (yellow) at the 5´ end. C) Generation of mMFc expression vector. An 
overlap PCR was performed to fuse the PCR products from A and B together using specific 
primers and the final product was digested with HindIII and EcoRI. pHCCR was digested with 
HindIII and EcoRI to obtain an open vector to ligate with the previously digested insert. 
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and MouseFcRev (Table 2.2, No.12 & 13) were used at an annealing temperature of 
62ºC to amplify the purified DNA insert to obtain a DNA product of approximately 
717bp, which contained an EcoRI site at the 3´ end. PCR products were run on a 
DNA agarose gel as described in section 2.4.4 and DNA bands of the correct sizes 
were extracted as described in section 2.4.5. 
 
Amplification of sequence encoding MAGE-A2 
pKz-hMFc was digested with restriction enzymes HindIII and EcoRI as described in 
section 2.4.1. Gel electrophoresis and DNA gel extraction were performed to purify a 
digested DNA fragment at about 2044bp, containing the DNA sequence of hMFc. 
Primers MAGE-FcKosak and MAGERev (Table 2.2, No. 11 & 8) were used at an 
annealing temperature of 66ºC to amplify the purified DNA insert to obtain a DNA 
product of approximately 1055bp, which contained a HindIII site at the 5´ end. 
 
Fusion of MAGE-A2 with murine IgG2a Fc region and generation of plasmid 
construct 
Using a PCR procedure described in section 2.4.3, an overlap PCR extension was 
performed by using a mix of 2μl of extracted MAGE-A2 and 2μl of extracted murine 
IgG2a Fc DNA fragments as templates and MAGE-FcKosak and MouseFcRev as 
primers (Table 2.2, No. 11 & 13) at an annealing temperature of 55ºC, to produce a 
final DNA product of approximately 1687bp. Gel electrophoresis and DNA gel 
extraction were carried out subsequently. Purified DNA fragment and plasmid 
pHCCR were then digested with restriction enzymes HindIII and EcoRI as described 
in section 2.4.1. Gel electrophoresis and DNA gel extraction were performed to 
purify the digested DNA fragment of 1675bp (insert) and digested pHCCR of about 
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8000bp (vector). Both purified DNA fragments were then ligated as described in 
section 2.4.6 and transformed into competent DH5α E. coli as described in section 
2.4.7. After purifying the plasmids from positive clones as described in section 2.4.9, 
DNA sequencing was carried out (section 2.4.11) to ensure that sequence encoding 
MAGE-A2 had been correctly fused with that encoding the Fc region of murine 
IgG2a. A plasmid with the correct DNA sequence was named as pKz-mMFc. 
 
6.3.3 PRODUCTION AND CHARACTERISATION OF hMFc AND mMFc 
 
6.3.3.1 hMFc and mMFc production and purification from FreeStyle 293-F cells 
Frozen FreeStyle 293-F cells were thawed and maintained in appropriate growth 
conditions as shown in section 2.6.2. Before the day of transfection, each flask of 
cells was split and seeded at 5 x 105 cells/ml in an Erlenmeyer flask in a total volume 
of 25ml, so that on the day of transfection the cells were at 1 x 106 cells/ml with a 
viability of 90% or above. For transfection, 293Fectin (Invitrogen) and Opti-MEM 
(1X) (Gibco Life Technologies) were brought to room temperature. For a single 
transfection, aliquots of 0.833ml of Opti-MEM (1X) were pipetted into two 30ml 
Universal tubes. In one tube, the DNA listed in Table 6.1 was added and mixed 
gently. In the other tube, 33.25µl of 293Fectin was added and allowed to incubate for 
exactly 5 minutes at room temperature before the addition of the DNA mixture 
prepared earlier. Once the DNA mixture was added, the solution was gently mixed 
and allowed to incubate for 20-30 minutes at room temperature. When completed, 
the solution was added to the FreeStyle 293-F cells and incubated on a shaker in an 
incubator in 8% CO2 at 37ºC. Fusion protein was ready to be harvested and purified 
after 4 days as described in section 2.8. 
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Table 6.1: Amount of DNA required for FreeStyle 293-F cells transfection 
Note: The ratio of fusion plasmid to pAdvantage is 1:1. 
 
6.3.3.2 Characterisation of hMFc and mMFc  
Fc fusion protein purifications were carried out as described in section 2.8. Purified 
Fc fusion proteins were subjected to SDS-PAGE as described in section 2.8.6. 
Protein gels were stained with Coomassie as described in section 2.8.8 to determine 
the purity of the Fc fusion proteins generated. To further analyse the purified proteins, 
they were subjected to western blotting as described in section 2.8.7. After the 
blocking and washing procedure, the membranes were incubated with the detecting 
antibodies shown below. All membranes were washed and developed with 
appropriate substrate. 
 
Antibodies for hMFc detection 
To detect hMFc, the following antibodies were used: polyclonal rabbit anti-human 
IgG HRP conjugated (Table 2.1, No.2), monoclonal mouse anti-human MAGE-A2 
(6C1) (Table 2.1, No.18), monoclonal mouse anti-human MAGE-A2 (1H4) (Table 





Type of DNA expression vector Amount of DNA 
pKz-hMFc or pKz-mMFc 4.17µg 
pAdvantage vector (Promega) 4.17µg 
	 211	
Antibodies for mMFc detection 
To detect mMFc, the following antibodies were used: polyclonal goat anti-mouse 
IgG HRP conjugated (Table No.20), monoclonal mouse anti-human MAGE-A2 (6C1) 
(Table 2.1, No.18), monoclonal mouse anti-human MAGE-A2 (1H4) (Table 2.1, 
No.17) and polyclonal goat anti mouse kappa light HRP conjugated (Table 2.1, 
No.19).  
 
6.3.3.3 Prediction of the unstructured region of hMFc 
Due to the observation that both hMFc and mMFc proteins tended to form 
aggregates (described in Results), the stability of the protein structure of MAGE-A2 
was questioned, with the existence of unstructured regions being a possibility. Since 
the crystal structure of MAGE-A2 has not been solved, software 
(http://iupred.enzim.hu) which could predict the unstructured regions of a protein 
was used to investigate if MAGE-A2 might have any unstructured regions 
(Dosztányi et al., 2005). The amino acid sequence of hMFc was uploaded to the 




6.4.1 Generation of hMFc expression plasmid 
Using the primer combinations of MAGEForwLong and MAGERev to amplify the 
digested human MAGE-A2 insert from pMAGE-A2, and IgGForw and AG3´NEW 
to amplify the digested wt hIgG1 Fc insert from pHCCR, DNA amplified fragments 
of the correct sizes of 1050bp and 1034bp respectively were obtained as shown in 




encoding an immunoglobulin secretion signal peptide, 
MGWSCIILFLVATATGVHS, to the 5´ end of the MAGE-A2 gene sequence to 
allow MFc to be secreted to the extracellular compartment for easier purification. On 
the other hand, primer MAGERev was designed to incorporate sequence encoding a 
13 amino acids peptide linker, GSSGGGSSGGSSS, at the 3´ end of MAGE-A2 gene 
sequence. The DNA sequence of the peptide linker served as a complementary 
region, shown in yellow in Figure 6.5, to aid the fusion of MAGE-A2 sequence with 
that of wt hIgG1 Fc region via overlapping PCR. The result of the subsequent 
overlapping PCR procedure, using the primer combinations of MAGEForwShort and 
AG3´NEW, is shown in Figure 6.8 C. The band obtained of approximately 2000bp 
indicated that the 1050bp and 1034bp DNA fragments had annealed through their 
complementary regions leading to successful amplification. The purified PCR 
product and pHCCR vector were ligated together after digestion with restriction 
Figure 6.8: Results of molecular cloning for the generation of the hMFc expression plasmid. 
A) MAGE-A2 amplification. Lane 1050bp shows PCR amplification using 
MAGEForwLong and MAGERev to obtain a DNA fragment of 1050bp. B) wt hIgG1 Fc 
amplification. Lane 1034bp shows PCR amplification using IgGForw and AG3’NEW to 
obtain a DNA fragment of 1034bp. C) Overlapping PCR amplification. Complementary 
DNA fragments of 1050bp and 1034bp from A and B were amplified using 
MAGEForwShort and AG3´NEW to produce a fragment of 2056bp. 
	 213	
enzymes HindIII and EcoRI. After transforming the plasmids into E.coli, DNA 
plasmids were purified from positive clones and subsequent DNA sequencing 
confirmed that sequences encoding the immunoglobulin secretion signal, peptide 
linker had been incorporated and that fusion of sequences encoding MAGE-A2 and 
wt hIgG1 Fc had been successful, as shown in the final hMFc DNA and translated 
protein sequences in Figure 6.9. The correct plasmid was named as phMFc.  
 
6.4.2 Introduction of Kozak consensus sequence into the hMFc expression 
plasmid 
phMFc and pAdvantage were used to transfect FreeStyle 293-F cells and the hMFc 
protein was purified using Protein G-Sepharose. SDS-PAGE and western blotting 
were carried out. However, it was discovered that the expression of hMFc protein 
were very low and hardly detectable (data not shown). It was realised that the 
expression plasmid phMFc was lacking the Kozak consensus sequence which 
promotes high protein expression. To resolve this, primer combinations of MAGE-
FcKosak, which contained the Kozak consensus sequence, and AG3´NEW were used 
to amplify the hMFc insert, which was first purified from the digestion of phMFc 
with restriction enzymes HindIII and EcoRI. The purified PCR product and phMFc 
vector were ligated together after digestion with restriction enzymes HindIII and 
EcoRI (data not shown). After transforming the plasmids into E.coli, DNA plasmids 
were purified from positive clones and subsequent DNA sequencing confirmed that 
introduction of Kozak consensus sequence prior to the start codon of hMFc encoding 
sequence had been successful, as indicated in the final mMFc DNA and translated 







6.4.3 Generation of mMFc expression plasmid 
Using the primer combinations of MAGE-FcKosak and MAGERev to amplify the 
digested human MAGE-A2 insert from pKz-hMFc, and MouseFcForw and 
MouseFcRev to amplify the digested mIgG2a Fc insert from pFUSEN-mG2AFc, 
DNA amplified fragments of the correct sizes of 1055bp and 717bp respectively 
were obtained as shown in Figures 6.10A and 6.10B. Similar to the previous 
generation of hMFc, the DNA sequence of the peptide linker served as a 
complementary region, shown in yellow in Figure 6.10, to aid the fusion of 
sequences encoding MAGE-A2 and mIgG2a Fc via overlapping PCR. The result of 
the subsequent overlapping PCR procedure, using the primer combinations of 
MAGE-FcKosak and MouseFcRev, is shown in Figure 6.10C. The band obtained of  
Figure 6.9: The DNA sequence encoding hMFc and corresponding translated protein sequences. 
Red, Kozak consensus sequence; Purple, protein sequence of immunoglobulin secretion signal 
peptide; Blue, protein sequence of full length human MAGE-A2 protein; Yellow, protein 
sequence of the 13 amino acid peptide linker; Green, protein sequence of wt hIgG1 Fc region; 




approximately 1687bp indicated that the 1055bp and 717bp DNA fragments had 
annealed through their complementary regions leading to successful amplification. 
The purified PCR product and pHCCR vector were ligated together after digestion 
with restriction enzymes HindIII and EcoRI. After transforming the plasmids into 
E.coli, DNA plasmids were purified from positive clones and subsequent DNA 
sequencing confirmed that the fusion of sequences encoding MAGE-A2 and mIgG2a 
Fc had been successful (data not shown). The correct plasmid was named as pKz-





Figure 6.10: Results of molecular cloning for the generation of mMFc expression plasmid. 
A) MAGE-A2 amplification. Lane 1055bp shows PCR amplification using MAGE-FcKosak 
and MAGERev to obtain DNA fragment at 1055bp. B) mIgG2a Fc amplification. Lane 
717bp shows PCR amplification using MouseFcForw and MouseFcRev to obtain DNA 
fragment at 717bp. C) Overlapping PCR amplification. Complementary DNA fragments of 
1055bp and 717bp from A and B were amplified using MAGE-FcKosak and MouseFcRev 






6.4.4 Production and characterisation of Fc fusion proteins 
Two Fc fusion expression plasmids, pKz-hMFc and pKz-mMFc, were each 
transfected together with pAdvantage into FreeStyle 293-F cells. After 4 days, 
supernatants of the cell cultures were harvested and incubated with Protein G-
Sepharose, and the expressed Fc fusion proteins purified. The success of Fc fusion 
protein purification from the supernatants of the cell cultures indicated that the 
introduction of the immunoglobulin secretion signal peptide was successful and that 
the Fc fusion proteins were being secreted into the extracellular space. More 
importantly, the success of Fc fusion protein purification using Protein G-Sepharose 
indicated that, at least, the Fc region of the Fc fusion proteins had folded up correctly, 
since recognition of Fc by protein G is dependent on IgG Fc having its correct three-
dimensional conformation. In addition, the results also suggested that the fusion of 
human MAGE-A2 did not cause major steric hindrance to the Fc region. It was 
presumed that the introduction of the 13 amino acid peptide linker kept MAGE-A2 
and the Fc region apart from each other, thus, allowing the Fc region to bind 
Figure 6.11: The DNA sequence encoding mMFc and corresponding translated protein 
sequences. Red, Kozak consensus sequence; Purple, protein sequence of immunoglobulin 
secretion signal peptide; Blue, protein sequence of full length human MAGE-A2 protein; 
Yellow, protein sequence of the 13 amino acid peptide linker; Green, protein sequence of wt 
mIgG2a Fc region; *, stop codon. 
	 219	
efficiently to Protein G-Sepharose. The amount of Fc fusion protein obtained from a 
single 25ml transfection was around 80-120µg for both Fc fusion proteins. 
 
Purified fusion proteins were subjected to SDS-PAGE, as described in Section 2.8.6. 
Figure 6.12A shows the results of Coomassie staining of purified Fc fusion proteins 
after SDS-PAGE under both non-reducing and reducing conditions. Figure 6.12B 
shows the western blotting results obtained for purified Fc fusion proteins after 
probing with anti-human IgG heavy chain HRP or anti-mouse IgG heavy chain HRP 
or with the different monoclonal anti-human MAGE-A2 antibodies (6C1 or 1H4). 
The results from Coomassie staining of both MFc proteins, Figure 6.12A, suggest 
that there were major protein aggregations. Neither protein appeared to enter the 
stacking gel of SDS-PAGE, as seen in the lanes run under non-reduced conditions. 
However, both Fc fusion proteins entered the protein gel under reducing conditions, 
suggesting that the aggregates were held together, at least in part, by disulphide 
bridges. It was noticed that several protein bands were detected under Coomassie 
staining, Figure 6.12A, and the positions of these protein bands were identical for 
both hMFc and mMFc. This suggests that either there were other proteins binding to 
the MFc proteins which were co-purified during Protein G-Sepharose step or the 
MFc proteins were undergoing protein degradation. 
 
To further understand the situation of the Fc fusion proteins, western blotting was 
carried out. Using antibodies targeting against the human MAGE-A2 and human or 
murine IgG heavy chain, several protein bands were detected as shown in Figure 




Figure 6.12: Coomassie and western blot staining of purified hMFc (human MAGE-A2 fused 
with wt hIgG1 Fc region) and mMFc (human MAGE-A2 fused with murine IgG2a Fc region) 
after SDS-PAGE and western blotting. A) Coomassie staining of purified hMFc and mMFc under 
both non-reducing and reducing conditions. mIgG2a was loaded as a molecular weight indicator 
control. Molecular weight markers were run in the middle lane. B) Western blotting of purified 
hMFc and mMFc under reducing condition. Molecular weight markers were run in the left hand 
lane in all cases. Detecting antibodies are shown below the relevant part of each blot. 
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(with the assumption that there were no posttranslational modifications) and the IgG 
Fc region for both human IgG1 and murine IgG2a were around 25-30kDa. As a 
result, the molecular weight for a single full length MFc polypeptide under reduced 
condition would be expected to be around 65kDa. Bands that gave the strongest 
detection signal and which were consistently detected in all investigations were 
located at around 75kDa, which was quite close to the estimated molecular weight of 
MFc. This suggests that the major band detected around 75kDa is most likely full 
length MFc. The identity of a band, located at above 250kDa, that was detected in all 
western blotting investigations, is most likely to be aggregates of MFc that are not 
fully reduced. By comparing the protein bands observed between Coomassie staining 
and western blotting, it was also found that a noticeable protein band located 
between 75kDa-100kDa was seen in Coomassie staining but not in western blotting. 
This indicates that there were contaminations of other proteins during protein 
purification and most likely these proteins were bound to MAGE-A2 rather than IgG 
Fc because previous antibody purification (Chapter 3) had shown no such 
contamination. In addition, there were also multiple minor protein bands detected 
below 75kDa which might also be contaminating proteins. However, these smaller 
molecular weight proteins were recognised by anti-human/mouse IgG Fc and anti- 
human MAGE-A2 antibodies. Thus, the results suggest that the MFc proteins might 
be suffering from some level of degradation. 
 
6.4.5 Unstructured region of hMFc 
Due to the observation that MAGE-A2 fusion proteins were forming aggregates, it 
was hypothesised that MAGE-A2 protein might be relatively unstable and might 
contain unstructured regions which might drive undesired aggregation. Software  
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which could help in predicting unstructured regions of a protein was utilised to 
predict unstructured regions in hMFc. The result of the prediction was shown in 
Figure 6.13, and indicates that the first N-terminal 100 amino acids of MAGE-A2 
may be unstructured. More importantly, there was a cysteine residue within this 
predicted unstructured region, which, if easily accessible, might be factor in 
Figure 6.13: Result of prediction of unstructured regions in hMFc. A) The protein sequence of 
hMFc was uploaded to a webpage capable of predicting unstructured regions of a protein. The 
graph represents disorder frequency of amino acids of the uploaded protein in which the higher the 
disorder frequency (above 0.5), the more likely the involved region is unstructured. The blue bars 
indicate structured regions. B) The protein sequence of the uploaded hMFc corresponding to the 
result of prediction. Protein sequence in red represents the predicted unstructured regions. 
Highlighted protein sequence represents different region of the hMFc, Blue, full length human 
MAGE-A2 protein; Yellow, 13 amino acid peptide linker; Green, wt hIgG1 Fc region. 
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promoting protein aggregation through disulphide bonding. In addition, the last 15 
amino acids located at the C-terminus of MAGE-A2, the 13 amino acid peptide 
linker, and the first 16 amino acids located of wt hIgG1 Fc region (hinge region) 
were also predicted to be unstructured. However, the unstructured state of the peptide 
linker and the hinge region of hIgG1 were within our expectation because the peptide 
linker was designed to provide flexibility to keep MAGE-A2 and the IgG Fc region 
separated by some distance. These two sites are expected to be flexible rather than 
unstructured. As a result, the unstructured region of the N-terminal of MAGE-A2 
might be responsible for the protein aggregation of MFc, however, further 
investigations were required to confirm this hypothesis. 
 
6.5 DISCUSSION 
This chapter aimed to fuse human MAGE-A2 protein, which is a member of the 
CTA class of proteins, to the Fc region of either wt hIgG1 and murine IgG2a using 
recombinant antibody technology. MAGE-A2 protein is not a secretory protein. 
Therefore, in order for the Fc fusion protein to be secreted to the extracellular 
environment, a secretory signal peptide had to be introduced to the N-terminus of 
MFc. By directing the protein to the extracellular environment, the purification of the 
protein would be a lot easier as there is no requirement to break open the cells, thus, 
this approach should greatly reduce the contamination of other proteins. In addition, 
MAGE-A2 had been reported to be able to repress the activity of p53 which is a 
major cell proliferation regulator (Monte et al., 2006). As a result, directing MAGE-
A2 protein away from the intracellular environment of a cell would be the best 
option to prevent any potential effector mechanism of MAGE-A2. The procedures 
described in this chapter utilised a natural secretory signal peptide of 
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immunoglobulin to drive secretion of MFc into the extracellular environment. The 
production of the Fc fusion proteins was successful and the Fc fusion proteins could 
be purified using Protein G-Sepharose from the supernatant of the transfected cells. 
However, it was noticed that the amount of Fc fusion proteins being expressed and 
purified were quite low compared to earlier antibody production and purification in 
Chapter 3. The amount of Fc fusion protein obtained was around 80-120µg per 25 ml 
transfection whereas the amount of antibody obtained in Chapter 3 was around 200-
250µg per 25 ml transfection. Thus, there was more than 50% reduction in the 
amount of purified Fc fusion proteins obtained compared to antibodies. Attempts to 
improve expression levels were made, in which the amount of DNA for Fc fusion 
protein expression vector used during transfection was increased up to 3 times. 
However, no significant increase in the amount of purified Fc fusion protein resulted. 
Hence, the exact reason for the low level of protein recovery was not known. It 
might be that the transfection procedure requires further optimisation, or MFc 
proteins might be suffering from protein degradation as the earlier result suggests. 
 
The molecular weight of a single monomeric full length MFc polypeptide chain 
under reducing condition was expected to be around 65kDa (35kDa for MAGE-A2 
and 25-30kDa for IgG Fc). However, the result from western blotting indicated that 
the molecular weight of MFc was around 75kDa which suggests that MAGE-A2 
might contain other post-translational modifications, apart from the expected N-
linked glycosylation at Asn297 of the IgG Fc region (Burmeister et al., 1994; Burton, 
1987; Davies et al., 1975; Dekkers et al., 2016; Jefferis, 2005). Previous work had 
reported that MAGE-A2 could bind to the core of p53 resulting in the repression of 
p53 transcriptional activity (Monte et al., 2006). p53 is a major protein that governs 
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cell proliferation and is highly regulated. Therefore, there is a high possibility that 
the activity of MAGE-A2 is dependent on post-translational modification to control 
its activity on p53. However, whether post-translational modification exists in the 
secreted MAGE-A2 form requires further investigation. It is well known that the IgG 
Fc does not contain post-translational modifications other than the N-linked 
glycosylation that occurs at Asn297. Therefore, one approach to determine the post-
translation modification of MAGE-A2 would be to mutate Asn297 to alanine to 
abolish the N-linked glycosylation at IgG Fc. As a result, any other post-translational 
modifications detected from further investigations would suggest that MAGE-A2 is 
being post-translationally modified. As mentioned above, it is expected that Asn297 
located at the CH2 domain of IgG will be glycosylated. However, no investigation 
was carried out in this project to confirm this hypothesis. One approach to confirm 
the presence of the N-linked glycosylation at Asn297 would be the use of 
Concanavalin A (Con A), which binds specifically to α-D-mannosyl and α-D-
glucosyl groups that are found present at the N-linked glycosylation of IgG (Huang 
et al., 2016; Dekkers et al., 2016), to detect the presence of N-linked glycans at Asn 
297. Since it is not known if MAGE-A2 would also contain any glycans that could 
associate with Con A, therefore, it is best to cleave MAGE-A2 prior to Con A 
detection by using the enzyme papain because the cleavage site of papain, indicated 
in Figure 1.11B, is still retained within hMFc, as shown in Figure 6.9 above. As 
mentioned in Section 6.1.2, MFc was expected to form a homodimer like an 
immunoglobulin via disulphide bonds within the hinge region. However, no protein 
bands were detected around 150kDa (2 x 65kDa), which was the molecular weight of 
full length MFc. Notably, a strong protein band was visible above 250kDa and was 
reactive against antibodies which could recognise both human or mouse IgG Fc and 
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human MAGE-A2 via western blotting. Due to the molecular weight being much 
greater than the expected molecular weight of 150kDa, the identity of this protein 
being MFc assembled into homodimers is quite unlikely. Therefore, further 
experiments are required to determine the precise assembly of MFc protein.  
 
The Coomassie staining of purified Fc fusion proteins under non-reducing conditions 
suggests that the Fc fusion proteins were forming protein aggregates which most 
likely involved disulphide bond formation because all non-covalent interactions 
should be abolished under non-reducing conditions. More importantly, the protein 
sequence of MAGE-A2 indicates that there were five cysteine residues within 
MAGE-A2. The structure of MAGE-A2 is still unsolved, but if all cysteine residues 
within MAGE-A2 are assumed to form intrachain disulphide bonds there will still be 
one remaining free cysteine which could react with other free cysteines of other 
proteins if it is located at an exposed position. More importantly, it was predicted 
that the first 100 amino acids of MAGE-A2 may be an unstructured region and 
within these 100 amino acids there is a cysteine residue. If the above reasoning is 
true, then this cysteine-10 might be responsible for protein aggregation via 
disulphide bonding. 
 
In addition, the existence of single soluble MFc polypeptide chains should not be 
neglected. Normally, the heavy chain of an immunoglobulin is retained within the 
endoplasmic reticulum (ER) by the binding of a protein known as heavy chain 
binding protein (BiP) to the CH1 domain of the heavy chain until the heavy chain 
assembles with the light chain (Hendershot et al., 1987). Hendershot and colleagues 
had shown that light chain negative cell lines that expressed mutant IgG with CH1 
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domain deletion were able to secrete free heavy chains, including monomeric heavy 
chain, which highlighted the role of CH1 domain in immunoglobulin assembly 
(Hendershot et al., 1987). In the case of MAGE-A2 fusion protein, the CH1 domain 
of IgG had been removed to allow the fusion of MAGE-A2. There is a possibility 
that monomeric MFc may be secreted into the extracellular environment. More 
importantly, these monomeric MFcs would contain two free cysteines at the hinge 
region.  With the addition of the 13 amino acid peptide linker at the N terminus of 
the hinge region, the free cysteine residues may be quite exposed to participate in an 
interaction with other proteins, including other monomeric MFcs. Whether the 
protein aggregation was formed due to interchain disulphide bonding with other 
proteins after secretion or after SDS denaturing is yet unknown. However, the 
presence of other proteins which were not detected by either anti human/mouse IgG 
Fc and anti human MAGE-A2 antibodies suggests that may be other proteins 
associating with MFc and mostly likely the interaction is via interchain disulphide 
bonding. Therefore, the aggregation of MFc has to be solved in order ensure that 
MFc could carry out its intended function as anticipated. 
 
On the other hand, under reducing conditions there was evidence of several protein 
bands with molecular weights smaller than the full length 75kDa MFc, which 
contained IgG Fc epitopes and MAGE-A2 epitopes detectable during western blot 
analyses. It is possible that MFc might be suffering from protein degradation. In this 
case, it is very likely that the MAGE-A2 protein of MFc was subjected to protein 
degradation alone because the Fc region has to be intact in order to bind to Protein 
G-Sepharose. More importantly, there were no protein bands detected at 25kDa or 
below in both Coomassie staining and western blotting, suggesting that the Fc region 
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of the MFc remained intact. Secreted proteins are usually protected from protein 
degradation as they are removed from the intracellular proteolysis system in 
mammalian cell culture. If MFc is indeed being degraded, it is possible that proteases 
were secreted into the extracellular environment by cells during culture or were 
released to the extracellular environment upon cell death. Protein degradation of 
MAGE-A2 may be initiated due to the predicted unstructured region located at the 
N-terminus of MAGE-A2. Clincke and colleagues showed that protease activity 
existed in human recombinant interferon-g (IFN-g) expressing CHO cell cultures and 
such protease activity could be minimised with the addition of iron citrate during cell 
culture (Clincke et al., 2011). Therefore, it may of interest in future experiments to 
test whether addition of iron citrate to the culture medium might prevent MFc 
degradation.  
 
One possible approach to overcome the protein aggregation and protein stability 
issue of MFc would be to use a stable domain of MAGE-A2 to fuse with Fc region 
of IgG rather than the full length MAGE-A2 protein. Although the crystal structure 
of MAGE-A2 protein has not been solved, Newman and colleagues have determined 
the crystal structures of the MAGE Homology Domain (MHD) and the C terminal 
structure of MAGE-A3 and -A4 (Newman et al., 2016). The authors described that 
the structure of the MHD were very similar for both MAGE-A3 and MAGE-A4 
(Newman et al., 2016). In addition, MHD is a highly conserved region within 
MAGE-A family proteins and is found in the majority of the MAGE-A proteins, 
including MAGE-A2, as shown in Figure 6.2. Indeed, the aligned MHD protein 




MHD of MAGE-A2 has a similarity of up to 84.8% with MAGE-A3 and 71.9% with 
MAGE-A4. There is a high possibility that the same MHD structure would be 
adopted by the MAGE-A2. The success in crytallizing the MHD of MAGE-A3 and 
A4 proteins suggests that MHD might be a stable domain. Therefore, MFc could be 
reengineered to consist only of the MHD of MAGE-A2 fused directly to the Fc 
region of IgG in the hope of reducing the overall protein aggregation and increasing 
protein stability. 
 
Finally, MAGE-A3 has been used as cancer vaccine in the past. GlaxoSmithKline 
Biologicals generated a cancer vaccine by fusing a lapidated protein D derived from 
H. influenzae to the N-terminus of human MAGE-A3 (Marchand et al., 2003). With 
the combination of immunological adjuvant, this MAGE-A3 vaccine was first tested 
on MAGE-A3 positive patients by Marchand and colleagues (Marchand et al., 2003). 
The authors reported that a few patients showed signs of tumour regression and the 
vaccine was generally well tolerated (Marchand et al., 2003). The MAGE-A3 
Figure 6.14: A diagram illustrating the aligned sequences of the Mage Homology Domain 
(MHD) of MAGE-A2,-A3 and -A4. Red coloured letters represent mismatches. Accession 
code for MAGE-A2 is P43356. Protein sequence of MAGE-A3 and -A4 was obtained from 
the crystal structure of MAGE-A3 (4V0P) and MAGE-A4 (2WA0). 
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vaccine managed to enter a phase III clinical trial over the past few years, but the 
clinical trial was halted when the vaccine was found to be unable to improve overall 
survival of patients (Vansteenkiste et al., 2016). However, it was reported by the 
authors that ~100% (921/925) patients had shown expression of anti-MAGE-A3 IgG 
antibodies after four treatment doses when compared to 9% (42/491) in the placebo 
group (Vansteenkiste et al., 2016). The finding of anti-MAGE-A3 IgG antibody 
production was in agreement with our reasoning that MAGE-A proteins would be 
recognised as foreign proteins when being vaccinated. The major difference between 
the MAGE-A3 vaccine mentioned above and our MAGE-A2 Fc fusion protein was 
the incorporation of the IgG Fc region rather than a bacterial protein. It is expected 
that the MAGE-A2 Fc fusion protein described in this project would perform better 
than the MAGE-A3 vaccine mentioned above due to an increase in plasma half-life, 
which should stimulate extensive host antibody production, and the better association 
with FcRn to induce antigen cross presentation. However, more investigations are 
required to confirm this expectation.  
 
In summary, MFc can be produced from FreeStyle 293-F transfected cell culture and 
purified using Protein G-Sepharose. However, more studies are required to determine 
if the MAGE-A2 protein is stable in secreted form as MAGE-A2 protein seems to 
have a possibility of being degraded. Investigation into the association of MAGE-A2 
with other soluble proteins needs to be carried out as well due to the observation of 
strong protein aggregations because the association of other proteins with MAGE-A2 
would possibly reduce exposure of MAGE-A2 epitopes to host antibodies which 
would in return reduce the formation of MFc immune complexes that is required for 
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CHAPTER 7 ANALYSIS OF ANTIGEN CROSS PRESENTATION 
ELICITED BY Fc FUSION PROTEIN 
 
7.1 INTRODUCTION  
Exogenous antigens are usually taken up by phagocytes or antigen presenting cells 
(APC) via pinocytosis or phagocytosis and undergo proteolysis before digested 
peptides are presented in complex with MHC Class II molecules. However, studies 
have shown that exogenous antigens can be presented in complex with MHC Class I 
molecules by a process known as antigen cross presentation, described previously in 
Figure 6.1. The exact mechanism mediating antigen cross presentation is yet unclear 
and remains under investigation.  
 
Several APC, such as macrophages and B cells, are capable of antigen cross 
presentation (Hon et al., 2005; Delamarre et al., 2005). However, dendritic cells (DC) 
had been identified as the most efficient APC for antigen cross presentation in vivo 
(Amigorena and Savina, 2010; Delamarre et al., 2005). Recently, Liu and colleagues 
reported that after IgG-IC phagocytosis the pH within the phagosome of 
macrophages reduced rapidly to a pH below 6. In contrast, the pH of the phagosome 
of DC following IgG-IC phagocytosis remained neutral (Liu et al., 2011). The 
authors suggested that the difference in pH might have an effect on the initiation of 
different proteases and that full proteolysis is required for antigen cross presentation 
to enrich the digested peptide pool for both MHC Class I and II presentation (Liu et 
al., 2011). Acidification relies on the activity of the ATP-dependent vacuolar pump 
(V-ATPase) which controls the transport of protons. Trombetta and colleagues 
reported that DC in different stages of maturation exhibit different efficiency in the 
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assembly of V-ATPase in lysosomes, which in turn results in a difference in the pH 
regulation of dendritic cell lysosomes (Trombetta et al., 2003). In addition, 
Delamarre and colleagues reported that DC have a lower expression of most 
lysosomal proteases when compared to macrophages (Delamarre et al., 2005). 
Differences in DC lysosome pH and protease levels might be responsible for 
differing antigen cross presentation efficiency because both may impact on the time 
required for the antigen proteolysis necessary to generate digested peptides suitable 
for presentation on MHC Class I molecules.  
 
Although DC perform most effectively in regards to antigen cross presentation, the 
efficiency of antigen cross presentation varies within different subsets of DC. It is 
now believed that the murine CD8+ DC subset (counterparts of human BDCA-3+ DC) 
is the most competent antigen cross presenting cell when compared to other subsets 
(Baker et al., 2014; Joffre et al., 2012). However, Baker and colleagues showed that 
CD8-CD11b+ DC were able to cross present in a FcRn-dependent manner when 
incubated with a 10-fold lower antigen concentration compared to CD8+CD11b- DC 
(Baker et al., 2011). The functional specialisations of different murine DC subsets is 
reviewed in (Joffre et al., 2012). The intracellular mechanisms mediating antigen 
cross presentation are believed to involve two different pathways termed the 
“cytosolic” and “vacuolar” pathways (Joffre et al., 2012). The main difference 
between the two is the location where the antigen is degraded. The cytosolic pathway 
is sensitive to proteasome inhibitors and involves antigen being exported out of the 
phagosome into the cytosol and subjected to proteasomal degradation. The digested 
peptides are suggested to be transported into the endoplasmic reticulum or 
phagosome and loaded onto MHC-Class I molecules with the assistance of 
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transporter associated with antigen processing 1 (TAP1) and TAP2 (Joffre et al., 
2012). On the other hand, the vacuolar pathway can be inhibited by lysosomal 
proteolysis inhibitors and involves the antigen being degraded within the phagosome 
after lysosomal fusion. The digested peptide is then loaded onto MHC Class I 
molecule with the assistance of TAP1 and TAP2 without the involvement of the 
endoplasmic reticulum (Joffre et al., 2012). It has been noted that components of the 
MHC Class I loading machinery such as TAP have been detected within the 
phagosome as well as MHC Class I molecules themselves (Amigorena and Savina, 
2010). However, the regulation of antigens into different pathways is still unknown 
and remains under investigation.  
 
As mentioned in Chapter 6, the rationale behind development of the MAGE-A2 Fc 
fusion protein (MFc) was to utilise FcRn antigen cross presentation ability in DC to 
initiate a cytotoxic T cell response against MAGE-A2-expressing cancer cells. To 
investigate if MFc could be phagocytosed by DC and cross presented on MHC Class 
I molecules to activate cytotoxic T cells, an antigen cross presentation system 
(explained below), involving an eight amino acid peptide, SIINFEKL, and a 
cytotoxic T cell cell line known as B3Z was utilised. In the past, Moore and 
colleagues immunised mice of different strains with transfected cells which produced 
chicken ovalbumin (OVA) endogenously and demonstrated that only the mouse 
strain C57BL/6 expressing the murine MHC Class I allele, H-2Kb, was capable of 
inducing a cytotoxic T cell immune response against transfected cells (Moore et al., 
1988). More importantly, the authors cultured the reactive T cells and showed that a 
similar T cell immune response was not induced with cells incubated with soluble 
OVA for up to 24 hours when compared with transfected OVA-producing cells. 
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Thus, effective presentation of the digested OVA peptide was highly restricted to 
MHC Class I rather than MHC Class II (Moore et al., 1988). It was later discovered 
by Falk and colleagues that the H-2Kb restricted OVA peptide sequence was 
SIINFEKL, also known as OVA257-264 (Falk et al., 1991). Taking this further, 
Karttunen and colleagues utilised a NFAT-lacZ reporter construct and transfected the 
murine cytotoxic T cell which was capable of recognising the MHC Class I, H-2Kb, 
when loaded with SIINFEKL peptide, to generate a cell line known as B3Z that is 
capable of producing β-galactosidase enzyme upon activation via the recognition of 
SIINFEKL peptide (Karttunen et al., 1992). As a result, a system to study antigen 
cross presentation using OVA or proteins with SIINFEKL incorporation was 
developed. Schuurhuis and colleagues incubated OVA IC with DC and showed that 
they could efficiently activate B3Z T cells but a similar activation was not possible 
with soluble OVA (Schuurhuis et al., 2002). On the other hand, Gil-Torregrosa and 
colleagues incubated DC of different maturation stages with OVA IC and fixed the 
cells after 3 hours. This enabled them to study the antigen cross presentation 
efficiency of DC at different maturation stages by analysing the activation of 
corresponding B3Z T cells (Gil-Torregrosa et al., 2004). In a different scenario, 
Shaw and Starnbach fused the SIINFEKL peptide to the N-terminus of diphtheria 
toxin and showed that diphtheria toxin receptor-expressing DC from transgenic mice 
was capable of activating B3Z T cells. This finding suggested that SIINFEKL-
diphtheria toxin was cross presented to MHC Class I molecules (Shaw and Starnbach, 
2006). Based on these results, it was proposed that investigation of the antigen cross 
presentation of MFc might be possible by incorporating the eight amino acid 
SIINFEKL sequence into the MAGE-A2 protein. The rationale was that when MFc 
was digested after phagocytosis by DC, the SIINFEKL peptide would be loaded onto 
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MHC Class I molecules resulting in the activation of corresponding B3Z T cells, 
thereby providing a useful in vitro indicator of antigen cross presentation of MFc.  
 
7.1.1 Formation of MFc immune complexes (IC) 
As mentioned earlier, in the tests described above soluble OVA was unable to 
activate a cytotoxic T cell response unlike OVA IC (Moore et al., 1988). Therefore, 
the formation of IC seems to be an important factor in antigen cross presentation. It 
was considered that the ideal situation would be to generate polyclonal mouse anti- 
human MAGE-A2 antibodies and used the antibodies to form IC with hMFc. 
However, due to time constraints this approach was not carried out. Fortunately, 
Ober and colleagues when investigating the binding of IgGs of different species to 
human or mouse FcRn showed that mouse FcRn displays binding to IgG from a 
wider range of species than human FcRn (Ober et al., 2001). In this chapter, rabbit 
anti-mouse IgG antibodies were used to form IC with mMFc proteins. Rabbit IgG is 
one of the few immunoglobulin species capable of binding to both human and mouse 
FcRn (Ober et al., 2001). Schuurhuis and colleagues used OVA-specific rabbit IgG 
to form IC with OVA in order to study antigen cross presentation with mouse DC 
(Schuurhuis et al., 2002). Similarly, Rafiq and colleagues used OVA-specific rabbit 
IgG to form IC with OVA to ‘immunise’ DC in order to demonstrate tumour 
immunity in mouse models (Rafiq et al., 2002). As a result, rabbit IgG was 
considered a suitable antibody to be used in this chapter as a means to generate IC 
with mMFc for antigen cross presentation analyses. 
 
7.1.2 B3Z T cells  






peptide loaded onto H-2Kb MHC Class I molecules (Karttunen et al., 1992). More 
importantly, B3Z T cells produce β-galactosidase upon activation due to having been 
transfected with a NFAT-lacZ reporter construct (Karttunen et al., 1992). The basics 
of the NFAT-lacZ reporter construct are illustrated in Figure 7.1.  
 
During an immune response, a cytotoxic T cell only produces interleukin-2 (IL-2) 
when activated (Fiering et al., 1990). The reason for this is that IL-2 is highly 
regulated and it requires the binding of several transcription factors to induce IL-2 
gene transcription. One of these transcription factors was identified to be nuclear 
factor of activated T cells (NFAT) (Fiering et al., 1990). Fiering and colleagues 
reported that NFAT binding activity was only found in activated T cells, and 
therefore they utilised the NFAT binding site to create a NFAT driven lacZ reporter 
construct (Fiering et al., 1990), shown in Figure 7.1. The authors reported that the 
NFAT-lacZ reporter construct required the concentration of NFAT to reach a certain 
threshold in order to initiate the transcription of the lacZ gene. This requirement was 
suggested to be due to the transcription being governed by three NFAT binding sites 
(Fiering et al., 1990). It was expected that all three NFAT binding sites had to be 
bound in order to initiate transcription (Fiering et al., 1990). As a result, β-
galactosidase would only be produced upon activation of T cells. 
 
Figure 7.1: A schematic diagram illustrating the NFAT-lacZ reporter construct. 
Transcription of the lacZ gene is regulated by three NFAT binding sites. It was expected that 
all three NFAT binding sites had to be bound to initiate transcription of the lacZ gene. 
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7.2 AIMS 
This chapter hypothesised that SIIN-MFc proteins in IC formation would be 
phagocytosed by dendritic cells and digested in order to generate the SIINFEKL 
peptide to be cross presented on MHC Class I molecule. As a result, this chapter 
aimed to determine if SIIN-MFc protein could be taken up by DC and enter the 
antigen cross presentation pathway in order to activate corresponding cytotoxic T 
cell. The digested peptide SIINFEKL of SIIN-MFc protein was expected to be 
presented on MHC Class I molecules and activate correspondent B3Z T-cells if the 
antigen cross presentation pathway was successfully engaged. 
 
7.3 MATERIALS AND METHODS 
 
7.3.1 MATERIALS AND BUFFER 
 
Mice 
All mice were wildtype C57BL/6 (gift from Prof. Colin Watts’ group, University of 
Dundee). 
 
Red blood cell (RBC) lysis buffer 
Red blood cell lysis buffer (155mM ammonium chloride, 12mM sodium bicarbonate, 
0.1mM EDTA, pH 7.3) was prepared and stored at 4ºC. Buffer was warmed to 37ºC 




Complete RPMI medium (cRPMI) 
Supplements listed in Table 7.1 were added to RPMI-1640 and stored at 4ºC. 
Medium was warmed to 37ºC prior to use. 
 
Table 7.1: Supplement details to make complete RPMI medium 
Note:  1X Kanamycin = 100 μg/ml Kanamycin 
1X Sodium Pyruvate = 1mM Sodium Pyruvate 
1X Non-Essential Amino Acids = A mixture of 7 amino acids, 0.1mM of each amino acid 
1X L-Glutamine = 2mM L-Glutamine 
 
 
Murine bone marrow dendritic cell medium (BMDC-Medium) 
200ml of cRPMI was filter sterilised through a 0.22μm pore size polyethersulfone 
membrane unit (Corning Inc.) to remove any potential pathogens which could 
activate dendritic cells during cell culture. Recombinant murine granulocyte-
macrophage colony-stimulating factor (GM-CSF) (PeproTech) was then added to the 
medium to a final concentration of 10ng/ml. Completed medium was stored at 4ºC 
and was warmed to 37ºC prior to use. 
 
Murine splenic dendritic cell medium (SDC-Medium) 
200ml of cRPMI was filter sterilised through a 0.22μm pore size polyethersulfone 
membrane unit (Corning Inc.) to remove any potential pathogens which could 
activate dendritic cells during cell culture. Recombinant murine GM-CSF 
Supplements Final concentration 
Sodium pyruvate 1X 




Foetal calf serum (low endotoxin) 10% 
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(PeproTech) and recombinant human transforming growth factor beta 1 (TGF-β1) 
(R&D Systems Europe, Ltd.) were then added to the medium to a final concentration 
of 10ng/ml and 1ng/ml respectively. Completed medium was stored at 4ºC and was 
warmed to 37ºC prior to use. 
 
CPRG Buffer 
0.15mM chlorophenolred-β-D-galactopyranoside (CPRG) (Calbiochem®, Merck 
Millipore), 0.5% (v/v) Nonidet P-40 (Sigma) was prepared in PBS. The solution was 
stored at 4ºC prior to use. 
 
PBN Buffer 
0.5% (w/v) BSA (Sigma), 0.1%(w/v) NaN3 was prepared in PBS. The solution was 
stored at 4ºC and kept on ice during usage. 
 
RIPA Buffer 
50mM Tris-HCl, pH 7.4 
1% (v/v) Nonidet P-40 
0.5% (w/v) sodium deoxycholate 





Solution with the above content was prepared in Milli-Q water and stored at room 
temperature. HaltTM Protease Inhibitor Cocktail EDTA-free (Thermo Fisher 






A plasmid, pKz-mMFc, encoding a Fc fusion protein of human MAGE-A2 fused to 
the Fc region of mouse IgG2a which was derived previously in Chapter 6, Figure 6.7.  
 
7.3.3 INCORPORATION OF SIINFEKL PEPTIDE TO MFc 
 
7.3.3.1 Insertion of SIINFEKL peptide DNA encoding sequence to mMFc 
expression plasmid 
Within the DNA sequence of MAGE-A2, there is a unique ApaI restriction site 
suitable for digestion, shown in Figure 7.2. Primer Siinfekl1 (Table 2.2, No.14) was 
designed to utilise this restriction site to incorporate sequence encoding SIINFEKL 
peptide into MAGE-A2 as shown in Figure 7.2. Unfortunately, this approach was 
unable to proceed due to unsuccessful digestion with ApaI enzyme. As a result, a 
different approach was carried out which involved multiple PCR amplification steps. 
This procedure was described in Figure 7.3. 
 
 
 Figure 7.2: A diagram illustrating the ApaI site within MAGE-A2 DNA sequence and the 
design of primer Siinfekl1 for the incorporation of SIINFEKL peptide.  
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First step 
pKz-mMFc was digested with restriction enzymes HindIII and EcoRI at 37ºC for 1 
hour as described in section 2.4.1. Gel electrophoresis and DNA gel extraction were 
performed to purify a DNA fragment at about 1732bp, containing the sequence of 
mMFc (insert). Primers MAGE-FcKosak, and Siinfekl1 (Table 2.2, No.11 & 14) 
were used at an annealing temperature of 65ºC with the purified DNA insert as 
template to amplify a DNA product of approximately 930bp, which contained a N-
terminal HindIII site and C-terminal ApaI site. PCR products were run on a DNA 
agarose gel as described in section 2.4.4 and DNA bands of the correct sizes were 
extracted as described in section 2.4.5.  
 
Second step 
Purified mMFc (insert) from pKz-mMFc restriction enzyme digest was used as DNA 
template and amplified using a primer combination of the purified PCR product from 
step 1 and MAGERev (Table 2.2, No. 8) at an annealing temperature of 65ºC to 
obtain a DNA product of approximately 1079bp. PCR products were run on a DNA 
agarose gel as described in section 2.4.4 and a DNA band of the correct size was 
extracted as described in section 2.4.5. Purified PCR product would be used as a 
primer in the subsequent PCR amplification. 
 
Third step 
Purified mMFc (insert) from pKz-mMFC digestion was used as DNA template and 
amplified using a primer combination of purified PCR product from step two and 










Figure 7.3: A schematic diagram illustrating the incorporation of sequence encoding the SIINFEKL 
peptide into MAGE-A2 and the generation of an expression vector. A) Incorporation of sequence 
encoding SIINFEKL peptide into MAGE-A. pKz-mMFC was digested with HindIII and EcoRI to 
obtain the insert containing mMFc DNA sequence (insert), and this was used as template in an 
amplification with specific primers to introduce SIINFEKL sequence (red). The PCR product was 
purified and further amplified with a specific primerMFC. Finally, the second PCR product was 
purified and again further amplified with another specific primerMFC. B) Generation of an expression 
vector. Final PCR product from A was digested with HindIII and EcoRI. pHCCR was digested with 
HindIII and EcoRI to obtain a cut vector to ligate with the previously digested insert. 
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obtain a DNA product of approximately 1762bp. Gel electrophoresis and DNA gel 
extraction were carried out subsequently. Purified DNA fragment and plasmid 
pHCCR were then digested with restriction enzymes HindIII and EcoRI as described 
in section 2.4.1. Gel electrophoresis and DNA gel extraction were performed to 
purify the digested DNA fragment of 1750bp (insert) and digested pHCCR of about 
8000bp (vector). Both purified DNA fragments were then ligated as described in 
section 2.4.6 and transformed into competent DH5α E. coli as described in section 
2.4.7. After purifying the plasmids from positive clones as described in section 2.4.9, 
DNA sequencing was carried out (section 2.4.11) to ensure that the desired mutations 
had been incorporated, and that no errors had been introduced. A plasmid with 
correct DNA sequence was named as pMoMAGE-SIIN. 
 
7.3.4 PRODUCTION AND CHARACTERISATION OF SIIN-mMFc 
 
7.3.4.1 SIIN-mMFc production and purification from FreeStyle 293-F cells 
FreeStyle 293-F cells were thawed from liquid nitrogen and maintained in 
appropriate growth conditions as shown in section 2.6.2. On the day before 
transfection, each flask of cells was passaged and used to seed 5 x 105 cells/ml in an 
Erlenmeyer flask in a total volume of 25ml, so that on the day of transfection cells 
were at 1 x 106 cells/ml with a viability of 90% or above. For transfection, 293Fectin 
(Invitrogen) and Opti-MEM (1X) (Gibco Life Technologies) were brought to room 
temperature. For a single transfection, two aliquots of 0.833ml of Opti-MEM (1X) 
were pipetted into two 30ml Universal tubes. In one tube, the amount of DNA listed 
in Table 7.2 was added and mixed gently. In the other tube, 33.25µl of 293Fectin 
was added and allowed to incubate for exactly 5 minutes at room temperature before  
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Table 7.2: Amount of DNA required for FreeStyle 293-F cells transfection 
 
the addition of the DNA mixture. Once the DNA mixture was added, the solution 
was gently mixed and allowed to incubate for 20-30 minutes at room temperature. 
When completed, the solution was added to the FreeStyle 293-F cells and incubated 
on a shaker in an incubator in 8% CO2 at 37ºC. SIIN-mMFc was ready to be 
harvested and purified after 4 days as described in section 2.8. 
 
7.3.4.2 Characterisation of SIIN-mMFc 
SIIN-mMFc purifications were carried out as described in section 2.8. Purified SIIN-
mMFc were subjected to SDS-PAGE as described in section 2.8.6. Protein gels were 
stained with Coomassie as described in section 2.8.8 to determine the purity of the Fc 
fusion protein generated. To further analyse the purified protein, SIIN-mMFc was 
subjected to western blotting as described in section 2.8.7. After the blocking and 
washing procedure, the membranes were incubated with polyclonal goat anti-mouse 
IgG HRP conjugated (Table No.20) and monoclonal mouse anti-human MAGE-A2 
(6C1) (Table 2.1, No.18) or monoclonal mouse anti-human MAGE-A2 (1H4) (Table 
2.1, No.17). Both monoclonal antibodies were detected with polyclonal goat anti 
mouse kappa light HRP conjugated (Table 2.1, No.19). All membranes were washed 
and developed with appropriate substrate. 
 
 
Type of DNA expression vector Amount of DNA 
pMoMAGE-SIIN 4.17µg 
pAdvantage vector (Promega) 4.17µg 
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7.3.5 GENERATION OF BONE MARROW DERIVED DENDRITIC CELLS 
AND SPLENIC DERIVED DENDRITIC CELLS 
 
7.3.5.1 Bone marrow dendritic cell (BMDC) isolation and culture 
A sacrificed mouse was sterilised with 70% (v/v) ethanol. Tibia and femur from both 
hind legs were extracted with minimal flesh attached. All bones were sterilised using 
70% (v/v) ethanol and washed with cRPMI. Both ends of the bones were cut using a 
bone cutter to expose the bone marrow. All bone marrow was flushed out with 
cRPMI using a 10ml syringe and a 25G needle onto a 70μm pore size EASYstrainer 
(Greiner Bio-One) that was placed on top of a 50ml polypropylene tube (Greiner 
Bio-One). The strainer was washed with 10ml cRPMI and the collected cells were 
centrifuged for 5 minutes at 250g. The supernatant was discarded and the cell pellet 
was resuspended in 1ml RBC lysis buffer. The mixture was allowed to stand for 1 
minute before being washed twice with 20ml cRPMI and centrifuged for 5 minutes 
at 250g each time. The supernatant was discarded and the cells were resuspended in 
BMDC-Medium at 106 cells/ml. 2ml bone marrow cells were added to each well of a 
Costar® 6 well plate - Ultra low attachment surface (Corning Inc.) and incubated for 
5-7 days in an incubator at 37ºC, 5% CO2. The medium was changed whenever 
required until BMDC had been generated. 
 
7.3.5.2 Splenic dendritic cell (SDC) isolation and culture 
A sacrificed mouse was sterilised with 70% (v/v) ethanol. The spleen of the mouse 
was isolated and washed briefly in 10ml cRPMI in a 50ml polypropylene tube. The 
spleen was then squashed through a 70μm pore size EASYstrainer into a 50ml 
polypropylene tube using a plunger of a 10ml syringe to homogenise the spleen cells. 
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The strainer was washed with 10ml cRPMI and the collected cells were centrifuged 
for 5 minutes at 250g. The supernatant was discarded and the cell pellet was washed 
twice with 20ml cRPMI and centrifuged for 5 minutes at 250g each time. The 
supernatant was discarded and the cells were resuspended in 30ml of SDC-Medium. 
5ml splenic cells were added to each well of a Costar® 6 well plate - Ultra low 
attachment surface and incubated for 14-20 days in an incubator at 37ºC, 5% CO2. 
The medium was changed whenever required until SDC had been generated. 
 
7.3.5.3 Harvesting BMDC and SDC 
BMDC were ready to be used at day 5-7 while SDC was ready at day 14-20. BMDC 
and SDC were pipetted into separate 50ml polypropylene tubes. 5ml BMDC or SDC 
medium were used to wash the wells to collect any remaining DC and added to their 
respective tubes. Cells were centrifuged for 5 minutes at 250g before being washed 3 
times with 20ml cRPMI and centrifuged for 5 minutes at 250g each time. BMDC and 
SDC were resuspended in cRPMI at 1 x 106 cells/ml. 
 
7.3.6 ANTIGEN PRESENTATION ASSAY 
 
7.3.6.1 Formation of IC 
mMFc (without SIINFEKL) and SIIN-mMFc (with SIINFEKL) were each incubated 
with rabbit anti-mouse IgG (Table 2.1, No.16) and mouse anti-human MAGE-A2 
(1H4) (Table 2.1, No.17) in cRPMI at a concentration ratio of 1:2.5:2.5 for 1 hour at 
room temperature. The final concentration of each component was 10μg/ml mMFc 
or SIIN-mMFc, and 25μg/ml of each antibody respectively.  
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Chicken ovalbumin (OVA) (Sigma) was incubated with rabbit anti-ovalbumin 
antibody (Table 2.1, No.15) in cRPMI at a concentration ratio of 1:2.5 for 1 hour at 
room temperature. The final concentration of each component was 10μg/ml OVA 
and 25μg/ml antibody. 
 
7.3.6.2 B3Z antigen presentation assay 
100μl of 10μg/ml mMFc or SIIN-mMFc was prepared in cRPMI in either 
monomeric or IC format were pipetted into a 96 well U-bottom plate (Falcon®, 
Corning Inc.). Serial dilution was performed resulting in a final volume of 50μl of 
protein in each well with a descending concentration gradient across the assay plate. 
50μl BMDC or SDC at 1 x 106 cells/ml in cRPMI were then added to each well and 
incubated for 4 hours at 37ºC in an incubator, to allow protein uptake and digestion 
to occur. When the incubation had completed, 50μl B3Z T cells at 1 x 106 cells/ml in 
cRPMI were added to each well and incubated overnight at 37ºC in an incubator, to 
allow sufficient time for antigen presentation and β-galactosidase enzyme to be 
produced. Chicken ovalbumin in soluble format (5mg/ml) or IC format (10μg/ml) 
and 1μM of SIINFEKL peptide (InvivoGen) was was prepared in cRPMI and added 
to BMDC as a positive control. cRPMI was added to BMDC as a negative control. 
 
To analyse antigen presentation efficiency, after the above incubations cells were 
centrifuged for 5 minutes at 250g. The supernatant was discarded and the cells were 
washed twice with 200μl PBS and centrifuged for 5 minutes at 300g each time. Cells 
were lysed with 200μl of CPRG buffer and allowed to develop for 6 hours or 24 
hours at 37ºC in an incubator. Absorbance at 595nm was measured after either 6 
hours or 24 hours using a UV spectrophotometer (Ultrospec 2000, Pharmaia Biotech).  
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7.3.7 INVESTIGATION OF THE EXPRESSION LEVEL OF DIFFERENT Fc 
RECEPTORS  
 
7.3.7.1 Flow cytometry analysis 
2 x 106 cells were required for a single flow cytometry test. B3Z T cells, BMDC and 
SDC were harvested as described earlier using cold PBN buffer as the washing 
buffer. After the final wash, cells were resuspended in 100μl human anti-mouse 
CD64 PE (Table 2.1, No.7) in PBN buffer to detect murine FcγRI expression or 
100μl goat anti-mouse CD32/CD16/FcγRIIB (Table 2.1, No.8) in PBN buffer to 
detect murine FcγRII and FcγRIII expression. 100μl goat anti-human IgA (Table 2.1, 
No.12) was used as the primary control antibody for the latter test. Cells were then 
kept in the dark and incubated on ice for 1 hour. After the primary incubation, cells 
were washed with 500μl cold PBN buffer and centrifuged for 5 minutes at 300g each 
time for 3 times. After washing, cells that were for detection of the expression of 
murine FcγRI were resuspended in 500μl cold PBN buffer and were transferred to a 
5ml polystyrene round-bottom tube (BD Bioscience) for flow cytometry analysis. 
Cells that were for detection of the expression of murine FcγRII and FcγRIII were 
resuspended in 100μl of anti-sheep/goat IgG FITC (Table 2.1, No.11) in PBN buffer 
and kept in the dark and incubated on ice for 1 hour. Cells were then washed with 
500μl cold PBN buffer and centrifuged for 5 minutes at 300g each time for 3 times 
before resuspending in 500μl cold PBN buffer for flow cytometry analysis. 
 
7.3.7.2 Preparation of cell lysate and whole liver lysate 
5 x 106 - 7 x 106 BMDC, SDC or bone marrow derived macrophages (BMDM) (gift 
from Dr. Kathleen Reyskens, University of Dundee) were harvested in 1.5ml 
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microfuge tubes. Cells were washed with 500μl PBS and centrifuged for 5 minutes at 
300g each time for 3 times. After the final wash, cells were resuspended in 100μl 
RIPA buffer. Cells were then sonicated for 10 seconds using an Ultrasonic Processor, 
Model CV33 to fully lyse the cells. Cell lysate was centrifuged for 10 minutes at 
16000g and the supernatant was transferred into a 1.5ml microfuge tube and stored at 
-20ºC prior to use.  
 
The liver of a wildtype C57BL/6 mouse (gift from Dr. Sarah Thomson, University of 
Dundee) was squashed through a 70μm pore size EASYstrainer the into a 50ml 
polypropylene tube using a plunger of a 10ml syringe to homogenise the liver cells. 
The strainer was washed with 10ml PBS and the collected cells were centrifuged for 
5 minutes at 250g. The supernatant was discarded and the cell pellet was 
resuspended with 5ml RBC lysis buffer. The mixture was allowed to stand for 1 
minute before being washed 3 times with 20ml PBS and centrifuged for 5 minutes at 
250g each time. After the final wash, the cell pellet was resuspended in 2ml RIPA 
buffer. Cells were then sonicated for 10 seconds using an Ultrasonic Processor, 
Model CV33 to fully lyse the cells. Cell lysate was centrifuged for 10 minutes at 
16000g and the supernatant was aliquoted into 1.5ml microfuge tubes and stored at -
20ºC prior to use. Protein concentrations of all cell lysates were determined using 
BCA assay analysis (Section 2.8.5.2). 
 
7.3.7.3 Western blotting 
Protein molecular weight markers (section 2.7.3) and 10μg protein of each cell lysate 
was loaded to sample wells of a SDS-PAGE gel and SDS-PAGE electrophoresis was 
performed. Proteins were then transferred to nitrocellulose membrane and the 
	 252	
membrane was blocked with 5% non-fat milk. Membrane was incubated with 5ml of 
rabbit anti-mouse FcRn (Table 2.1, No.9) in PBS-T overnight at 4ºC on a roller. 
After primary incubation, the membrane was washed 3 times with PBS-T and 
incubated with 5ml goat anti-rabbit IgG-HRP conjugate (Table 2.1, No.14) in PBS-T 
for another hour at room temperature on a roller. After secondary incubation, the 
membrane was washed 3 times with PBS-T and developed using Pierce® ECL 
Western Blotting Substrate (Thermo Fisher Scientific). Protein bands were visualised 
on a LI-COR Odyssey Fc (LI-COR Bioscience UK Ltd). After visualisation of 
desired protein bands, the membrane was washed 3 times with PBS-T and incubated 
in rabbit anti-actin (Table 2.1, No.13) in PBS-T for 1 hour at room temperature on a 
roller. Membrane was then washed 3 times with PBS-T before being incubated with 
5ml goat anti-rabbit IgG-HRP conjugate (Table 2.1, No.14) in PBS-T for another 
hour at room temperature on a roller. The membrane was then developed using the 




7.4.1 Incorporation of SIINFEKL peptide into MAGE-A2 
Using the primer combinations of MAGE-FcKosak and Siinfekl1 to amplify the 
digested mMFc insert from pKz-mMFc, an amplified fragment of the correct size of 
930bp was obtained as shown in Figure 7.4A. After the introduction of SIINFEKL 
coding sequence into the DNA sequence of MAGE-A2, the purified PCR product 
was used as a primer for further amplification along with primer MAGERev using 
mMFc insert as template. An amplified fragment of the correct size of 1079bp was 
obtained as shown in Figure 7.4B. Finally, the purified product from the second PCR 
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was used as a primer for further amplification along with primer MouseFcRev using 
mMFc insert as DNA template to generate the full length DNA sequence for 
SIINFEKL containing mMFc (SIIN-mMFc). An amplified fragment of the correct 
size of 1762bp was obtained as shown in Figure 7.4C. The purified DNA fragment 
and pHCCR was digested with restriction enzymes HindIII and EcoRI and ligated 
together to generate the expression vector for SIIN-mMFc. The incorporation of the 
SIINFEKL encoding sequence was verified by DNA sequencing, as indicated in 
Figure 7.5.  
 
7.4.2 Production and characterisation of SIIN-mMFc 
The SIIN-mMFc expression plasmid, pMoMAGE-SIIN, was transfected into 
FreeStyle 293-F cells. After 4 days, supernatants of the cell cultures were incubated 
with Protein G-Sepharose and SIIN-mMFc proteins were efficiently purified. The 
Figure 7.4: Results of molecular cloning for the incorporation of SIINFEKL peptide into mMFc. A) 
SIINFEKL coding sequence introduction into MAGE-A2. Lane 930bp shows PCR amplification 
using MAGE-FcKosak and Siinfekl1 to obtain DNA fragment at 930bp. B) PCR product extension. 
Lane 1079bp shows PCR amplification using PCR product from A. and primer MAGERev to obtain 
DNA fragment at 1079bp. C) Full length SIINFEKL containing mMFc amplification. Lane 1762bp 
shows PCR amplification using PCR product from B. and primer MouseFcRev to obtain DNA 






amount of SIIN-mMFc obtained from a single 25ml transfection was around 80-
120µg, which was very similar to the amount of protein obtained for both hMFc and 
mMFc in Chapter 6. This suggests that incorporation of the SIINFEKL sequence into 
MAGE-A2 protein did not have any significant impact on the production and 
expression of SIIN-mMFc in FreeStyle 293-F cells. 
 
Purified SIIN-mMFc protein was subjected to SDS-PAGE, as described in Section 
2.8.6. Figure 7.6A shows the results of Coomassie staining of purified SIIN-mMFc 
and mMFc proteins after SDS-PAGE under both non-reducing and reducing 
conditions, and Figure 7.6B shows the western blotting results obtained for purified 
SIIN-mMFc and mMFc proteins after probing with anti-mouse IgG heavy chain 
HRP or with the different monoclonal anti-human MAGE-A2 antibodies (6C1 or 
1H4) followed by anti-mouse kappa-HRP antibody. The SIINFEKL sequence was 
not added at the N- nor C- termini of mMFc but incorporated within the mMFc 
protein sequence. The success in producing and purifying SIIN-mMFc indicates that 
incorporation of SIINFEKL sequence into mMFc did not affect the expression of the 
Figure 7.5: The DNA sequence encoding SIIN-mMFc and corresponding translated protein 
sequences. Red, Kozak consensus sequence; Purple, protein sequence of immunoglobulin secretion 
signal peptide; Blue, protein sequence of full length human MAGE-A2 protein; Orange, SIINFEKL 
peptide; Yellow, protein sequence of the 13 amino acid peptide linker; Green, protein sequence of 




protein. It was noticed that after both Coomassie staining and western blotting 
investigations, similar protein bands for both SIIN-mMFc and mMFc were obtained, 
as shown in Figure 7.6. Thus, it suggests that both SIIN-mMFc and mMFc were 
suffering from similar protein aggregations and that the incorporation of SIINFEKL 
peptide probably did not have any major effect on the overall protein conformational 
structure.  
 
7.4.3 Antigen presentation assay 
Both mMFc and SIIN-mMFc in both soluble and IC forms were used to carry out 
antigen presentation assays. mMFc was used as negative control as mMFc did not 
contain the SIINFEKL peptide necessary to activate B3Z T cells when presented on 
MHC-Class I. On the other hand, soluble OVA, OVA IC and SIINFEKL peptide 
Figure 7.6: Coomassie staining and western blot of purified SIIN-mMFc (human MAGE-A2 with 
SIINFEKL incorporation fused with murine IgG2a Fc region) and mMFc (human MAGE-A2 fused 
with murine IgG2a Fc region) after SDS-PAGE and western blotting. A) Coomassie staining of 
purified SIIN-mMFc and mMFc under both non-reducing and reducing conditions. Molecular 
weight markers were run in the middle lane. B) Western blotting of purified SIIN-mMFc and mMFc 
under reducing conditions. Molecular weight markers were run in the left hand lane in all cases. Blot 
on left was probed with anti MAGE-A2 (1H4) detecting antibody. Blot in middle was probed with 
anti-mouse IgG heavy chain detecting antibody. Blot on right was probed with anti MAGE-A2 
(6C1) detecting antibody. 
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were used as positive controls. The results of antigen presentation assays using 
BMDC are shown in Figure 7.7 and using SDC in Figure 7.8. Under the conditions 
of the assay, it was found that incubation of SIIN-mMFc at 5μg/ml for 4 hours with 
either BMDC and SDC did not activate B3Z T cells. In addition, incubation of 
5mg/ml soluble OVA or 5μg/ml OVA IC with either BMDC and SDC were also 
found unable to activate B3Z T cells.  
 
Three major factors might be considered as contributing to the disappointing failure 
of B3Z T cell activation by all antigens other than SIINFEKL peptide. The first 
factor which may account for this failure is improper antigen digestion. However, 
this factor does not seem to be true because the antigens used as positive controls in 
this assay, OVA and OVA IC, were also found to be unable to activate B3Z T cells. 
OVA was the original antigen used to generate B3Z T cells, and therefore, it was 
expected that OVA would efficiently activate B3Z T cells when incubated with DC. 
As a result, the failure of OVA and OVA IC to activate B3Z T cells suggests that 
antigen digestion was not responsible for the failure of B3Z T cell activation. The 
second factor was reasoned to be due to the malfunction of B3Z T cells to produce β-
galactosidase enzyme upon recognition of SIINFEKL peptide presented on MHC 
Class I molecule. However, this possibility could be excluded because incubation of 
0.175-1μM of SIINFEKL peptide with both BMDC and SDC was found to 
efficiently activate B3Z T cells. With such findings, it was concluded that the B3Z T 
cell was not responsible for the failure of OVA and SIIN-mMFc in the antigen 
presentation assay. The third factor, which was reasoned to be the malfunction of the 
dendritic cells in antigen cross presentation, was therefore considered to be the most 








Figure 7.7: β-galactosidase enzyme activity of B3Z T cells following MAGE-A2 Fc fusion 
protein antigen cross presentation by BMDC. BMDC were incubated with SIIN-mMFc, mMFc 
or chicken ovalbumin in either soluble or immune complex form for 4 hours before incubation 
with B3Z T cells. β-galactosidase enzyme activity was assayed 6 hours (A) and 24 hours (B) 
after the introduction of B3Z T cells. 1μM SIINFEKL peptide was used as positive control. The 
results shown are the average of two determinations, and the bars represent standard error. A 







Figure 7.8: β-galactosidase enzyme activity of B3Z T cells following MAGE-A2 Fc fusion 
protein antigen cross presentation by SDC.  SDC were incubated with SIIN-mMFc, mMFc or 
chicken ovalbumin in either soluble or immune complex form for 4 hours before incubation 
with B3Z T cells. β-galactosidase enzyme activity was assayed 6 hours (A) or 24 hours (B) 
after the introduction of B3Z T cells. 1μM SIINFEKL peptide was used as positive control. The 
results shown are the average of two determinations, and the bars represent standard error. A 





7.4.4 Investigation on the expression level of different Fc receptors in DC 
Due to the reasoning that the unsuccessful activation of B3Z T cells in antigen cross 
presentation assay might be due to the malfunction of dendritic cells, an investigation 
into the expression level of Fcg receptors and FcRn was carried out. Fcg receptors are 
required for the internalisation of antigen IC via receptor mediated phagocytosis. 
Thus, the expression of Fcg receptors on the surface of dendritic cells is crucial for 
efficient and successful cross presentation of antigen IC. The results of assays to 
determine the expression levels of FcgRI and FcgRII via flow cytometry are shown 
in Figure 7.9. Both BMDC and SDC exhibited strong expression of both FcgRI and 
FcgRII as indicated by the fluorescent intensity shift in the flow cytometry analysis 
graph in Figure 7.9. With such findings, it is believed that both SIIN-mMFc IC and 
OVA IC should not have any problems in triggering antigen phagocytosis via 
association with both FcgRI and FcgRII on the surface of dendritic cells. On the other 
hand, FcRn is required for the effective induction of antigen cross presentation of 
antigen IC. Therefore, the expression level of FcRn is also very important for 
efficient antigen cross presentation. The expression level of FcRn on both BMDC 
and SDC was determined via western blotting is shown in Figure 7.10. B3Z T cells 
were used as a negative control, whereas BMDM and whole liver cell lysate were 
used as positive controls for FcRn expression. The molecular weight of mouse FcRn 
was previously reported to be 55kDa (Neuber et al., 2014). As a result, the strong 
visible protein band detected in the lane loaded with liver lysate at around 50kDa, 
shown in Figure 7.10, is expected to be mouse FcRn. Interestingly, it was found that 




The expression level of FcRn in BMDC appeared especially low, with the FcRn 
protein band being hardly noticeable. This finding suggests that the low expression 
level of FcRn in both SDC and BMDC might be the factor leading to non-activation 
of B3Z T cells because there were probably insufficient of FcRn available to bind 
Figure 7.9: Flow cytometry analyses of the expression level of different Fcg receptors on the 
surface of bone-marrow derived dendritic cells (BMDC) and spleen derived dendritic cells (Spleen 
DC). Cells were probed using anti-mouse CD64 antibody or anti-CD32/16, FcgRIIB antibody. 




to antigen IC in order to induce an efficient antigen cross presentation. However, it 
must not be neglected that the soluble OVA antigen was not able to induce an 
activation in B3Z T cells either. The concentration of soluble OVA, 5mg/ml, used to 
incubate with dendritic cells was 10-fold higher than the OVA IC form and at such 
high concentration soluble OVA does not require the formation of antigen IC to 
induce antigen cross presentation. As a result, the failure of soluble OVA to activate 
B3Z T cells suggests that the low expression level of FcRn might not be the sole 
factor in causing the unsuccessful attempt at antigen cross presentation assay. 
 
7.0 DISCUSSION  
In this chapter, an antigen presentation assay was carried out to determine if MFc 
Figure 7.10: Western blotting for the detection of FcRn expression. DC were lysed with RIPA 
buffer and sonicated. The position of FcRn protein band is expected to lie in the region bounded by 
the red dotted line. Marker, protein molecular weight markers. From left to right the cells shown 
were: BMDC (bone marrow derived dendritic cells), Spleen DC (spleen derived dendritic cell), 
B3Z T cells (cytotoxic T cell), BMDM (bone marrow derived macrophage), Liver lysate (whole 
liver cell lysate). B3Z T cells were used as a negative control and BMDM and liver cell lysate were 
used as positive controls for FcRn expression. Expression of actin was detected as a loading 
control. 	
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protein would be taken up by dendritic cells via phagocytosis and cross presented on 
MHC Class I molecule after protein digestion to activate corresponding cytotoxic T 
cells. The antigen presentation assay using SIIN-mMFc was unable to activate the 
corresponding cytotoxic B3Z T cell. The result from western blotting suggests that 
both BMDC and SDC have low expression levels of FcRn and this might be one of 
the possible factors contributing to the unsuccessful antigen cross presentation. As 
mentioned in Chapter 6, the association of FcRn is important for the induction of 
antigen cross presentation. In experiments conducted by others, FcRn-expressing DC 
were able to activate cytotoxic T cells when a 100-fold lower antigen concentration 
was used when compared to DC that did not express FcRn (Baker et al., 2011). The 
authors also showed that the association of FcRn with IgG retained that IgG IC 
within an intracellular compartment whereas IHH-IgG IC were not retained (Baker et 
al., 2011). In addition, Baker and colleagues utilised an induced colorectal cancer 
system and showed that the adoptive transfer of wildtype DC to Fcgrt-/- mice greatly 
improved the activation of cytotoxic T cells and improved the protective immunity in 
such mice (Baker et al., 2013). As a result, the low expression level of FcRn detected 
in both BMDC and SDC described here might have cause a reduced association of 
antigen IC with FcRn. If the association with FcRn is required to achieve a certain 
signaling threshold to retain antigen IC in an intracellular compartment for antigen 
cross presentation induction, the low expression level of FcRn might abolish such 
signaling activity, thereby leading to inefficient antigen cross presentation. Having 
said that, the actual binding capability of SIIN-mMFc to FcRn has not been 
confirmed in this chapter. It was expected that SIIN-mMFc would be able to bind to 
FcRn due to the successful purification of SIIN-mMFc using Protein G-Sepharose. 
Both protein G and FcRn binds to a similar but distinct region at the CH2-CH3 
	 264	
interface of IgG Fc region. The binding of SIIN-mMFc to Protein G-Sepharose 
indicated that the CH2-CH3 domain of the IgG Fc region is most likely in an intact 
conformational structure, suggesting it should not have any problem in binding to 
FcRn. Nonetheless, due to the FcRn binding site being different from that for Protein 
G, it would be important to investigate whether SIIN-mMFC can actually associate 
with FcRn in a future investigation. SPR analysis would be a good choice for 
determining the binding activity of MFc to different Fc receptors such as Fcg 
receptors and FcRn and would allow comparison to the binding of wild type IgG. 
Such an approach would allow investigation of whether there is any significant 
difference between the two.  
 
Another point to consider is that proteolysis of endogenous proteins usually involves 
the ubiquitination system and the digested peptides are presented on MHC Class I 
molecules. Hence, in future experiments SIIN-mMFc could be transfected into MHC 
Class I H-2Kb expressing cells (cells from mouse strain C57BL/6 are suitable), and 
the ability of such transfected cells to activate B3Z T cells could be investigated. 
This experiment would confirm whether SIIN-mMFc can be properly digested to 
produce SIINFEKL peptide during the antigen cross presentation mechanism.  
The rationale behind the use of MFc protein in this project was to utilise the IgG Fc 
region to achieve long plasma half life via association with FcRn in order to 
stimulate production of anti-MAGE-A2 host antibodies and induce efficient 
formation of MFc IC, which in turn might promote induction of antigen cross 
presentation through FcRn engagement. Although the association of IgG IC with 
FcRn was shown to play a crucial role in antigen cross presentation in previous 
studies (Baker et al., 2011; Baker et al., 2013), there are other ways of achieving 
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antigen cross presentation other than the formation of IgG IC. Lasarte and colleagues 
fused the extra domain A (EDA) from fibronectin with SIINFEKL peptide or OVA 
protein. Upon incubation of these fusion proteins with BMDC, the authors showed 
that the SIINFEKL peptide from both proteins was presented on the MHC Class I 
molecule and activated B3Z T cells (Lasarte et al., 2007). EDA is an endogenous 
ligand for Toll-like Receptor 4 (TLR4) which is expressed on the surface of DC 
(Lasarte et al., 2007). The authors reported that the binding of the fusion proteins to 
TLR4 facilitated entry of the fusion protein into the MHC Class I cytosolic pathway, 
which resulted in antigen cross presentation, and such activity was blocked when a 
monoclonal antibody against TLR4 was used (Lasarte et al., 2007). Based on this 
approach, MAGE-A2 might be fused with EDA as an alternative option to achieve a 
similar cancer vaccine effect. However, due to the absence of IgG Fc region, MAGE-
A2-EDA might be compromised in terms of a low plasma half-life. 
 
In a different scenario, Fayolle and colleagues fused a known MHC Class I viral 
peptide originating from lymphocytic choriomeningitis virus (LCMV) to the 
catalytic domain of adenylate cyclase toxin (CyaA) of B. pertussis and immunised 
mice with the resultant toxin (Fayolle et al., 1996). The authors showed that 
cytotoxic T cells isolated from immunised mice were able to lyse cells that were 
coated with immunised viral peptide (Fayolle et al., 1996). It is believed that the 
toxin penetrated the membrane of cells and delivered the LCMV peptide into the 
cytosolic compartment before being subjected to MHC Class I cytosolic pathway 
(Fayolle et al., 1996). The findings from the studies suggested another alternative 
option in promoting antigen cross presentation activity in which MAGE-A2 protein 
could be utilised. However, there are several limitations regarding the approach of 
	 266	
using CyaA as the carrier protein. First, it might not be feasible to fuse full length 
MAGE-A2 protein to CyaA since it might disturb the invasive activity of CyaA. As a 
result, the restricted MHC Class I peptide of MAGE-A2 would first need to be 
identified and fused with CyaA. This approach will restrict the corresponding 
cytotoxic T cell recognition to the fused peptide after immunisation which limits the 
activation of different cytotoxic T cell clones. On the other hand, use of MAGE-A2 
Fc fusion protein should allow digestion of the full length MAGE-A2 protein, thus, 
generating different peptides that might associate with MHC Class I leading to a 
higher possibility of activating multiple cytotoxic T cell clones and inducing a 
stronger immune response. The second limitation is the identity of the CyaA target. 
It was reported that CyaA is capable of penetrating directly into different types of 
cells through the plasma membrane and does not require any specific receptors for its 
invasive activity (Fayolle et al., 1996). The activation of cytotoxic T cells requires 
the specific stimulation from antigen presenting cells such as macrophages and 
dendritic cells. It is expected that specific targeting of DC by CyaA would be 
problematic unless DC were isolated from the patient and reintroduced back to the 
patient after treatment with the toxin.  
 
In summary, efforts to demonstrate presentation of peptides derived from MFc-based 
antigens were unsuccessful. However, the SIIN-mMFc does not seem to be 
responsible for the failure because the positive controls were unsuccessful also. 
Further investigations are required to identify the problem and to confirm that MFc 
protein can undergo the antigen cross presentation mechanism. Nonetheless, some of 
the alternative options which might induce antigen cross presentation of MAGE-A2 
























CHAPTER 8: CONCLUDING REMARKS 
The work detailed in this thesis took advantage of protein engineering techniques and 
recombinant antibody technology to generate novel IgG hinge mutants and potential 
cancer vaccines in the format of Fc-fusion proteins, to further extend the 
understanding of antibody biology and function. 
 
Many recent antibody studies have been focusing on identifying new potential 
targets and improving the binding affinity to Fc receptors as a mean to diversify 
different antigen targets as well as improving effector function. However, there are 
still many areas concerning the antibody molecule itself that are worthy of 
investigation.  The hinge region has long been believed to provide flexibility to the 
antibody. In this study, it has been demonstrated that the upper hinge length of IgG 
may have the capacity to modulate the bivalent binding activity of IgG to enhance 
overall avidity. In addition, the importance of the presence of glycans at the hinge 
region was also highlighted by the reduced rosette formation noted for different IgG 
hinge mutants. Although some of modifications may not contribute to a significant 
enhancement in antibody functionality, a combination of several modifications may, 
in fact, help to significantly improve antibody functionality. As a result, all antibody 
engineering techniques which could improve antigen binding or effector function are 
highly valuable and any future investigations aimed at improving the understanding 
of antibody biology are highly encouraged. A better performing antibody would 
reduce the overall required dosage in therapeutic applications, which, in return, 
would reduce the overall cost of the drug.  
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This study has used a novel approach to calculate the bivalent antigenic distance of 
an antibody. The combination of surface plasmon resonance and the molecular ruler, 
NIP-dsDNA, has proven useful in investigation of the molecular distance involved. 
The NIP-dsDNA measuring model is expected to be much more accurate when 
compared to conventional approaches, such as protein crystallography, X-ray or 
neutron scattering techniques, because the length of dsDNA can be easily calculated, 
and, more importantly, the measurement is the actual functional antigen binding 
distance of the antibody. In addition, DNA production and DNA conjugation is 
relatively cost-effective and easy. As a result, this measuring model will be useful for 
other proteins if the related protein-protein binding distance is of interest. 
 
Finally, this study has attempted to generate a potential cancer vaccine by fusing 
human MAGE-A2 to IgG Fc. Unfortunately, a strong protein aggregation was 
encountered and the generated Fc-fusion protein was unable to stimulate a 
corresponding cytotoxic T cell response. The outcome of protein aggregation 
highlighted the importance of fully understanding protein characteristics. MAGE-A2 
is not very well studied and information regarding the protein is rather scarce. As a 
result, it is difficult to pinpoint the exact reason for protein aggregation. More 
importantly, the crystal structure of MAGE-A2 is not available. Thus, it is hard to 
predict the events that might happen after fusion to IgG Fc. In the event of the 
continuation of MAGE-A2-Fc protein production, studies on the characteristics of 
MAGE-A2 or, at the very least, the structural conformation of MAGE-A2 ought to 
be carried out. Although the generated Fc-fusion protein was unable to activate 
cytotoxic T cells during the antigen cross presentation assay, it was shown that the 
failure is expected to be due to the incompetence of the dendritic cells. As a result, 
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the hope that MAGE-A2 Fc-fusion protein could be a potential cancer vaccine 
should not be abandoned. More investigations are required to further confirm the 
significance of MAGE-A2 Fc-fusion as a cancer vaccine. 
 
8.1 Future perspectives  
The understanding and rewards concerning the IgG hinge mutants, dsDNA 
measuring model and MAGE-A2-Fc fusion protein have not been fully discovered 
and are worth continuing. Some of the future directions which could be taken for 
each of the study compoents are described below. 
 
1. Unfortunately, an ADCC assay was not performed using the IgG hinge 
mutants. It would be valuable to determine if the extension in hinge length or 
the presence of glycans at the hinge region have any effect on ADCC activity. 
With regard to antibody effector function, efficiency in complement fixation 
is also worth investigating as CDC is one of the main immune defensive 
mechanisms. 
 
2. Now that the dsDNA measuring model is established, it would be worthwhile 
to determine the bivalent antigenic distance of each of the naturally occurring 
antibody classes and subclasses. 
 
3. With regard to the MAGE-A2-Fc fusion proteins, some of the possible 
experiments have been previously discussed in Chapters 6 and 7. For 
example, fusion of just the MAGE MHD domain, rather than full length 
MAGE-A2, to IgG Fc might be attempted in order to tackle the problem of 
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protein aggregation. SIINFEKL incorporated MAGE-A2 Fc fusion protein 
could be expressed intracellularly to determine if the fusion protein might be 
properly digested to yield the correct sequence of SIINFEKL peptide. 
 
Antibodies are some of the most fascinating protein molecules due to their high 
specificity in antigen targeting and low immunogenicity in inducing an unwanted 
immune response. More importantly, the antibody format has been diversified 
immensely and different functionalities have been achieved to provide better 
therapeutic purposes. Antibody therapy is likely to remain an active and exciting area 
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